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11. Introduction
The world population is ageing. At present, people who are born in developed 
countries now, are expected to live in average more than 80 years, with women 
living a few years longer than men. With this demographic development, the 
prevalence of old-age-related diseases, such as dementia, will increase rapidly in 
the future. Understanding dementia is essential for future public health.
In health care, dementia is characterized by dependency on caregivers. Dementia 
patients can't perform their daily activities without help from others. They become 
unable to organize or prepare their own meals; therefore eating and drinking 
become difficult processes.  Nutritional problems then emerge at some time during 
disease's progression. Such patients are likely to forget mealtimes, have no 
appetite or even refuse to eat.  Malnourishment is frequently seen in this group, as 
a result of deficient energy intake over a period of years. In the end stage, as the 
medical condition worsens, tube feeding in the form of PEG (percutaneous 
endoscopic gastronomy) is often deployed.
This diploma thesis will try to explore ways of establishing the optimal solution for 
feeding dementia patients, with the primary objective of improving quality of life in 
its last stages. The first chapter will present background information and outline 
recent researches into dementia . Following this, there will be a description of 
nutrients suspected to have a connection with the development of dementia. The 
next section will deal with nutritional issues connected with psycho-social 
problems in the middle and advance stages, which may affect  the daily lives of 
the elderly with dementia.  Tube and oral feeding are the main topics in the last 
two chapters. Based on recent studies reported in books and scientific journals, 
the advantages and disadvantages of each feeding type will be examined. The 
author is very much aware of the multidisciplinary nature of this issue, and 
2therefore although nutrition is the main emphasis in these writings, brief survey of 
the relationship with issues in other fields, such as ethics, law and psychology, will 
be included in the last chapter. Improvements in nutritional knowledge alone would 
not  mean so much, if decision making as to whether to apply or withhold tube 
feeding is not supported by suitable social controls.
In the last instance, I would like to thank Prof. Elmadfa, who has lead the way, and 
to give the opportunity to learn about life from a terminal illness such as dementia 
and how to see 'the big picture' instead of looking at issues in isolation like small 
pieces of puzzle. It is hoped this work will be of benefit to all aspects of the 
treatment and therapy of dementia.
Vienna,   February  2012
32. Background
2.1. History of dementia
Descriptions of memory damage in the history of relevant literature can be traced 
back as far as 400 BC in the writings of Plato and Aristotle [KARENBERG and 
FÖRSTL 2006]. The term dementia1 itself, is used by Roman poet and philosopher 
Lucretius to describe the condition of being out of one's mind [MALGORZATA et al. 
2004]. 
In the 18th century, the term senile dementia was first used in 1798 by French 
psychiatrist Philippe Pinel in his book Nosographie. His student, Esquirol, then 
differentiated dementia from amentia2 and defined dementia as a “cerebral 
disease characterized by sensibility, intelligence and will impairment” 3[ROMÁN 
2002].
Advances in the fields of microscopy, histology, genetics, neuropathology and 
other areas of medicine  in the 20th century contributed to a better understanding 
of dementia. Dementia today refers to a condition in which there is a loss of 
cognitive function, caused by brain disorders, severe enough to interfere with daily 
social and occupational life [MALGORZATA et al. 2004] . Based on clinical 
presentation, neuropathology and etiology, dementia is categorized further into 
four major groups; AD, Parkinson's  groups, FTD groups and vascular groups 
[GROSSMAN et al 2006]. 
1 The word 'dementa' is derived from latin, dement-demens, which means out of one's mind.
2 According to Esquirol, amentia or idiocy is “not a disease, but a conditions in which the intellectual 
faculties are never manifested or have developed sufficiently to enable the idiot to acquire knowledge”
3 Esquirol also explained a parable comparison between amentia and dementia; “demented person is like a 
rich man who become poor, meanwhile amentia has always in a state of want and misery” 
4To date, there still no cure for these diseases, although medication and therapy 
are provided to slow the progression of the disease and patients in the advanced 
stages may receive palliative care4.
2.2. Definition of dementia 
According to ICD-105, “Dementia is a syndrome due to disease of the brain, 
usually of a chronic or progressive nature, in which there is disturbance of multiple 
higher cortical functions, including memory, thinking, orientation, comprehension, 
calculation, learning capacity, language, and judgement. Consciousness is not 
clouded. Impairments of cognitive function are commonly accompanied, and 
occasionally preceded, by deterioration in emotional control, social behaviour, or 
motivation.” 
DSM-IV 6 defines dementia as "multiple cognitive deficits, including memory 
impairment and at least one of the following disturbance:  
– aphasia (language problems, difficult to produce names of individuals and 
objects)
– apraxis  (poor motoric coordination)
– agnosia  (fail to recognize objects)
– disturbance in executive functioning, severe enough to cause impairment in 
daily activity and must show a decline from previously higher level of 
functioning". 
4 Palliative care is usually applied for patients with life-threatening illness, it aims to improve quality of life 
through prevention of  pain and regards dying as normal process.
5 ICD-10  is  International Classification of Diseases published by World Health Organization, current 
revision is from 2006, comprises definition, classification and diagnosis of diseases, thus provide basis 
for national statistic 
6 DSM-IV stands for Diagnosis and Statistical Manual of Mental Disorders, is published by American 
Psychiatric Association, 4th edition, 2000
5Difference from delirium and other diseases
Some conditions may appear similar to dementia. Age-related cognitive decline, 
delirium, schizophrenia, and depression develop similar symptoms, that seem to 
overlap and should be ruled out before dementia is diagnosed. Delirium for 
example, although also presenting memory impairment  as a symptoms, is 
characterized by disturbance of consciousness and develops over a short period 
of time, whereas persons with dementia remain  alert and progression of cognitive 
loss takes from months to years. If the underlying illness from other medical 
conditions or substance abuse are treated, delirium usually can be healed [DSM-
IV-TR 2000].
Another disease often linked with dementia is Mild Cognitive Impairment, where 
impaired memory is the only area affected, while the elderly with dementia show 
deterioration in other cognitive areas as well [PETERSEN 1999].  Although still 
curable, approximately 10-15% MCI's patients from certain subtype progress to 
Alzheimer's Disease, suggesting MCI may be a transition link between normal 
ageing and dementia [GRUNDMAN et al 2004].
Dementia is a chronic progressive illness, for which to date there is still no 
available cure, persons with dementia live approximately 2-6 years after the initial 
onset of symptoms [MITCHELL 2007]. The main causes of death are usually 
unrelated to dementia, such as  pneumonia, cardiovascular disease, and 
pulmonary embolus [KEENE et al 2001].
62.3. Epidemiology 
A Swedish review study investigating the correlation of  age and the prevalence of 
dementia showed, that the prevalence rises with increasing age, double in every 5 
years after the age of 65. In the group older than 95, almost half the population 
developed dementia [SBU 2008]. Incidence also increases with age, both 
prevalence and incidence data shows no geographic difference, but significant 
gender distinction. The data for women show a higher prevalence. Even so, 
gender is not considered a risk factor for dementia, higher life expectancy in 
women may be attributable here.  Figures from EURODEM7 meta-analyses for 
European studies show close similarities [HOFMAN 1991].
Age (years) Prevalence Incidence
(1000p/y)
60-64
65-69
70-74
75-79
80-84
85-89
90-94
>95
1 %
1.5 %
3 %
6 %
13%
24%
34%
45%
1
3-5
8-10
11-18
24-40
30-60
50-120
Table 1: Prevalence of dementia with increasing age [SBU 2008]..
Along with the growth of an older population, the number of dementia cases is 
expected to rise fourfold in the next 50 years. According to Alzheimer's Disease 
International, there were around 35.6 million8  dementia cases worldwide in 2010, 
this figure is estimated to nearly double every 20 years. 
7 European Community Concerted Action on the Epidemiology and Prevention of Dementia group, a meta- 
analysis study from 10 European countries.
8 World Alzheimer Report 2009
7Region Crude 
prevalence9
2010 2030 2050
Worldwide 4,7% 35,56 million 65,69 million 115,38 million
Europe 6,2% 9,95 million 13,95 million 18,65 million
North-and Latin 
America
6,5% 7,82 million 14,78 million 27,08 million
Asia 3,9% 15,94 million 33,04 million 60,92 million
Africa 2,6% 1,86 million 3,92 million 8,74 million
Austria10 1,27%11 108.400 163.400 233.800
Table 2: Estimation of dementia's prevalence by regions [World Alzheimer Report 2009]
An enormous rising percentage in incidence is to be expected in low and middle 
income countries, in 2050, it is estimated 70,5% people with dementia will live 
there [World Alzheimer Report 2009]. 
To predict the social burden in the future, Wancata et al calculated a relation 
between people of a productive working age and persons with dementia in Austria. 
Year People in working age 
(15 – 64y/o)
People with 
dementia 
Number of working-age people 
per demented person
2000 3.811.145 90.493 42
2010 4.103.910 108.983 38
2030 4.102.718 165.078 25
2050 3.963.473 269.603 15
Table 3: Ratio people in working age and with dementia in Austria [Wancata et al 2001]
9 Crude estimated prevalence: % prevalence from population over 60y-o.
10 [WANCATA et al 2001]
11 EURODEM, Austrian Dementia Report 2009 p 14
8According to the Austrian Dementia Report 2009, the average annual cost per 
person in Austria is 12.443,10€ for housecare and 34.887,55€ for care in nursing 
homes. In average 7 years duration of the disease, the prognosis for the total cost 
in Austria thereby are 1,84Mrd€ in 2010,  2,69Mrd€ in 2030 and 4,56Mrd€ in 2050 
[Austrian Dementia Report  2009]. 
International data is comparable with Austrian figures, for example, as in the 
Netherlands 14.854€ per demented person in 2004, Scandinavian countries 
17.860,14€ per person with AD in 2006, USA 19.404,55€ per person with AD in 
1996 [Austrian Dementia Report  2009].
Recognizing this huge burden in the future, prevention and effective treatment as 
well as disease management of dementia should have take priority in future 
research.
2.4. Forms of Dementia
9Based on etiology, DSM-IV-TR differentiate types of dementia as follow : 
• Alzheimer's Disease
• Vascular Dementia 
• Dementia due to other general medical condition 
• Dementia due to HIV Disease
• Dementia due to Head trauma
• Dementia due to Parkinson's Disease (Lewy body related neurodegeneration)
• Dementia due to Huntington's Disease
• Dementia due to Pick's Disease (focal degeneration in frontal and temporal 
lobes)
• Dementia due to Creutzfeldt-Jakob Disease 
• other conditions associated with dementia 
• structural lesion  (e.g. primary or secondary brain tumors, subdural 
hematoma)
• endocrine conditions (e.g. hypothyroidism, hypercalcemia, hypoglycemia)
• nutritional conditions (e.g. deficiencies of thiamine or niacine)
• other infectious conditions (e.g. neurosyphilis)
• immune disorders (e.g. temporal arteritis, systemic lupus erythematosus)
• derangements of renal and hepatic function
• metabolic conditions (e.g. Kufs' disease)
• other neurological conditions  (e.g. multiple sclerosis)
• Substance-Induced Persisting Dementia
• associated with substance clases : alcohol, inhalants, sedatives, hypnotics and 
anxiolytics)
• medications to cause dementia: anticonvulsants, intrathecal methotrexate
• toxin exposure : lead, mercury, carbon monoxide, organophosphate insecticides 
and industrial solvents
• Dementia due to Multiple Etiology
10
• Dementia not otherwise specified
Table 4: Types of dementia according to DSM-IV-TR 2000 
Subtype Dementia 
case 
proportion 
Neuropathology Characteristic symptoms
AD 50-70% Cortical amyloid plaques
neurofibrillary tangles
Impaired memory, apathy and 
depression, gradual onset
VaD 20-30% Celebrovascular disease
single or multi-infarct
Similar to AD but less memory 
affected, mood fluctuation 
prominent, physical frailty, and 
stepwise onset
DLB <5% Cortical Lewy bodies 
(alpha-synuclein)
Marked fluctuation in cognitive 
ability, visual hallucinations, 
tremor and rigidity
FTD 5-10% Damage to frontal and 
temporal lobes
Personality changes, mood 
changes, disinhibition, 
language difficulties
Table 5: Characteristic and proportion of dementia subtypes [World Alzheimer Report  
2009]
Another way of classifying dementia is by the brain area affected. When the 
cortical brain cortex is impaired, symptoms arise such as problems in memory, 
language, thinking and social behavior. Alzheimer's Disease is one example of 
cortical dementia. Disorders in the subcortical part of thebrain (layer under cortex) 
influence memory, emotion and movement [MUMENTHALER and MATTLE 2002].
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2.4.1. Alzheimer's Disease
Alzheimer Disease (AD) is the most common disorder that causes dementia. First 
described in 1906 by a German doctor Alois Alzheimer, early symptoms of this 
disease include memory impairment, followed by disturbance in language and 
recognition skills, and motor and sensory symptoms which eventually appear in 
the later stages. Neuropsychiatric symptoms such as aggression, agitation, 
depression, apathy and hallucinations may occur during disease progression. 
These behavioral symptoms are classified into 3 groups: affective syndrome, 
psychotic syndrome and other neuropsychiatric disturbances. This classification 
should help physicians in diagnosing and providing better treatment for people 
with AD [LYKETSOS et al 2001].
AD differentiation includes a senile and pre-senile form. In the pre-senile subtype, 
the onset of dementia is below the age of 65, half of this subtype has a genetic 
predisposition to AD, it is also known as early onset familial AD (eFAD). In late 
onset or sporadic AD, symptoms appear after the age of 65. DSM-IV also divide 
AD types into subtypes with and without behavioral disturbance. 
On average, patients live 6 years after being diagnosed with AD [KAY et al 2000]. 
Although survival rate is also correlates with the age when AD is diagnosed, 
persons diagnosed with AD at age 65 have approximately 8,3 years to live, 
meanwhile those diagnosed at 90 only 3,4 years [BROOKMEYER et al 2002]. 
However, AD is not main cause of death. Losing their ability to swallow, AD 
patients often die because of aspiration pneumonia or other infections [FORSTL et 
al 2005]. 
12
The hallmark of AD is neuropathological changes in the brain known as amyloid 
plaques12 and neurofibrillary tangles13, although other pathological alterations such 
as neuropil threads, granulovacuolar degeneration, and amyloid angiopathy may 
also be presented.
Amyloid senile plaques
Amyloid plaques accumulate between neurons, contain beta amyloid peptides 
(Aß) and fibrils, which are formed due to subsequent cleavage of amyloid 
precursor protein (APP) by ß- and γ- secretase [SWARTZ 1999] (Illustration 1). 
APP is an integral membrane  protein, whose functions are still unknown, but it is 
suspected to play a role in synapses formation and plasticity.
APP is cleavaged by  α- , ß- and γ- secretase through either amyloidogenic or 
non-amyloidogenic pathways. In non-amyloidogenic pathway,  α-secretase split 
APP within Aß domain, forming sAPPα and C83. The cleavage in the middle of Aß 
domain is believed to have a protective property, preventing its deposition and 
aggregation [YAN and WANG 2007].  Alternatively via the amyloidogenic pathway, 
ß- secretase derived sAPPß and C99  from APP. C99 will be processed further by 
γ- secretase, generating 40 and 42 amino acids moieties [Aβ (1-40) and Aβ (1-
42)]. [FRYER and HOLTZMANN 2005]
Although Aß40 is the most common14 form in human plasma and cerebrospinal 
fluid,  Aß42  is the predominant form of amyloid plaques and tends to aggregate 
more rapidly than Aß40 in vitro. Aß42  aggregation is suggested to play an 
important role in the initiation of plaque formation. 
12 Amyloid plaques are clumps of protein, are found in the extracellular tissue between nerve cells.
13 Neurofibrillary tangles are twisted filaments within neurons (intracellular).
14 Aß40 make out around 90% of all amyloid peptide produced by APP, while Aß42 only 10%.
13
The ratio between Aß40 to Aß42 seems to determine toxicity and pathological 
distribution of AD. At equimolar ratio ( Aß40 to Aß42 :  0,5-1) , Aß40  may inhibit the 
formation of fibril by  Aß42 in vivo [KIM 2007]. This effect, may be due to the 
competition of monomeric Aß40 and  Aß42 for binding to the ends of fibrillar 
amyloid aggregates [JAN et al 2008].
 
 
Accumulation of the beta amyloid peptide in senile plaques triggers some 
physiological changes in brain that may lead to cognitive deterioration (Illustration 
2). Aß aggregation may cause disturbance in membrane integrity, causing 
depolarization of ion channel, alteration of ion homeostasis  and dysregulation of 
signal transduction, leading to apoptosis [ARISPE et al 1993].  Oxidative stress, 
perturbation of intracellular calcium homeostasis, and inflammation may also be 
involved in this process [MATTSON et al 1993] [WYSS-CORAY and MUCKE 
2002]. 
Illustration 1: Proteolytic processing of amyloid precursor protein (APP)
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Illustration 2: Amyloid cascade [CUMMINGS 2004]
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Since it is generally thought, that accumulation of Aß is responsible for the 
neurodegeneration in AD, researchers are trying to develop medication by finding 
an agent either to stop or inhibit Aß production. One approach is to make a 
vaccine that makes the immune system prevent accumulation of amyloid plaques 
or destroy them. After successful preliminary studies in mice, a clinical trial with 
vaccine AN-1792 failed and caused brain inflammation described as 
meningoencephalitis in humans [CHECK 2002]. Autopsy showed clearance of Aß 
from the AD brain, but numerous neurofibrillary tangles and neuropil threads 
lesions were unaffected, and severe dementia symptoms remained [NICOLI et al 
2003]. Thus, although accumulation of amyloid plaques are significant in the 
development of AD, increasing evidence shows that beta amyloid is not the 
exclusive cause of cognitive deterioration [CARTER and LIPPA 2001].
Neurofibrillary tangles
Neurofibrillary tangles (NFTs) occur within cells, they consist of  tau15 protein, 
which is hyperphosphorylated and therefore tangles form insoluble aggregates 
called paired helical filaments (PHF). This aggregation result in loss of tau main 
function in stabilizing microtubules, causing disturbance in microtubule-dependent 
axonal transport and cognitive decline [VANDEBROEK et al 2006].
Phosphorylation of tau is regulated by the enzymes kinases and phosphatases. 
Some of the kinases, such as glycogen synthase kinase 3ß (GSK3ß) , 
phosphatidyl inositol 3-kinase (PI3K), and mitogen-activated protein (MAP) kinase, 
are activated by the increased Aß status and thus may play a role in tau 
hyperphosphorylation [FERREIRA et al 1997]. Protein phosphatase-2A (PP2A) on 
the other hand, has a function in regulating tau dephosphorylation [WANG et al 
2007]. It is hypothesized that a decrease in PP2A activity is crucial for the 
15 Tau is a microtubuli-associated protein.
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increased level of tau phosphorylation, rather than an increase in kinase activity 
[PLANEL et al 2001]. Regulation of PP2A is influenced by methylation reaction, 
thus it is postulated that there may be a link between tau phosphorylation, S-
adenosylmethionine and homocysteine status in plasma [ VAFAI and STOCK 
2002]. 
Density of tangles is correlated with diseases duration and severity of cognitive 
loss [SPIRES and HYMAN 2005]. Neurofibrillary tangles are also abundant in FTD 
and other so-called tauopathies [LEE et al 2001].
A recent study suggests that Aβ toxicity may depends on tau-protein concentration 
[ROBERSON et al 2007]. In mice, decreasing tau-protein without changing the Aß 
level, results in behavioral improvement, postulating that tau is required for Aß 
toxicity  [RAPOPORT et al 2002].
In addition, neurochemical change is also present in AD brain. The level of 
acetylcholin, a neurotransmitter involved in memory processing and learning, is 
decreased in the AD brain, where its decline is more evident in the advanced 
stages [DAVIS et al 1999].   Loss of cholinergic neurons16 due to a decline in 
cholinergic activity of  the cholinergic synthetic enzyme ChAT (Cholin 
Acetyltransferase) is associated with memory impairment in AD17  [PAPPAS et al 
2000]. Glutamate activity  is also decreased, excitotoxicity18 of glutamate mediated 
by N-methyl-D-aspartate (NMDA) receptors could lead to neuron death 
[GROSSBERG and KAMAT  2009].
16 Cholinergic neurons are neurons that utilize acetylcholin.
17 Two enzymes involved in Acetylcholin regulation are synthesizing enzyme Cholin Acetyltransferase 
(ChAT) and catabolic Cholinesterase .
18 Excitotoxicity means over-stimulation to its membrane receptor.
17
Illustration 3: Pathophysiology of dementia [KASOHA 2010]
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2.4.2. Vascular Dementia
Vascular dementia (VaD) is dementia caused by cerebrovascular disease. Unlike 
AD, memory impairment might not become prominent in the early stages and 
cortical dementia symptoms such as apraxia and aphasia might not be present. A 
connection between CVD and dementia is difficult to judge on symptoms alone, 
since infarcts may be small or localized in subcortical regions [KRAMER and 
WETZEL 2009]. 
Furthermore, the heterogenity of cerebrovascular disorders make it difficult to 
diagnose. Neuron death in VaD caused by stroke could result from ischemia19 or 
hemorrhages20. 
To date, although there are some clinical diagnostic criteria for vascular 
dementia21, most of them diagnose vascular dementia based upon symptoms of 
AD imposed with vascular events. Differences between each clinical criterion 
include varied definitions of cognitive decline, vascular cause, onset and disease 
progression, and subtypes of vascular dementia. These  many standards may 
cause confusion in research and clinical practice, thus may affect disease 
recognition and treatment [WIEDERKEHR et al 2008]. An international consensus 
for diagnosing vascular dementia is urgently needed. 
19 Ishemia is condition of  restricted blood flow, disturbing blood transport to cells.
20 Hemorrhage means bleeding, caused by ruptured blood vessel or arteriovenous malformation.
21 Reviewed by Wiederkehr et al (2006) are DSM-IV, ICD-10, Hachinski Ischemic Scale (HIS), Ischemic 
Scale of Rosen, California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC), and 
National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et 
l'Enseignement en Neurosciences (NINDS-AIREN).
19
Cerebrovascular 
events
Disorder  Pathological Cause Features
Hemorrhage Non traumatic 
subarachnoid 
hemorrhage
Ruptured cerebral 
aneurysm
Arteriovenous 
malfomation
- high morbidity rate
- significant cognitive 
deficiency
- memory impairment 
- deficit in executive 
functions
Cerebral Amyloid 
Angiopathy (CAA)
Aß accumulation in 
cerebral blood vessels22
Ischemia Subcortical 
atherosclerotic 
encephalopathy 
(Binnswanger's 
Disease)
Extensive demyelination 
and destruction of 
subcortical
White Matter (WMLs)
- apathy
- lack of drive
- mild depression
- alterations of mood
- slow information 
processing
Strategic infarcts Infarction of thalamus, 
frontal white matter, 
basal ganglia; 
disconnect neuron 
systems
- memory impairment
- depend on localization 
of infarcts
Large vessel 
disease23 or Multi 
Infarcts Dementia 
- sudden onset
- stepwise progression
- not often combined with 
AD compared to other 
ischemic dementia 
- neurological symptoms 
vary, depend on size and 
localization of lesions
- aphasia, apraxia and 
agnosia
- inattention syndromes
Small vessel disease 
or Subcortical 
Ischemic Vascular 
Dementia (SIVD)
Lacunar infarct24, also 
known as lacunar state 
dementia 
- associated with age 
and hypertention
Cerebral Autosomal 
Dominan Arteriopathy 
with Subcortical Infarcts 
and 
Leukoencephalopathy 
(CADASIL)
- genetic disorder, 
mutation of chromosome 
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- cognitive decline at 
early age
Table 6: Cerebrovascular events that cause dementia symptoms. [KRAMER and WETZEL 
2009]
22 ACC is common in AD patients, and could make cerebral blood vessels more prone to rupture
23 Large vessel disease or MID refers to occlusion of  main branch of cerebral arteries, caused by 
atherosclerotic plaques or emboli from cardial origin
24 Lacune is cavity filled with Cerebrospinal Fluid (CSF) in basal ganglia or white matter.
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VaD is essentially preventable, since onset of dementia happens after a 
cerebrovascular event. Therefore, recent studies propose the use of a broader 
term to include mild cognitive loss before dementia, namely Vascular Cognitive 
Impairment (VCI). The definition of VCI covers all cognitive burden resulting from 
cerebrovascular disease, and some VCI may develop into incurable dementia. 
[ ERKIJUNTTI and GAUTHIER 2009].
2.4.3. Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia 
(PDD)
 
Lewy bodies are  abnormal protein structures in the brain, consisting of α-
sycnuclein and ubiquitin protein, normally found in brain stem and cerebral cortex. 
Clinical symptoms and pathological findings of DLB often overlap with AD and 
PDD [BYRNE 1997]. At autopsy, most DLB patients also have neuritic plaques and 
neurofibrillary tangles and memory loss may be profound in the early stage, 
leading to false diagnosis. Indeed, difficulties in distinguishing LBD and AD in its 
early phase, has lead to the development of a new term, the Lewy Body Variant of 
Alzheimer's Disease (LBV) [HANSEN et al 1990].
The clinical features of DLB are fluctuations in cognitive performance, visual 
hallucinations and systematized delusions and spontaneous parkinsonism, thus 
psychiatric symptoms are usually more prominent than cognitive. Compared to 
AD, DLB patients seem to show greater deficits of attention, psychomotor speed 
and visuospatial ability [HANSEN et al 1990]. 
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Lewy bodies are also found in Parkinson's patients, with or without dementia 
symptoms. While in DLB, Lewy bodies are found predominantly in the cortical 
area, in PDD they are found in subcortical [LENNOX and LOWE 1996]. In addition, 
decline of dopamine activity due to neuron degeneration in substantia nigra  may 
explain motoric symptoms typical to PD, such as bradykinesia25, rigidity but no loss 
of muscle strength, tremor, and postural instability.  
About 40% of PD patients developed dementia with cognitive, mood and behavior 
disturbance in later stage and prevalence may increased with disease duration 
[EMRE 2008]. 
2.4.4. Alcohol related dementia 
Clinically, dementia from chronic alcohol abuse could be caused by direct 
neurotoxicity effect of alcohol, known as primary alcohol dementia, or due to 
chronic thiamine malabsorption and deficiency, which leads to Wernicke-Korsakoff 
syndrome (WKS).
 
In primary alcohol dementia, there exist some biochemical changes in the brain, 
such as NMDA receptor hyperexcitability and hyperhomocysteinemia, although its 
relationship to brain disorder is still uncertain. Cases of this disorder are rare and 
probably still could be cured with appropriate treatment  such as thiamine 
supplementation and alcohol abstinence [MORIYAMA et al 2006]. 
Wernicke’s encephalopathy is an acute neurological disorders, characterized by 
oculomotor abnormalities, cerebellar dysfunction, and altered mental state or 
memory impairment, usually followed by Korsakoff’s syndrome, which appears as 
25 Bradykinesia is slowed ability to start and continue movements.
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profound amnesia, disorientation and frequent confabulation. Jeusen and 
Pakkenberg (1993) have suggested, that neurotoxic features of  alcohol may 
cause a disconnection syndrome between neurons, preventing nerve pathways 
from being activated. Another theory by Pfefferbaum et al (2004) hypothesized a 
combination of liver dysfunction, poor nutrition and chronic exposure to alcohol, to 
cause brain damage [PFEFFERBAUM et al 2004]. 
The exact mechanism of this syndrome is still unclear at present. Scientists 
suspect, there may exist a genetic predisposition to thiamine deficiency caused by 
chronic alcohol abuse. This could explain why some people tend to develop WKS, 
but further researches are still needed to confirm this. It should be noted that 
Wernicke-Korsakoff syndrome is partially reversible [DOWEIKO 2001].
2.4.5. HIV Dementia 
Dementia due to HIV is widely known as AIDS Dementia Complex (ADC). The 
death of nerve cells in the brain in this disorder is caused by neurotoxins produced 
by the HIV-virus. These toxins, such as  TNF-alpha, cytokines, interleukins, 
chemokines, nitric oxide, and excitatory amino acids, induce inflammation in the 
surrounding environment [BRABERS and NOTTET 2006]. HAART (highly active 
antiretroviral therapy) medication seems to increase the average life span of AIDS 
patients with dementia, from 6 months without treatment to 38 months with a 
regular regimen [MC ARTHUR 2004].
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2.5. Risk Factors and Preventions
The development of dementia, so some scholars believe, takes place over a long 
period of time before first symptoms appear. During this process, some factors 
may accelerate or delay the onset of disease. Old age seems to be the significant 
risk factor for dementia. Epidemiological studies show, that the risk of developing 
dementia rises with advancing age. 
Risk factors for dementia may be different for each gender [ARTERO et al 2008]. 
Many scientists believe, women are more at risk because of the decline of 
estrogen after the menopause. Moreover, women live longer than men and are 
more prone to diabetes, another risk associated with dementia. 
Risk factors such as depression, becoming emotionally dependent on others, and 
becoming socially isolated has more damage on women, where for men, physical 
health such as diabetes and stroke increase more chance of developing dementia.
Researchers believe, the development of neurodegenerative diseases are 
multifactorial and not caused by a sole risk factor, but from interactions between 
genetic susceptibility and environmental exposures [GREENAMYRE et al 2003].
Swedish Council on Technology Assessment in Health Care (SBU) in its review 
"Dementia - Epidemiology and Etiology" in 2008 suggested some hypotheses as 
risk and protective factors, summarized from studies between 1985 to 2004. 
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Hypothesis
Genetic Familial aggregation
ApoE Ɛ4 allele 
Vascular Smoking
Alcohol consumption
Blood pressure
Diabetes Mellitus
Cholesterol/Obesity
Cardiovascular diseases/Atherosclerosis
Homocysteine
Anti-hypertensive statins 
Hormonal Therapy
Inflammatory NSAIDs (Non-steroidal Anti-Inflammatory Drug)
Inflammation markers
Toxic Head trauma
Aluminum
Occupational exposure
Oxidative Diet : Folate / Cobalamine deficiencies
Psychosocial Depression
Low education
Socioeconomic status
Leisure activities
Social network
Personality
Table 7: Risk factors of dementia [SBU 2008]
2.5.1. Genetic hypothesis 
Suspicion that dementia may be due to genetic defects, is derived from studies of 
Down's Syndrome. About half the people with Down's Syndrome develop AD after 
they reach the age of 35 [SCHALLENBERG et al 1992]. The hallmark of Down's 
Syndrome is an extra copy of chromosome 21 in each cell; as a result, the genes 
that cause AD have 3 copies instead of 2. The mutation of amyloid-beta precursor 
protein (APP) gene in chromosome 21 may cause the excess production of beta 
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amyloid  peptide in cells therefore account for the increased risk.  Moreover, 
presenilin1 (PSEN1) and presenilin (PSEN2) genes, which are located in 
chromosome 14 and 1 respectively,  are also  suspected to cause Familial AD with 
early onset dementia. Presenilin mutations are linked to γ-secretase activity 
[SCHEUNER et al 1996]. The mutation in PSEN1 may increase the proportion of 
C99 peptide that is cleaved by  γ-secretase, therefore causing an increased 
production of Aß42 [SMALL et al 2010].
For late onset of the condition, which is more common, the ApoE Ɛ4 gene on 
chromosome 19 is taken into account [BOOKHEIMER et al 2000]. There is further 
evidence concerning an increase of the involvement of  chromosome 10, 12 and 3 
to late onset AD [BERTRAM et al 2000].
Genetic factors may also play a role in the development of Parkinson's disease . 
Mutation in gene coding for α-synuclein protein, parkin and ubiquitin carboxy-
terminal hydrolase L1 (UCH-L1) are known to be associated with protein 
misfolding and aggregation in PD [GREENAMYRE et al 2003].
Dementia that develops purely from gene mutations is very rare, it accounts for 
only less than 1% of all cases of dementia.  Even people with this genetics 
disposition have only an increased risk of developing dementia, and not all cases 
develop into disease itself. Approximately half of AD's patients carry none of above 
mentioned genes, which leaves other unknown genetic  factors, or environmental 
interactions that respond to genetic disposition to determine onset.
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2.5.2. Vascular hypothesis
Risk factors for cardiovascular disease, such as hypertension, high cholesterol 
level, obesity, high homocysteine plasma levels, also smoking, alcohol 
consumption, and obesity may increase the risk of atherosclerosis, and hence 
reduce blood supply to brain, resulting in stroke and other brain damage. In the 
matter of  VaD  and diabetes type 2, lower cognitive function is found in persons 
with high HbA1c26. [CUKLERMAN-YAFFE et al 2009]  
Vascular pathology of dementia involved inflammation of blood vessels, vascular 
fibrosis and structural changes such as denervated cortical microvessel. 
Impairment of perivascular cholinergic nerve terminals from the basal forebrain 
may cause deregulation of cortical cerebral blood flow (CBF). The brain need a 
constant blood supply, since it has no reserve of glucose and oxygen, reduced 
blood flow (perfusion) to the brain may disturb neuronal function [HAMEL et al 
2008]. 
Most scholars agree that lowering homocysteine, cholesterol levels and blood 
pressure is important to prevent  vascular dementia. Exercise, controlling 
inflammation and nonsteroidal anti-inflammatory drugs are also considered 
beneficial. 
2.5.3. Inflammatory hypothesis
High concentration of inflammation markers such as cytokine, C-reactive protein 
(CRP) and activated complement cascade protein, are found in senile plaques and 
neurofibrillary tangle in the brains of people with AD [McGEER and McGEER 
26 Average blood sugar control over  6-12 weeks period, normal rate 6%
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2004], suggesting a possible involvement of inflammatory process in the 
development of AD. Beta amyloid deposition and neurofibrillary tangles may act as 
irritants, stimulating a chronic inflammation that leads to neuron degeneration and 
synaptic changes. Further, signals emanate from injured neurons and imbalances 
between pro- and antiinflammatory process may also trigger inflammation 
response in the brain [WYSS-CORAY and MUCKE 2002].
Interaction between beta amyloid (Aß) and cells involved in the inflammatory 
process such as the microglia27 and the astrocytes are thoroughly investigated in 
recent years. The clustering of migroglia around beta amyloid deposits may be an 
attempt to clear beta amyloid through phagocytosis [KOPEC and CARROLL 
1998]. Some reports indicate that the degradation mechanisms of phagocytosed 
Aß fibrils may be overloaded or even impaired, causing the undegraded Aß 
remnants remain stored within microglia for a long time [ARD et al 1996]. 
Moreover, Aß can induce expression of nitric oxid synthase (NOS) in microglia and 
thus resulting the loss of neurons. This finding suggests that neuronal damage 
may result from products released by activated microglia rather than direct action 
of beta amyloid [WELDON et al 1998]. Microglia may also produced reactive 
oxygen species, which exacerbate neuron damage through oxidative stress 
[TUPPO et al 2005]. 
Since inflammatory factors such as microglia, astrocytes, cytokines and 
complement factors have multiple functions, their role in the development of 
neurodegenerative diseases is unclear [WYSS-CORAY and MUCKE 2002]. The 
debate, whether inflammation process has beneficial or detrimental effect, lead to 
discussion to what extent inhibiting inflammation can reduce neuron degeneration. 
27 Microglia are the immunologically competent cells whose functions include chemotaxis, phagocytosis 
and secresion of a variety of cytokines and proteases, they are the resident macrophage of the central 
nervous system [KOPEC and CARROLL 1998]
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Long-term NSAID (Non-Steroidal Anti-Inflammatory Drugs) use are proved to have 
a preventive effect on dementia, particularly ibuprofen [VLAD et al 2008]. This 
effect may be due to partial clearance of beta amyloid in the brain, since certain 
NSAIDs have inhibitory effect on Aß production  [WEGGEN et al 2001].
However one cohort study in 2009 [BREITNER et al 2009] and one randomized 
double blind trial [ADAPT Research Group 2008]  showed that drugs such as 
naproxen and celecoxib did not delayed the onset of dementia and naproxen even 
seemed to have a detrimental effect28.  This contradiction may be related to 
immunologic diversity of person with AD;  the outcome of inflammatory responses 
depends on the specific trigger and on the genetic background on which it occurs 
[WYSS-CORAY and MUCKE 2002].
2.5.4. Oxidative hypothesis and nutrient deficiencies
Oxidative stress29 has been identified to play an important role in the pathogenesis 
of  Alzheimer's disease. Age-related accumulation of  reactive oxygen species 
(ROS) may result in cellular damage and neurons seem to be vulnerable to free 
radicals attack for various of reasons. Reactive oxygen species (ROS), including 
superoxide, hydroxyl radicals, hydrogen peroxide and nitric oxide, are normal 
byproducts of oxidative phosphorylation and various tissue oxidases. Some events 
may trigger the overproduction of ROS and  thus impair antioxidant defense 
system [BEHL and MOOSMAN 2002]. Factors such as microvasculature changes, 
increase in oxidized proteins and lipids, alterations in membrane micro-
environment and structure, as well as alteration in calcium buffering ability and an 
increase vulnerability of neurotransmitter receptors to oxidative stress, may 
28 ADAPT trial had to be stopped early, due to possible negative side effect of two painkillers ; naproxen 
and celecoxib.
29 Oxidative stress is defined as imbalance between the production of reactive oxygen species (ROS) and 
the defense antioxidant mechanism for removing ROS.  
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facilitate the formation of ROS [JOSEPH et al 2005].
Compared to other organs, the human brain is believed to have relatively reduced 
capacity for cellular regeneration. A high proportion of easily oxidizable 
polyunsaturated fatty acids in neuron's membrane and its high rate of oxygen 
utilization make neuron prone to oxidation process [CHRISTEN 2000]. Moreover, 
redox-active transition metal ions are abundantly present and there are also a 
critical decline in endogenous antioxidant production [JOSEPH et al 2005]
[BUTTERFIELD et al 2002].  In the brain, oxidative stress manifested as lipid 
peroxidation, protein oxidation, DNA oxidation and mitochondrial abnormalities, 
they all are related with free radicals formation in its process [ZANA et al 2007].  
These oxidative events seem to be target specific. The nitration of tyrosine30 
within the  α-synuclein protein is found to accumulate in the Lewy bodies in 
Parkinson Disease, and within the tau protein in Alzheimer's disease. Moreover, 
the affected brain regions showed a reduced activity of antioxidant enzymes such 
as superoxide dismutase (SOD), catalase, glutathione peroxidase (GSHPx) and 
glutathione reductase (GSHRd) [ANDERSEN 2004].
The ability of cells to counteract oxidative stress seems to decline with age, this 
may contribute to beta amyloid protein buildup in the brain of elderly with 
Alzheimer's disease [ANDERSEN 2004]. Increased oxidation of mitochondrial 
DNA, protein oxidation  and lipid peroxidation have been observed in the elderly 
brain, with and without AD, but they seem to be more marked in the AD brain. End 
products of lipid peroxidation,such as  malondialdehyd, peroxynitrite, carbonyls, 
advanced glycosylation end products, superoxide dismutase-1 and heme 
oxygenase -1 , are found within the AD brain, especially in neurofibrillary tangles 
[CHRISTEN 2000]. 
30 Protein nitration is a marker of protein oxidation. 
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In animal experiment, the increased deposition of beta amyloid induces production 
of superoxide, which then in turn may triggers the synthesis of other oxygen 
species, the sequestration31 of nitric oxide (NO), and impairment of membrane 
calcium pumps and enhancement of calcium influx through glutamate receptor 
[MATTSON and CHAN 2003]. 
But recently, evidence suggests that the formation beta amyloid and 
neurofibrillatory tangles may be  parts of the protective response against oxidative 
stress [MAMELAK 2007] [PERRY et al 2002]. At physiological concentrations, beta 
amyloid has been shown to have a neuroprotective and antioxidant properties, 
thus beta amyloid generation is postulated to be aimed to reduce oxidative stress, 
prevent apoptosis, and promote tissue degeneration [MAMELAK 2007] 
[ROTTKAMP et al 2001]. This may explain, why beta amyloid is not toxic as a 
whole substance. Aggregated amyloid species is produced when energy shortage 
and calcium dysregulation alters amyloid metabolism [ROTTKAMP et al 2001].   
The role of oxidative stress in the pathology of dementia is still a matter of debate. 
It may act either as the primary initiation event of neuronal injury or as the 
intermediate event that potentiate the cell damage. Recent studies conclude some 
events leading to the generation of reactive oxygen species and their interactions 
(Illustration 4). Beta amyloid accumulation, glial inflammation and mitochondrial 
dysfunction are associated with the production of free radicals [ANDERSEN 2004].
31 Sequestration of nitric oxide molecules may impair NO-dependent dilatations. 
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Considering oxidative stress as an important event in neuron degeneration, 
reducing brain vulnerability to oxidative stress or inhibition of this reaction may 
serve as an effective approach in prevention and therapy of dementia. Indeed, the 
oxidative stress induced by beta amyloid can be completely abrogated in mice 
experiment with antioxidant therapy [HAMEL et al 2008]. 
Nutrition may be utilized as source of antioxidants, supplementation of vitamin E in 
combination with vitamin C at high dose, may be beneficial to prevent 
neurodegeneration [ZANDI et al 2004]. The protective effect of antioxidant 
vitamins and its limitations have been investigated in various studies and will be 
discussed later in the next chapter. 
Other condition, that may induce oxidative stress in the brain is hyper-
Illustration 4: ROS production in the cycle of events leading to 
neurodegeneration [ANDERSEN 2004]
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homocysteinemia. In animal experiment and human culture brain cells, 
homocysteine is toxic to neuronal cells and potentiate the effect of beta amyloid, 
as they both induce calcium influx and oxidative stress leading to cell's apoptosis 
[PEI et al 2001]. Moreover, homocysteine is reported to modulate copper toxicity, 
by enhancing the generation of  hydrogen peroxide [WHITE et al 2001], 
Elevated level of plasma homocysteine is usually accompanied by low folate and 
cobalamine level, since they are all involved in one-carbon metabolism32. The 
folate metabolism may provide an epigenetic link between nutritional intake and 
the development of neurodegenerative illnesses. Deficiencies of folate and 
cobalamine intake with food, but also gene polymorphisms in enzymes regulating 
homocysteine may increase plasma homocysteine level, thus disturbing the 
production of S-adenosyl methionin (SAM), an important methylating agent for 
various functions in cell. In vitro, disturbance in homocysteine metabolism 
increases the  production of S-adenosylhomocysteine (SAH) and results in 
reduced methylation of protein phosphatase 2A (PP2A), by inhibiting PP2A 
methyltransferase (PPMT). Reduced PP2A methylation is associated with the 
accumulation of phosphorylated tau. On the other hand, incubation of neuron with 
SAM enhance PP2A methylation, thus resulting  neuroprotective effect  [SONTAG 
et al 2007].
Membrane lipid peroxidation may have a role in the impairment of glucose 
transport by beta amyloid peptide. The product of lipid peroxidation, 4-
hydroxynonenal, tends to conjugate with the neuronal glucose transport protein 
GLUT 3, thus impairs glucose uptake into the cells. When glucose uptake is 
compromised, cellular ATP level decreases, preceding neuron degeneration 
[MARK et al 1997].
32 More about one-carbon metabolism and methylation process in chapter 3.
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2.5.5. Toxin hypothesis
Dementia symptoms can be shown by kidney failure patients, who are exposed to 
aluminum through dialysis machines. It is then postulated that higher aluminum 
consumption, for example through drinking water, may increase the risk of 
cognitive decline. People with kidney failure are most vulnerable, since aluminum 
elimination is less than people with healthy kidneys, and thus may accumulate in 
the body. Recent studies have shown there is insufficient evidence to cite 
aluminum as the direct cause of dementia, since concentration of aluminum in the 
AD brain is little or absence  [LANDSBERG et al 1992]. 
On the contrary, the level of zinc is significantly increased  in an AD-affected cortex 
[RELIGA et al 2006]. Redox reactive metals such as copper and iron are also 
believed to play a role in neurodegeneration. They are reported to accumulate in 
the brain of people with AD and may promote generation of reactive oxygen 
species by amyloid peptide [WHITE et al 2001]. 
Environmental toxins seem to play an important role in the development of 
Parkinson's disease (PD). Occupational exposure to manganese and some 
pesticides such as rotanone and paraquat are suspected to trigger the 
neurodegeneration of brain cells by causing mitochondrial dysfunction 
[GREENAMYRE et al 2003]. 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is another chemical 
substance known to cause symptom of Parkinson's disorder. MPTP is a protoxin 
that can cross blood brain barrier and  is metabolized to form  1-methyl-4-
phenylpyridinium (MPP+ )  ion. MPP+ is then actively transported into dopamine 
neurons, where it inhibits respirations at the level of complex I in mitochondria 
[GREENAMYRE et al 2003]. 
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In experiments with rats, insecticide rotenone causes the death of dopaminergic 
neurons in substantia nigra and thereby inducing parkinsonian syndromes. Like 
MPP+ ion, rotanone inhibits complex I enzyme in electron transport chain, resulting 
systemic mitochondrial dysfunction [BETARBET et al 2006]. Complex I inhibition is 
uniformly happened throughout the brain and the rest of the body, but dopamine 
neurons of substantia nigra are particularly sensitive to this defect 
[GREENAMYRE et al 2003].
Data from epidemiological studies have constantly shown, that pesticide exposure 
is associated with Parkinson's disease in dose and time-dependent manner 
[BROWN et al 2006] [HANCOCK et al 2008] [ELBAZ et al 2009]. A significant 
positive association was  observed if the pesticides being used for long period 
(>10years)  or in a large dose [BROWN et al 2006].  At current knowledge, there 
are enough evidences to associate a long-term pesticide exposure to Parkinson's 
disease, but insufficient for causal relationship [BROWN et al 2006].
2.5.6. Psychosocial hypothesis
A higher level of education has been thought to act as a protective factor against 
dementia. Indeed, according to some studies, people with higher education have 
delayed the onset of disease, but deterioration of cognitive function after onset is 
more rapid than people with less education  [HALL et al 2007]. Furthermore, 
Snowdon et al (2000) have found an association between writing style and the 
occurrence of AD. Low linguistic ability in early life may lead to a higher risk of 
susceptibility of developing AD in old age [SNOWDON et al 2000].
Another psychological factor could be depression, elderly people with a depressed 
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mood have more risk of developing Alzheimer Dementia [DEVANAND et al 1996], 
but it still not clear whether depression is a risk factor or an early sign of changes 
in brain. Inflammation of brain tissue during depression might play a role in the 
onset of dementia [SACZYNKSI et al 2010].   
Socioeconomic conditions such as poverty, affect the risk of developing dementia 
indirectly, since  it could be responsible for poor nutrition in childhood as well as 
limited educational opportunities both of which may be instrumental in the 
development of dementia in later life. 
Physical activity is regarded as a protective factor against dementia, although 
some studies have been unable to demonstrate a direct link between exercise and 
dementia, one benefit would be a reduction in the risk of cardiovascular diseases. 
People who exercise tend to be more socially active, which can enhance cognitive 
function, which is beneficial in terms of prevention as well as therapy treatments 
[HEYN et al 2004]. Furthermore, activities that have mental, physical or social 
components might have a preventive effect on dementia [FRATIGLIONI 2004]. 
2.6. Diagnosis
Early diagnosis of dementia is very desirable ; it may decelerate the progression of 
the illness, through medication and planning for future since the patients are still 
able to make decisions for themselves. The patient's history, physical examination, 
laboratory test and psychiatric evaluation are crucial to differentiate dementia from 
other dementia-like conditions. 
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In practice, neuropsychiatric symptoms are identified using screening instruments. 
Test like MMSE33,  MOCA34, clock drawing test, TFDD Test35 , DemTec36 could 
measure memory, language, orientation, visuospatial skills, concentration, and 
executive functioning. Some tests may have limitations in sensitivity and the ability 
to determine the severity of symptoms thus a combination of multiple tests is 
advised.  
There is a range of electronic diagnostic imaging tools available now, such as 
Magnetic Resonance Imaging, Single-photon Emission Computed Tomography, 
Positron Emission Tomography and Computed Tomography, which provide 
visualization on structural or physical changes in brain neurons, thus identifying 
the severity of disease. EEG37 may help to differentiate brain disorder from 
delirium or depression, as the AD brain has slow wave. 
 
Measuring the concentration of beta amyloid, total tau and hyperphosphorylated 
tau in cerebrospinal fluid may give a clue about initial damage to brain neurons 
and therefore allow the early detection of dementia. Although acquiring these 
biomarkers requires invasive and uncomfortable procedures, this method has high 
sensitivity and selectivity.
33 Mini-Mental State Examination
34 Montreal cognitive assessment
35 TFDD is german abbreviation , it stands for "Test zur Früherkennung von Demenz mit 
Depressionabgrenzung",  early identification of dementia in dissociation from depression
36 DemTec is Dementia Detection Test
37 Electroencephalography is an instrument to measure brain wave activity.
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2.7. Therapy and treatment
Medication
Since dementia cannot be healed, medication could only therefore slow the 
progression of the disease. In people with AD, deficiencies in the brain cholinergic 
system and of other neurotransmitters38 are present, thus drugs such as 
cholinesterase inhibitors39 (donepezil, galantamine and rivastigmine) and 
glutamate regulator40 (memantine) could help the improvement of cognitive 
symptoms. Serotonin reuptake inhibitors (SSRIs)  may help lighten depression, a 
symptom that often occurs during the disease's progress.
Some studies suggest a supplement of high dose vitamin E might slow 
progression of Alzheimer's disease [SANO et al 1997], while others  postulate that 
vitamin E may have an adverse effect and thus a higher risk of mortality [ISAAC et 
al 2008]. Neither hormonal treatment with estrogen nor use of anti-inflammatory 
agents can have a beneficial effect on symptoms of Alzheimer's dementia 
[SHUMAKER et al 2003]. 
Managing the vascular risk factor may also help decelerate the progression of 
VaD,  statins to lower cholesterol level, maintaining blood pressure, blood sugar 
and the homocysteine level may prevent future strokes.
Antipsychotic medication dispensed to alleviate behavioral symptoms, such as 
anxiety, agitation, aggression and hallucinations, may have undesirable side effect 
namely an increased risk of death [WANG et al 2005] and therefore should be 
38 Other than acetylcholin and glutamate,  norepinephrine, serotonin, somatostatin, and corticotrophin-
releasing factors are also decline in AD brain.
39 Cholinesterase is a catabolic enzyme that breaks down acetylcholin to cholin and acetate group. Inhibiting 
this enzyme would result in an increased level of acetylcholin in brain. This drug is usually used in the 
early to moderate stage of AD.
40 In the case of AD, glutamate receptor (NMDA) is overactive. Memantine, which  usually used in the 
moderate to severe stage of dementia, is NDA antagonist.
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used with careful consideration. Pharmacological treatment of sleep disturbance 
should be applied only if other therapies have failed. 
Psychosocial Therapies
The American Psychiatric Association (2007) Guidelines for Treatment of Patients 
with Alzheimer's Disease and other dementias classifies nonpharmacological 
interventions into 4 categories:
– behavior-oriented approaches
– emotion oriented (reminiscence therapy, validation therapy, supportive 
psychotherapy, sensory integration, and simulated-presence therapy)
– stimulation oriented (recreational activities, music or dance therapies, 
exercise, aromatherapy)
– cognition oriented (reality orientation, cognitive retraining, skills training)
Although researches into long-term efficacy of psychosocial therapies are limited, 
a positive effect of behavior might be observed on sensory stimulation or music 
therapies [GODDAER and ABRAHAM 1994].
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3. Nutrients associated with central nervous system disturbance 
Neurodegenerative diseases such as Alzheimer's or Parkinson's disease are not 
considered nutrition-related diseases. However, neurological and psychological 
symptoms have long been associated with nutrient imbalance41. Researches in the 
last decade seem to support the notion, that nutritional factors may be important to 
prevent  neuron degeneration. 
To date, it is still unclear of how nutrition may affect neuronal cell death. Neurons 
needs nutrients to assure their functions, namely to transmit and process electrical 
and chemical signals, a chronic severe nutrient deficiency or excess may present 
symptoms of brain disturbance.  
Indeed, nutritional status of elderly with dementia is significantly different from 
healthy elderly. Low serum levels of vitamin B12, vitamin E, vitamin C, folate as 
well as the condition of hyperhomocysteinaemia (which can be caused by B-group 
vitamin deficiencies) are observed in dementia patients in clinical studies and 
these factors have been associated with an increased risk of AD [SCHELTENS 
2009]. 
Scientists are still unsure, if nutritional deficiency is one of the risk factors for 
developing dementia or one consequence from neuronal cell defect. Either way, 
evidences show that some nutrient-related metabolic pathways, such as oxidative 
stress, lipid peroxidation, mitochondrial dysfunction, glucose transport system and 
abnormal methylation process, may be involved in protein misfolding and 
aggregation, the hallmark of Alzheimer's disease. In cell cultures, these events can 
be affected with nutritional intervention. Studies have already showed promising 
results with antioxidants, ω-3 fatty acids and homocysteine-related vitamins. As a 
41 One of the classical symptoms of pellagra, a disease caused by the chronic deficiency of niacin, is 
dementia.
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modifiable risk factor, nutrition may be able to play the key role in the prevention of 
cognitive decline.
Nutrition, cardiovascular diseases and neurodegenerative diseases
Considering the strong relationship between nutrition and cardiovascular diseases, 
even if nutrients do not affect neuron degeneration directly, they may influence the 
development of dementia through vascular-related risk factors. The case of 
vascular dementia show that integrity of vascular system is essential for the 
functioning of the brain [KALARIA 2010].  Based on this fact, the current dietary 
recommendations to prevent dementia are the same with those to maintain a 
healthy heart [MORRIS 2011].  Either from vascular or neurodegenerative 
mechanisms , or both, increasing evidence is supporting the relevance of nutrition 
in the prevention of dementia.  
Nutrition and the brain's transport systems
On current knowledge, there are 2 pathways for nutrients to enter the brain, either 
from blood through blood-brain barrier or through the choroid plexus of the blood-
cerebral spinal fluid barrier by mechanisms of facilitated diffusion, active transport, 
binding receptors and ion channels. To ensure the brain high rate of nutrient 
turnover, these complex transport systems and physiological mechanisms have 
homeostatic functions, which transport less into the brain when plasma levels are 
high and vice versa [MORRIS 2011].  
Data show a connection between disturbances in nutrients transport and neurons 
degeneration. Such as the glucose transport systems, which facilitated glucose 
passage across neurons' membrane, the membrane transporter proteins GLUT 1 
and GLUT 3 were found to be decreased in AD brain . This impairment in glucose 
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metabolism may lead to hyper-phosphorylation of tau protein by down-regulating 
the tau O-GlcNAcylation42 [LIU et al 2008]. The same condition of the decreased 
GLUT 3 level also found at a bigger extent in the brain of diabetes type 2 patients, 
which may explain why diabetes is one risk factor for AD [LIU  et al 2009]. 
The brain glucose utilization is only one example of how nutrient being processed 
in a long complex pathway before getting utilized in the brain. The process of 
nutrient breakdown, absorption, transportation and utilization depend on many 
enzymes, metabolites, and other components of cells that continuously interact 
with each other. That considered, nutrition can not be the sole cause nor solution 
for dementia related diseases. Interplay between genetic disposition with nutrient 
and   environmental exposure, is postulated to be mediated by epigenetic43 
mechanism. 
Epigenetic approach 
Like many chronic diseases, the most common form of AD (late onset Alzheimer's 
disease) do not follow Mendelian hereditary rules of genetic. Environmental 
exposure, occurring at specific stage of development e.g. during gestation, may 
increase illness' susceptibility. Epigenetics is defined as the heritable, but 
reversible, regulation of various genomic functions that occur independently of the 
DNA sequence [SMITH and MILL 2010]. Changes in gene expression and cellular 
phenotype are caused by non-genetic factor, without changing DNA gene 
sequence. Environmental changes, such as exposure to toxins, stress and 
nutrients deprivation during important phase of life, may lead to epigenetic 
42 O-GlcNAcylation is a type of protein O-glycosylation by which the monosaccharide β-N-
acetylglucosamine (GlcNAc) attaches to serine/threonine residues via an O-linked glycosidic bond [LIU 
et al 2004].
43 Epigenetics literally means “above genetics”, the term is born from the understanding, that above the 
DNA sequence there is a second layer of information (the epigenome) that regulates genomic functions, 
including where and where genes are turned on or off [SMITH and MILL 2010]. 
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modifications [IRAOLA-GUZMÁN et al 2011]. 
Epigenetic mechanisms that might affect the functioning of genes are e.g. 
nucleosome positioning, post-translational histone modifications, the action of 
small RNAs, and DNA methylation44. Altered in methylation has been proposed to 
explain the relationship between elevated level of plasma homocysteine and the 
development of neurodegenerative diseases  [IRAOLA-GUZMÁN et al 2011].  
3.1. Homocysteine and one-carbon metabolism
 
Elevated plasma homocysteine level has been proposed to be one of the risk 
factors for Alzheimer's disease [ZHUO et al 2011]. Homocysteine is a sulfur-
containing non protein amino acid, produced in the methionine cycle, which is 
known as one-carbon metabolism. This biochemical pathway is regulated by 
folate, vitamin B12 and vitamin B6, and leads to the production of S-adenosyl 
methionine (Illustration 5).
Being catalyzed by methionine synthase (MTR), which requires vitamin B12 as 
cofactor ,  5-MTHF from dietary folate transfers a methyl group to homocysteine, 
forming methionine and tetrahydrofolate (THF). Methionine is then converted to S-
adenosylmethionine (SAM), which serves as an universal methyl donor for various 
biological acceptors, such as DNA, RNA, proteins, neurotransmitters and 
phospholipids. After demethylation, SAM generates S-adenosylhomocysteine 
(SAH). The reversible hydrolysis of SAH leads to the formation of homocysteine. 
44 DNA methylation is a process of which S-adenosylmethionine (SAM) transfers a methyl group to the 
fifth carbon position of the cytosine pyrimidine ring base of a cytosine-guanine dinucliotide (CpG) and is 
catalyzed by DNA- methyltransferase (DNMTs).
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DHFdihydrofolate ; THF tetrahydrofolate ; MTHFR methylenetetrahydrofolate reductase ; MTHFD1 
methylenetetrahydrofolate dyhydrogenase ; MTR methionine synthase ; MTRR methionine synthase 
reductase ; SAM S-adenosylmethionine ;dUMP uracil ; dTMP thymine 
Illustration 5: One-carbon metabolism [FURNESS et al 2008]
Illustration 
6: 2 pathways of homocysteine conversion in one-carbon metabolism [ZHUO et al  
2011]
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Depends on methionine level, homocysteine is processed in two pathways; it is 
converted either to cysteine through trans-sulfuration pathway or remethylated to 
form methionine. When methionine levels are low, homocysteine is remethylated 
by the vitamin B12-dependent enzyme methionine synthase (MS). When 
methionine levels are high, homocysteine is condensed with serine into 
cystathionine in a reaction catalyzed by the vitamin B6-dependent enzyme, 
cystathionine beta synthase (CBS) [FUSO and SCARPA 2011]. Cystathionine then 
can be utilized to form glutathione (GSH)45, which is an antioxidant peptide 
compound.  
3.1.1. Methylation and chronic diseases
Methylation reactions is believed to have an important role in the pathology of 
many chronic diseases. In the brain, products of this methylation reactions are 
include neurotransmitters catecholamine, indoleamine, phospholipids and myelin, 
with SAM acts as an universal methyl donor. 
Alternative methylation pathway in liver is betaine-dependent methyl transfer, 
which catalyzed by betaine-homocystein methyltransferase (BHMT). In this methyl 
transfer, dietary cholin is used as a substrate instead of folate [MEDINA et al 
2001]. This pathway occurs mainly in liver and kidney, while the brain depends on 
folate-dependent methylation to eliminate homocysteine excess. 
Disturbance in this biochemical pathways may lead to accumulation of 
homocysteine and SAH, decreasing SAM level and in turn reducing DNA 
methylation. This hypomethylation is believed to play a role in the 
45 Glutathione is an antioxidant compound, it consists of 3 peptides: cystein, glycin,glutamic acid.
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neurodegenerative process [MEDINA et al 2001]. 
3.1.2. Hyperhomocysteinemia and neurons degeneration
The elevated plasma homocysteine is a risk factor for coronary artery diseases 
such as atherosclerosis and stroke. In the development of dementia and 
Alzheimer's disease, hyperhomocysteinemia is also a strong independent risk 
factor [SESHADRI et al 2002].  A systematic review showed, that when compared 
to healthy elderly, AD patients usually have high plasma homocysteine level in 
plasma and cerebrospinal fluid, but a decrease in folate and cobalamine plasma 
level [VAN DAM and VAN GOOL 2009] [CLARKE et al 1998]. 
Result from animal studies show the neurotoxic property of homocysteine, a direct 
injection into the rat's brain results in an increased beta amyloid level and tau 
phosphorylation, enhancing neuronal degeneration. In rat hippocampal neurons, 
homocysteine induces cell's apoptosis. The breaking of DNA strands, activation of 
poly-ADP-ribose polymerase and NAD depletion occurs rapidly after exposure to 
homocysteine, causing mitochondrial dysfunction, oxidative stress, and caspase46 
activation [KRUMAN et al 2000] .
Some authors suggested that the association of increased serum level of 
homocysteine and low folic acid with cognitive impairment in old age is likely to be 
a consequence of neurodegenerative disease and not a contributory cause 
[MOOIJAART et al 2005]. However, some studies propose several potential 
mechanisms, by which homocysteine may cause neurodegeneration in AD, such 
as oxidative stress, demethylation, cerebrovascular damage, endoplasmic 
reticulum stress, beta amyloid elevation and tau protein phosphorylation [ZHUO et 
46 The caspase is a cysteine-aspartic protease, an enzyme that play an essential roles in cell's apoptosis, 
necrosis and inflammation.
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al 2011]. 
Moreover, homocysteine may promote oxidative stress by generating the 
formation of superoxide and hydrogen peroxide, or by reducing the antioxidant 
activity of glutathione (GSH), thus provoke the calcium influx and neurons 
apoptosis [HOGG 1999].
In the state of hyperhomocysteinemia, the  production of S-adenosyl 
homocysteine (SAH) in the methylation reactions of one-carbon metabolism 
(Illustration 5) is elevated, increasing inhibition of DNA methyltransferase (DNMTs) 
[HULTBERG et al 2000]. Conversely, S-adenosylmethionine (SAM) level is 
depleted, thus resulting an overall decrease in cellular methylation [CAUDILL et al 
2001]. Some authors argue, that the decreased SAM/SAH ratio47 produce more 
critical damage than the increase of homocysteine concentration [ULREY et al 
2005]. High SAH level and depleted SAM may demethylate the promoters of 
BACE-1 and presenilin 1, enhancing enzymatic activity of the secretases48 and 
resulting in an increase in beta amyloid formation [SCARPA et al 2003]. Moreover, 
SAM activate the enzyme cysthathione beta synthase (CBS) and increase its 
activity about threefold. Low SAM concentration may lower CBS activity, thus 
directing homocysteine towards the transmethylation pathway and lesser 
glutathione production [SCARPA et al 2006]. Elevated homocysteine level may 
also support tau hyperphosphorylation. Demethylation of protein phosphatase-2A 
(PP2A)49 cause a decrease in PP2A activity, resulting in tau hyperphosphorylation 
and neurofibrillatory tangles formation [SONTAG et al 2007][WANG et al 2007]. 
47 SAM/SAH ratio is also known as methylation potential.
48 In the pathogenese of AD,  ß-amyloid production from APP is regulated by the balance between 
secretases enzyme activities. APP is processed by γ- and α-secretases to non-amyloidogenic peptides, 
while γ- and β-secretases produce toxic aggregated amyloid beta fragments. 
49  Phosphorylation of tau protein in the brain is regulated by a set of kinases and phosphatases.Several 
enzymes that regulate tau phosphorylation are glycogen synthase kinase 3ß (GSK3ß), phosphatidyl 
nositol 3-kinase (PI3K), mitogen-activated protein kinase (MAP). 
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Renal dysfunction, genetic polymorphisms50 of the enzymes correlated with folate 
metabolism, and B vitamins deficiencies are some conditions that may lead to 
elevated homocysteine level [KASOHA 2010]. Lowering homocysteine level is 
believed to have beneficial effect for cognitive function, this may be achieved 
through B vitamins intake.
3.1.3. Role of nutrients in one-carbon metabolism
Nutrients can affect the progress of one-carbon metabolism through its function as 
the supply of metabolites (i.e. SAM, folic acid and B vitamins), also as elements to 
modify the DNA methyltransferase (DNMT) activity directly (selenium, cadmium 
and nickel) [SCARPA et al 2006].
Folate, cobalamine and vitamin B6 have an important role as cofactor of enzymes 
in one-carbon metabolism. Since these vitamins are derived from dietary source, 
chronic deficiencies may cause disturbance of methylation process, and in turn 
induce neurodegeneration. Recent data shows that B vitamins deficiencies may 
lead to epigenetic modifications and subsequent deregulation of disease's related 
genes. In the culture medium of neuroblastoma cell, deprivation of cobalamine and 
folate increases beta amyloid production [FUSO et al 2005] and feeding mice with 
B-vitamin-deficient diet induces hyperhomocysteinemia and caused 
neurodegeneration [TROEN et al 2008].
50Polymorphisms in the genes coding for folate metabolism are investigated as AD risk factor. These genes 
are methylenetetrahydrofolate reductase (MTHFR), reduced folate carrier-1 (RFC1), methionine synthase 
(MTR), and cystathionine ß-synthase (CBS).   
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3.1.4. Homocysteine, folate, cobalamine plasma levels and cognitive 
functions
Indeed, plasma level of B vitamins from elderly subject with Alzheimer's Disease is 
often deficient. A systematic review from 22 studies concludes, that folate and 
cobalamine level of AD subjects is significantly lower  than the control group. 
Although there is little data found for vitamin B6,  but 2 available studies recently 
conclude that there is no difference in vitamin B6 plasma level of elderly with 
dementia compared to control healthy subjects [COPPEDÈ 2010] [LOVATI 2007].
Elevated homocysteine level is associated with poor performance of cognitive 
functions of nondemented elderly population in some case control studies 
[SOLFRIZZI et al 2006][RAVAGLIA et al 2003]. The result from the large 
prospective Framingham community study confirmed, that hyperhomocysteinemia 
may double the risk of developing dementia. Thus, some authors conclude that the 
increased level of homocysteine may precede the onset of dementia and it is a 
strong, independent risk factor for the development of dementia and AD 
[SESHADRI et al 2002]. 
Accordingly51, plasma folate and cobalamin levels are associated with cognitive 
performance. High plasma folate is associated with better cognitive function and 
better performance on tests of psychomotor speed, although in some studies this 
relation is independent of  homocysteine concentration [DE LAU et al 2007].
The results from National Health and Nutrition Examination Survey (NHANES) 
indicate the strong relationship between folate and vitamin B12 status. When 
cobalamin  status is normal, a high serum folate is associated with the protection 
from cognitive deterioration. But the combination of low cobalamin status with high 
51 Plasma folate has an inverse correlation with plasma homocysteine level.
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serum folate is related to anemia and cognitive impairment  [SELHUB et al 2007]. 
Consistent with this finding, among the persons with low cobalamin status, high 
homocysteine levels are found at both very low and very high serum folate levels. 
The reason  why folate excess may interfere with cobalamin metabolism and 
cause hyperhomocysteinemia is still unclear. One theory postulates that folate 
may act as an oxidizing agent and accelerate the rate of oxidation of methionine 
synthase cob(I)alamin to methionine synthase cob(II)alamin or it may oxidize 
vitamin B12 to form a free radical thus inactivating methionine synthase [SELHUB 
et al 2007].
Aside from its function as coenzym in remethylation reaction of homocysteine to 
methionine, vitamin B12 also plays an key role in the isomerization of L-
methylmalonyl-CoA to succinyl-CoA through the enzyme methylmalonyl-CoA 
mutase (MCM) in mitochondria. Cobalamin deficiency may cause the block in this 
isomerization reaction and result in methylmalonic acid (MMA) accumulation. 
Increased methylmalonic acid (MMA) concentrations often occurs in early stages 
of cobalamin deficiency before the decrease in plasma vitamin B12, thus 
researches regard this to be early and specific indicators of functional vitamin B12 
deficiency [KLEE 2000]. 
The decreased level of vitamin B status may not merely due to poor nutrient intake 
only, but also disturbance in B vitamins absorption and utilization52 [FIORAVANTI 
et al 1997]. Atrophic gastritis limits the bioavailability of folate and cobalamine and 
cause a change in gastric emptying, lower secretion of intrinsic factor, impair the 
52 Other reasons for vitamin B12 deficiency are diseases such as pernicious anemia, colibacteria, tapeworm, 
or exocrine pancreas insufficiency, postgastrectomy states, hypochlorhydria, and altered peptic ability to 
impair cobalamin uptake. Moreover, resection of terminal ileum or infl ammatory bowel disease, sprue, 
coeliac disease or other abnormalities of the ileum may also result in B12  deficiency [WAHLIN et al 
2001].
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acid secretion in the stomach and resulted in impaired release of vitamin B12 from 
food proteins and peptides. Bacterial overgrowth in stomach may also increased 
pH level53 and thus support malabsorption of these vitamins [SELHUB et al 2000].
3.1.5. Supplementation and dietary intervention to treat 
hyperhomocysteinemia and improve cognitive function
Epidemiology studies show that toxic effect of elevated plasma homocysteine 
occur over years, therefore the short duration of trials perhaps do not long enough 
to identify beneficial effect of homocysteine lowering therapy [BOTTIGLIERI 2005]. 
Cognitive impairment may indicate that the progression of neurons damage had 
occurred so severe that it is impossible to be cured by simple vitamin intake. 
Nevertheless, considering the neurotoxicity of high plasma homocysteine level, 
intervention with high intake of homocysteine-lowering vitamins may reduce the 
risk or even prevent the onset of dementia, improve the cognitive function in 
elderly people and, at some point, may reverse the deleterious effect of 
hyperhomocysteinemia if initiated early in life. Reducing plasma homocysteine 
level may be achieved through supplementation and dietary intake of folate, 
cobalamine and vitamin B6. SAM and betaine have also been proved to lower 
homocysteine. 
53 Folate is optimally absorbed at pH 6,3, atrophic gastritis normally increase intestinal pH. 
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3.1.6. Folic acid, cobalamine and vitamin B6 
Effectiveness of supplementation with a high dose of folic acid, vitamin B6 and B12 
to lower hyperhomocyssteinemia has been showed in some studies [SELHUB et 
al 2000]. Patients with elevated plasma homocysteine and mild-moderate 
dementia improved cognitive function with higher test scores after vitamin 
substitution, while demented patients with normal plasma homocysteine did not 
improve clinically in the test [NILSSON et al 2001]. Another randomized, double-
blind controlled clinical trial on 409 individuals with mild to moderate AD showed 
that folic acid and B vitamins supplementation had no beneficial effect on the 
cognitive function, although they were effective in reducing the high homocysteine 
levels. The trial used 1000 μg of folate, 500 μg of vitamin B12, and 10 mg of 
vitamin B6 and was conducted for 2 years [MC MAHON et al 2006]. The short 
duration of the trial may limit the result to point out the effect of long term treatment 
[AISEN et al 2008]. 
As described above, folate supplementation should consider total homocysteine 
(tHcy)  and methylmalonic acid (MMA) concentration in the plasma, since both 
tHcy and MMA are two functional indicators of vitamin B12 tissue status. Excessive 
folate intake through supplementation among the group of vitamin B12 deficient 
subjects may have adverse effect in lowering homocysteine.
Moreover, it seems that there is a threshold effect in the relationship between folic 
acid and plasma homocysteine concentration, above a certain dosage of 
supplementation, there is no additional effect on lowering homocysteine [DEL 
PARIGI 2006]. The minimum dosage of folate capable to reduce circulating 
homocysteine for about 25% is 0.8mg/day [WALD et al 2001] or 0.4mg/day [VAN 
OORT et al 2003].
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3.1.7. Betaine supplementation
Betaine (trimethylglycine), like folate, serves as methyl donor and has plasma 
homocysteine lowering effect. The reaction converts homocysteine to methionine 
by the enzyme betaine-homocysteine methyltransferase (BHMT). Low plasma 
betaine level is associated with high fasting plasma homocysteine concentrations 
and vice versa  [MELSE-BOONSTRA et al 2005]. 
Both remethylation pathways, namely folate-related and betaine-related 
methylation, may be interrelated, even though betaine methylation mainly occurs 
in kidney and liver. A choline deficient diet for 2 weeks decreases the hepatic folate 
concentration in rats, and a folate deficient diet result in depleted hepatic choline 
content. This suggests, that the limitation of one pathway may increase 
remethylation reaction via other pathway [MELSE-BOONSTRA et al 2005], thus 
making both pathways have significant role in controlling homocysteine level. 
The betaine pathway may be more important in metabolizing homocysteine after a 
mealtime, due to its location in liver, while folate pathway may be crucial in 
maintaining fasting plasma homocysteine [CHIUVE 2007]. Supporting this theory 
is the evidence that betaine can lower homocysteine level after a methionine load, 
while folate substitution has no effect [STEENGE et al 2003]. On the other hand, 
fasting homocysteine level is decreased more by folate supplementation [VAN 
OORT et al 2003].
In the clinical setting, dose of >6g betaine per day is used to lower plasma 
homocysteine in patients with genetic defects in homocysteine metabolism. In 
healthy subject, the dose of 6g/d betaine decreases fasting plasma homocysteine 
by 10-15% and postmethionine loading plasma homocysteine by 40%  [OLTHOF 
et al 2003]. Further, Olthof et al show that supplementation at the dose of 1,5g/d is 
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already effective to lower fasting plasma homocysteine.
In the body, betaine may be obtained from its precursor choline or from the diet. 
High dose supplementation of 2,6g/d choline in form of phosphatidylcholine in 
intervention trials, results in lower plasma homocysteine concentration in healthy 
subjects with mildly elevated plasma homocysteine [OLTHOF et al 2005]. Choline 
is then converted irreversibly into betain in liver and kidney by the enzyme choline 
oxidase.
According to Chiuve et al, who investigated 1477 women from NHS (Nurses' 
Health Study) , daily median intake of betaine and choline from dietary sources are 
323 and 189 mg respectively, which may be too low to derive homocysteine 
lowering effect [CHIUVE et al 2007] .  
3.1.8. S- adenosylmethionine supplementation
Evidence seem to support the protective effect of S-adenosyl methionine (SAM) 
against neurodegeneration. Decreased SAM level has been found in cerebrospinal 
fluid of Alzheimer's and depressed patients, also in post-mortem Alzheimers brain 
tissue [BOTTIGLIERI et al 1990]. 
The administration of SAM in human neuroblastoma cell line, results in 
downregulation of beta amyloid peptide production by inactivating the secretases 
through PSEN1 silencing [FUSO et al 2005]. 
Animal experiment using transgenic mice with genetically modified apoliprotein E 
(ApoE -/-) deficiency shows that supplementation of SAM results in a decrease of 
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oxidative damage by stimulating glutathione (GSH) system54 [TCHANTCHOU et al 
2005].  These transgenic mice undergo a more severe oxidative damage and 
cognitive impairment on low- folate diet than normal mice. They also display an 
elevated GSH level in brain tissue, possibly showing an impairment in the 
utilization of GSH [SHEA et al 2002]. Supplementation with SAM in ApoE -/- mice 
with folate deprived diet results in the restoration of glutathion S-transferase (GST) 
activity, reduced glutathione synthase (GS) transcription and reduced GSH levels 
to the level like those of normal  mice feed with complete diet. This result prove, 
how diet may affect and support the remethylation reaction of critical gene 
expression, making genetic predisposition less harmful or delay [TCHANTCHOU 
et al 2005].
Interestingly, both control and ApoE -/- mice when fed with folate deficient diet, 
show a reduced SAM level in the brain, but yet normal mice do not show 
symptoms of neuropathology.  Since ApoE -/- mice has a significant increase of S-
adenosyl homocysteine (SAH), a decrease of the SAM/SAH ratio may inhibit GST 
activity in the brain, leading to more severe oxidative damage despite of excess 
antioxidant glutathione [TCHANTCHOU et al 2005].
Evidence from human trials is also promising. An epidemiological study shows, 
that test person's cognitive function is better in the group with higher SAM/SAH 
ratio [OBEID et al 2009].  Intervention study with small subject numbers (n=4) of 
Alzheimer's patients during 3-5 months trial with the dose of 400mg SAM 3 times 
daily, results in an increased plasma and CSF SAM concentrations and improved 
cognitive function, mood and speed of mental processing [BOTTGLIERI et al 
1990]. On the other hand, another study shows no effect of 200mg-400mg/d 
intravenous SAM administration, although study duration of 2 weeks is considered 
too short to draw conclusion [COHEN et al 1988]. 
54 SAM has a role in methylating substrates for GSH-dependent enzymes. 
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Recent small trial involving 7 AD subjects provide 1200mg oral SAM supplement 
daily for 12 weeks. Slight improvement of cognition tests  is observed in all 
subjects, two improved moderately and none worsened in cognition nor behavior.  
moderate improvement of cognitive function after SAM intake [RUDOLPH et al 
2011]. 
SAM is apparently well tolerated and has been used to treat depression  and 
arthritis [MISCHOULON und FAVA 2002]. It holds a potential as therapeutic 
approach to prevent or delay progression of AD. 
To date, there is still no data on humans that correlates either folate and 
homocysteine plasma status or brain SAM level, to the methylation profile of 
specific AD gene in the brain [COPPEDE 2010]. Research in this area is 
important, to clarify, whether or not epigenetic modifications are reversible and 
could be modulated through nutrients intake such as SAM and folate.
3.2. Thiamine
The connection between a chronic deficiency of thiamine and dementia symptoms 
can be seen in Wernicke- Korsakoff syndrome55. In the case of alcohol dementia, 
high dose administration of thiamine can reverse the neurological symptoms,  thus 
understanding the mechanism of how thiamine  induces neuronal damage may 
give a hope for the treatment of neurodegenerative diseases. 
55 Wernicke-Korsakoff syndrome is a dementia caused by chronic and excessive alcohol consumption. 
Plasma thiamine level  is usually decreased in the group of alcohol dementia patients.
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Alcohol and reduced intestinal resorption are risk factors for thiamine deficiency. 
Alcohol seems to reduce thiamine phosphorylation to thiaminepyrophosphat 
(TPP)56 in brain. TPP is a cofactor for many  enzymes, such as transketolase, 
pyruvate dehydrogenase complex (PDHC) and α-ketoglutarate dehydrogenase 
(αKGDH). These enzymes are involved in carbohydrates57 and energy58 
metabolism, biosynthesis of neurotransmitters and also for the production of 
reducing equivalents used against free radicals [DROR et al 2010] [SINGLETON 
and MARTIN 2001]. 
There are indications, that the activity of these enzymes are reduced in thiamine 
deficiency and in neurodegenerative disorders, especially αKGDH [DROR et al 
2010][BUBBER et al 2004]. In the brain of the thiamine deficient (TD) animal 
model, reductions of αKGDH are associated with a decreased aspartate, 
glutamate and  γ-aminobutyric acid (GABA) but increased alanine level 
[BUTTERWORTH 1989].  Decreased activity of TPP-related enzymes may cause 
disturbance in brain glucose metabolism, energy shortage, mitochondrial 
dysfunctions and chronic oxidative stress  [ZHANG et al 2011]. 
In relation with plaque formation, thiamine deficiency in wild type mice induces 
accumulation of cluster of dystrophic neurites, but without the morphology of 
amyloid plaque. Instead of amyloid plaques, the center of lesions are formed from 
necrotic debris [CALINGASAN et al 1995]. Moreover, accelerated beta amyloid 
production by promoting the activity of  ß-secretase is observed in transgenic 
micel model [ZHANG et al 2011]. 
56 As a coenzym in catabolic metabolism,  thiamine exists in 3 forms in the body, free thiamine, 
     thiaminetriphophat (TTP) , thiaminepyrophosphat (TPP) and thiaminemonophosphat (TMP).
57 In cytosol, the enzyme transketolase is involved in pentose phosphate pathway, generating the sugars 
deoxyribose and ribose.
58 PDH and αKGDH are mitochondrial enzymes, that involved in producing ATP , a major energy source for 
the cell. 
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Human trials result in concordance with animal experiment.  A study of 38 elderly 
found that, the blood level of thiamine, TPP and TMP in AD patients are lower 
compared to the control group [GLASO et al 2004]. The TPP-dependent enzymes, 
αKGDH and transketolase, are found to have a decreased activity in the brain, 
while the levels of free thiamine and TMP are still normal, suggesting that TPP 
production may be impaired in the Alzheimer's brain rather than thiamine 
deficiency [MASTROGIACOMA et al 1996]. 
In animal models, administration of thiamine has successfully reverse TD-induced 
beta amyloid accumulation [ZHANG et al 2011], but the results of studies 
investigating the effect of thiamine supplementation on human AD patients are 
inconsistent. Mild beneficial effect was shown from one study with 3-8g thiamine 
per day  [MEADOR et al 1993], while another study with 100 mg/d thiamine 
tetrahydrofurfuryl disulfide for 12 weeks found little effect [MIMORI et al 1996]. In 
contrast, a longer interventional study showed effect at all with 3g/d thiamine over 
12 months [NOLAN et al 1991]. 
Considering the importance of thiamine in glucose and energy yielding 
metabolism, having sufficient thiamine status would be desirable, but the 
deficiency seems not only because of insufficient thiamine intake. Half of elderly is 
considered thiamine deficient, although consumed more than daily 
recommendation59 [NICHOLS and BASU 1994]. Moreover, thiamine resorption 
decreases with age and single oral dose of thiamine higher than 2.5 to 5mg are 
largely unabsorbed [LU'O'NG and NGUYÊN 2011], suggesting that 
supplementation alone is ineffective to maintain sufficient thiamine status and 
activity of thiamine-dependent enzymes.  
59 In D-A-CH reference values , thiamin's recommended daily intake for elderly is 1mg/d.
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Interestingly, dietary restriction60 attenuates neurodegeneration in thiamine 
deficient (TD) mice [CALINGASAN and GIBSON 2000]. Oxidative stress seems to 
play the key role in the selective loss of neurons during TD and caloric restriction61 
protects neurons by inducing a low level stress, which then enhances free radical 
scavengers that protect neuron.
How far diet influences thiamine homeostasis in the case of neurodegenerative 
diseases will be an exciting area of research in the future.
3.3. Niacin 
Dementia is one of the symptoms of pellagra62, a disease caused by severe niacin 
deficiency, suggesting a possible correlation of dementia with this nutrient. Niacin63 
or vitamin B3 is a collective term for nicotinic acid and nicotinamid. Nicotinic acid, 
nicotinamide and the newly identified nicotinamide ribose are salvageable64 
precursors of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine 
dinucleotide phosphate (NADP), which serve as coenzymes for many oxidation-
reduction reactions [AMANULLAH and SEEBER 2010] and as substrate for NAD+ 
consuming enzymes [BOGAN and BRENNER 2008]. In addition, amino acid 
60 In this study, diet is restricted gradually up to 60% of ad libitum intake. 
61 More about the effect of caloric restriction on modulation of oxidative stress will be described in the 
antioxidant sub-chapter.  
62 Symptoms of pellagra are dermatitis, diarrhea and dementia. Dementia usually presents in the last stage, 
in the form of confusion, hallucinations, psychosis, memory loss, apathy and depression. Untreated, 
pellagra may lead to death.
63 Niacin is an abbreviation of nicotinic acid vitamin, this term is made to differentiate nicotinic acid with 
nicotine in tobacco.
64 Salvage pathway is the opposite of de novo synthesis, where complex molecules are synthetized from 
simple ones. Salvageable molecules undergo a recycling reaction, in which degraded substances are used 
to form or recover the starting material, e.g. in nucleotide metabolisms.
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tryptophan65 may also be converted to NAD through de novo pathway, which 
requires vitamin B2  and B6
66 as coenzymes. 
Conversions of tryptophan, nicotinic acid, nicotinamide or nicotinamide ribose to 
NAD involve different biosynthetic pathways, which explain why each of them has 
different physiological and effects. Nicotinamide for example, does not reduce 
cholesterol nor cause skin flushing if consumed in high doses, where nicotinic acid 
does. 
Nicotinic acid
Nicotinic acid in pharmacological dose67 of 1,5g/d to  6g/d has been used to lower 
total cholesterol level, LDL, TG and increase HDL levels, thus lower the risk of 
atherosclerosis. Since increased cholesterol level is one of the risk factor of 
developing Alzheimer's, nicotinic acid may prevent cognitive deterioration through 
its function as cholesterol-lowering agent thus improving cardiovascular risk factor.
 
As the reason why nicotinic acid improves cholesterol level may be because the 
requirement for elevated NAD+ biosynthesis depends on sirtuin68, whose function 
is inhibited by nicotinamide  [BOGAN and BRENNER 2008]. 
Nicotinamide
At the cellular level, nicotinamide functions include enhancing energy metabolism, 
activating protein kinase B and inhibit poly(ADP-ribose)polymerases (PARPs) and 
65 60 mg tryptophan is equal to 1mg niacin equivalent.
66 Increased demand of vitamin B6, e.g. from anti-tubercolosis medications such as isozianid 
andpyrazinamide, inhibit the conversion of tryptohan to niacin thus may lead to deficiency.
67 High dose of niacin has been reported to cause reddening of the skin, known as  flushing, as well as dry 
skin and skin rashes. 
68 Sirtuins are  protein, which functions as enzymes for histone acetylation and ADP ribosylation reaction.
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sirtuins [YING 2007].
In mice model of Alzheimer's disease, Green et al observes, that nicotinamide 
does not affect beta amyloid pathology, but inhibits brain sirtuin (SirT2) 
deacetylation and therefore increase acetylated  α-tubulin level in the brain. A high 
acetylated α-tubulin concentration is associated with increased microtubule 
stability [GREEN et al 2008].  Furthermore, nicotinamide significantly reduce 
Thr231-phosphotau69 level.  Phosphorylation of tau at Thr231 marks the tau 
protein for degradation, preventing its aggregation and accumulation.  
In cognitive tests, nicotinamide-treated mice are observed to have improved 
spatial learning skills and restore short and long term memory. But molecular and 
cognitive effect of nicotinamide only occurs to mice with mild to moderate 
pathology. In the late stage, where aggregation and accumulation of tau has 
occured, nicotinamide has no effect in removing Thr231-phosphotau  [GREEN et 
al 2008]. Moreover, nicotinamide regulates the activity of NAD+  consuming 
enzymes, by its role as NAD+  precursor and by direct enzyme inhibition  [BOGAN 
and BRENNER 2008].
Beneficial effects of niacin derivates are postulated to be related to NAD+ 
biosynthesis, since it has essential roles as hydride donor and acceptor in many 
redox70 reactions of biological processes, such as energy production, synthesis of 
fatty acids, cholesterol and steroids. And recently, enzyme mediated and non-
redox functions of NAD+  have been discovered. Mitochondrial functions, calcium 
homeostasis, gene expression, DNA repairment, apoptosis, antioxidative reactions 
and neurotransmission are influenced by the activity of NAD+ (Illustration 7). 
69 Thr-231 phosphotau affects microtubule polymeration and its concentration in CSF is used as biomarker 
for AD [CHO and JOHNSON 2004]. 
70 Oxidation reduction.
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Illustration 7: Biological process and pathways mediated by nicotinamide adenine  
dinucleotide [YING 2007].
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NAD+  is utilized by the enzyme sirtuins, particularly SIRT171,  as a substrate to 
catalyze deacetylation of histone72. This reaction releases nicotinamide and forms 
a metabolite 2'-O-acetyl-(ADP) ribose as well as a deacetylated lysine product. 
Overexpression of sirtuin genes (silent information regulator two protein)  is also 
postulated to be responsible for lifespan extension in caloric restricted diet 
[GUARENTE and PICARD 2005].
Human studies also support the findings from animal studies about the protective 
effect of niacin on development of AD and cognitive decline. A prospective study 
from Morris et al  of 3718 elderly, showed that the consumption of niacin may 
decrease the risk of Alzheimer's disease. Niacin intake from food and 
supplements, niacin intake from foods only and tryptophan intake are inversely 
associated with incident of AD. Moreover, higher intake of niacin from foods is 
associated with slower annual rate of cognitive decline [MORRIS et al 2004]. 
Another randomized controlled trial with 26 AD subjects investigated the 
supplementation of 10mg stabilized oral NADH per day during 6 months period. 
The result showed a significantly higher scores on cognitive test in the intervention 
group, and better performance on verbal fluency, visual constructional ability and 
abstract verbal reasoning when compared to placebo. But there is no differences 
in measures of attention, memory and in clinical dementia rating  [DEMARIN et al 
2004].
Considering its important role in various biological metabolisms, niacin may 
present another possible approach of epigenetic modification to prevent 
neurodegeneration. 
71 There are 7 family members of sirtuins identified in human;SIRT1 to SIRT7. 
72 Histone acetylation and histone deacetylation reaction, which removes acetyl group from lysine residues 
within protein, regulates chromatin condensation and gene transcription involving the histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) as key enzymes. One of HDACs class, 
namely silent information regulator two (Sir2) is NAD+ dependent. 
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3.4. Lipids: Cholesterol, ω-3 fatty acids and phospholipid 
3.4.1. Cholesterol
Brain is an organ with the highest cholesterol content in the body. Almost 25% of 
the unesterified cholesterol present in the plasma membranes of glial cells, 
neurons, and in the specialized membranes of myelin [DIETSCHY and TURLEY 
2001].  In CNS, cholesterol is required for the synthesis of neuron synapses and 
myelin sheath, regulation of neuronal membrane plasticity and also the regulation 
of the membrane bound enzymes, receptors and ion channels [MATHEW et al 
2011].
The first link between cholesterol and AD come from the observation, that allele ε4 
of the Apolipoprotein E (ApoE) is a risk factor for the disease. ApoE is the main 
cholesterol transport protein in the brain, that coordinate the mobilization and 
redistribution of cholesterol and phospholipids in central nervous system. Although 
the exact mechanism of how cholesterol may influence the development of 
neurodegenerative diseases is still inconclusive, recent researches conclude that 
there may be a disturbance in the cholesterol homeostasis, which is maintained by 
the balance between cholesterol transport (by ApoE/ApoE receptor pathway), 
cholesterol synthesis (by HMGR73 pathway) and cholesterol elimination from the 
brain. 
Altered cholesterol homeostasis can modulate beta amyloid production and 
accumulation [PATEL and FORMAN 2004].  High brain cholesterol level is showed 
to increase the amount of beta amyloid generation in vitro [EHEHALT et al 2003]. 
But other study found that moderate cholesterol reduction in hippocampal neurons 
results in the enhancement of APP-ß-cleavage and beta amyloid production 
73  HMGR is 3-hydroxy-3-methylglutaryl coenzym A reductase
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[ABAD-RODRIGUEZ et al 2004].  Apparently, the distribution of cholesterol in 
plasma membrane is more important than total cholesterol level  [BURNS et al 
2006].
The reason why Aβ production is sensitive to cholesterol levels is, because the 
activity of β- and γ-secretase complexes are very dependent on cholesterol 
metabolism [WOLOZIN 2004]. Cholesterol binds to APP at the alpha secretase 
cleavage site, thus favoring ß-secretase activity and leading to increased 
production of beta amyloid [YAO and PAPADOPOULOS 2002]. Thus inhibiting 
cholesterol synthesis through cholesterol-lowering medications is thought to 
reduce Aß production.
Indeed, epidemiological data showed that there was up to a 70% lower prevalence 
and incidence of AD in subjects taking statins, a cholesterol-lowering drug [JICK et 
al 2000]. This result lead to the assumption , that high plasma cholesterol level 
predisposes for AD, and therefore lowering circulating cholesterol level may lead 
to a reduced risk of AD. 
But the mechanism of how  high plasma cholesterol may influence cellular 
cholesterol level and affect the development of neurodegenerative diseases, is still 
unknown. Experiment in rabbits showed that brain cholesterol level is not affected 
by increased dietary cholesterol [GHRIBI et al 2006]. This may be due to 
incapability of plasma cholesterol to cross blood brain barrier [PFIEGER et al 
2003]. Brain cholesterol is synthesized in situ from glial cells, and thus 
independent from variations that occur in plasma level [LEDESMA and DOTTI 
2006].
If cholesterol level in brain does not affected by blood plasma cholesterol, then 
how hypercholesterolemia become a risk factor for AD? Ledesma and Dotti 
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assume, that high cholesterol plasma level may lead to AD through a secondary 
event, such as poor oxygenation of the brain due to cholesterol-clogged blood 
vessels. Subsequently, statins would reduce pathology of AD not because of the 
inhibition of cholesterol brain synthesis nor the reduction of the amount of 
periphreral blood cholesterol reaching the brain, but because of the overall 
improvement of peripheral and cerebral circulation and its anti-inflammatory 
property [LEDESMA and DOTTI 2006].
3.4.2. Fat intake – the role of dietary fats in AD
In animal experiments, high cholesterol diet is associated with higher amyloid 
disposition [MATHEW et al 2011] [SHIE et al 2002],  intraneuronal accumulation of 
hyperphosphorylated tau [RAHMAN et al 2005] and decreased relative cerebral 
blood volume74 (rCBV) [HOOIJMANS et al 2009], suggesting a connection of 
dietary fats with the neurodegeneration in AD. Although the exact mechanisms are 
still uncertain, at least dietary fats intake has an influence on plasma cholesterol 
level, since diets with a high ratio of saturated fat to polyunsaturated or 
monounsaturated fats have been proved to lead to a poor plasma cholesterol 
profile [MORRIS 2009]. 
Three prospective studies in Chicago, New York and Rotterdam reported a 
connection between fats intake and the incident of Alzheimer's disease. In the 
Chicago Health and Aging Project (CHAP), Morris and colleagues conclude that 
intakes of saturated fat and trans-unsaturated fat were positively associated with 
the risk of Alzheimer's disease, while intakes of ω-6 polyunsaturated fatty acid and 
monounsaturated fatty acid were inversely associated . Further, according to this 
study, total fat, animal fat and dietary cholesterol were not correlated with the 
74 Relative cerebral blood volume 
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development of Alzheimer's disease [MORRIS et al 2003].
The New York study by Luchsinger et al found evidence of a greater risk of AD in 
subjects with higher intakes of total fat and saturated fat and either homozygous or 
heterozygous for the ApoE ε4 allele, but no evidence found of an association with 
the intake of polyunsaturated fat [LUCHSINGER et al 2002]. 
In the Rotterdam Study, the risk of AD increased with higher intake of total fat, 
saturated fat and cholesterol after 2 years of follow-up [KALMIJN et al 1997], but 
after 6years of follow-up, none of dietary fats was associated with AD 
[ENGELHART et al 2002]. Results from Italian Longitudinal Study on Aging 
reported the potential of monounsaturated and polyunsaturated fatty acids to 
prevent cognitive decline [SOLFRIZZI et al 2006].
Although data from human studies are unclear , whether or which dietary fats 
affect cognitive function in older age, studies from animal experiments and cell 
culture seem to support the role of lipids in pathology of neurodegenerative 
diseases.
3.4.3. Polyunsaturated fatty acids (PUFAs)
Neuron membranes are rich in polyunsaturated fatty acids (PUFAs), including the 
ω-3 fatty acid docosahexaenoic acid (DHA) and ω-6 fatty acid arachidonic acid 
(AA). In the central nervous system, PUFAs play an important role in the structural 
and functional maintenance of neuronal membranes, neurotransmission and 
eucosanoid biosynthesis, as well as the maintenance of membrane fluidity, 
modulation of ion channels, receptors and ATPases. The composition of these 
fatty acids in brain's membrane seems to reflect that of the dietary source 
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[HOOIJMANS and KILIAAN 2008] [YOUDIM et al 2000].  
Arachidonic acid (AA)
Arachidonic acid (AA) belongs to the group of ω-6 fatty acids. Through its 
metabolites prostaglandins, thromboxanes and leukotriene,  AA is a mediator of 
inflammatory pathways. Results from cell culture and animal experiment 
suggested , that AA and its metabolites are involved in the production of beta 
amyloid, thus affect the pathogenesis of AD. Mice supplemented with 2% AA 
showed higher levels of amyloid plaques in the brain [AMTUL et al 2011].
Docosahexaenoic acid (DHA) 
In vitro and in animal models, DHA has been shown to exert neuroprotective, 
antioxidant, antiinflammatory and beta-amyloid-reducing activities [COLE and 
FRAUTSCHY 2010]. 
But in human studies the link between dietary intake of fish or DHA and  the risk of 
dementia including AD is less consistent. A systematic review from 12 studies 
conclude that the results varied greatly, therefore no definitive link could be drawn 
between low DHA intake and loss of cognitive function during aging [PLOURDE et 
al 2007][Maclean et al 2005]. On the other hand, the protective role of fish intake 
against the risk of AD is confirmed in some large prospective studies such as 
CHAP [MORRIS et al 2003], Rotterdam study [KALMIJN et al 1997] and Three 
City study [BARBERGER-GATEAU et al 2007]. Statistically, fish intake has 
stronger association with risk of dementia and AD than DHA intake [CUNNANE et 
al 2011].
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Since lower fish consumption is associated with the risk of AD, one would presume 
that AD patients have a lower blood concentration of DHA, but the data on blood 
parameter of DHA are also inconsistent. Heude et al reported lower plasma DHA 
in AD patients  [HEUDE et al 2003] while other studies mean plasma DHA is not 
different from control subjects [CUNNANE et al 2011]. In the Framingham study, 
high plasma phosphatidylcholine (PC) DHA correlated with 47% risk reduction of 
AD [SCHAEFER et al 2006], and in other study erythrocyte phosphatidylcholine 
DHA is 400% lower in AD patients [SELLEY et al 2007] , leading to an assumption 
that PC DHA may be a stronger predictor of risk reduction as total DHA level 
[COLE and FRAUTSCHY 2010]. Data on brain DHA level in AD patients vary 
considerably, three studies indicate that DHA may be markedly lower in 
hippocampus in AD [CUNNANE et al 2011].
A randomized clinical trial investigated the protective effect of fish consumption for 
primary prevention of AD. A group of 302 healthy elderly received DHA and EPA 
supplement either 1800mg/d or 400mg/d or placebo for 26 weeks. There is no 
difference in any cognitive domain among 3 groups, only ApoE ε4 carrier improved 
with fish oil consumption in cognitive domain of attention [VAN DE REST et al 
2008]. While one smaller study of 49 healthy elderly women supplemented with 
either DHA, with or without lutein, and placebo, resulted in improved verbal fluency 
in DHA group [JOHNSON et al 2008].   
A systematic review of 11 observational studies and 4 clinical trials on AD patients
concludes that ω-3 fatty acids may be effective in slowing cognitive decline for 
elderly without dementia, but is not recommended for those who already 
developed dementia [FOTUHI et al 2009]. In patients with very mild AD, 
supplementation of DHA may have positive effects on cognition [FREUND-LEVI et 
al 2006]. On the other hand, Kotani et al found no benefit of DHA supplementation 
on cognitive function [KOTANI et al 2006].
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Study Design Inclusion 
criteria
ω-3 intake and 
measurement
Outcome 
measures
Results
Etude du 
Viellissement 
Arteriel 
(France)
4-year 
prospective 
cohort study; 
n=246; mean 
age 68
Normal 
volunteers
Measurement 
of erythrocyte 
membrane fatty 
acid content 
(total ω-3 
PUFA, 
ω-3:ω-6 ratio, 
DHA:AA ratio)
Cognitive decline 
measured with 
MMSE score
High proportion of 
plasma ω-3 fatty 
acids level were 
associated with 
41% less cognitive 
decline; results 
were statistically 
significant for DHA 
level and DHA:AA 
ratio, but not EPA 
levels
Chicago 
Health and 
Aging Project 
(USA)
6-year 
prospective 
cohort study; 
n= 3718 ; 
mean age 73
Normal 
cognition
Fish meals per 
week (zero, 
one or two) 
Change in rate 
of global 
cognitive decline 
estimated from 
mixed models
Rate of cognitive 
decline per year 
decreased by 10-
13% among 
subjects who 
consumed one or 
more fish meals per 
week. But the 
benefits of eating 
fish meals could not 
be accounted for by 
the amount of 
dietary DHA or EPA
Zutphen 
Elderly Study 
(The 
Netherlands)
5-year 
prospective 
cohort 
study ; 
n=210 ; 
mean age 75
Men with 
no 
dementia 
Fish 
consumption 
based on FFQ; 
levels of DHA 
and EPA from 
both fish and 
other sources
Cognitive decline 
measured by 
MMSE
A linear trend was 
seen between high 
intake of EPA plus 
DHA and reduced 
5-year cognitive 
decline.  400mg of 
DHA plus EPA per 
day was associated 
with a 1,1-point 
reduction  in 
cognitive decline 
over 5 years
Table 8: Observational studies of the connection between fish consumption or n-3 fatty  
acids and cognitive functions in normal person [FOTUHI et al 2009]
Abbreviations: FFQ = Food Frequency Questionnaire
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Study Design Inclusion 
criteria
ω-3 intake and 
measurement
Outcome 
measures
Results
Terano et al 
1999
12-month 
RCT: n=20 
Elderly 
individuals 
with mild-to-
moderate 
vascular 
dementia 
(MMSE score 
15-22) living 
in a home for 
the elderly
Placebo: no 
supplementatio
n; treatment : 
12 months of 
4,32g DHA/d
Cognitive 
decline 
measured by 
MMSE and 
HDS-R
DHA supplementation 
significantly reduced 
the rate of cognitive 
decline over 3 
months and 6 months 
of follow-up, but not 
over 12 months
Kotani et al 
2006
90-day RCT; 
n=39
Subjects with 
amnesia 
owing to mild 
cognitive 
impairment, 
AD or organic 
brain lesions
Placebo: 90 
days of 240mg 
per day olive 
oil; 
treatment: 
240mg DHA 
and AA per day 
and 6,4mg 
asthaxanthine 
per day
Cognitive 
dysfunction 
measured by 
repeatable 
battery for 
the 
assessment 
of neuro-
psychological 
status
No significant benefit 
for patients with AD; 
patients with organic 
brain lesions showed 
improvement in both 
immediate and 
delayed memory. 
Patients with MCI 
assigned to treatment 
improved their 
attention and 
immediate memory, 
but no change was 
noted in their delayed 
memory
Freund-Levi 
et al 2006 
(OmegAD 
study)
12-month 
RCT; n=174
AD according 
to DSM-IV; 
MMSE score 
15-30; living in 
own home
Placebo: 6 
months of 
placebo 
followed by 6 
months of DHA 
and EPA; 
Treatment : 12 
months of DHA 
and EPA
Cognitive 
decline 
measured by 
MMSE and 
cognitive 
subscale of 
the AD 
assessment 
scale
No statistically 
significant difference 
in MMSE score 
between two groups 
at 6-month and 12-
month time points. 
Statistically significant 
benefit in subgroup of 
patients with very 
mild AD; that is 
MMSE score >27
Van de Rest 
et al 2008 
(MEMO 
study)
26-week 
RCT; n=302
>65 years old 
with MMSE 
score >21; not 
on dementia 
or depression 
medications
DHA-EPA 
400mg or DHA-
EPA 180mg 
versus placebo 
(oil capsule); 
serum DHA and 
EPA 
measurement
Cognitive 
function and 
mental well-
being 
assessed by 
word learning 
test, forward 
and 
backward 
test of the 
Wechsler 
digit span, 
No statistically 
significant change 
was noted in any of 
the cognitive domains 
for either low-dose or 
high-dose fish oil 
supplementation 
compared with 
placebo
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trail making 
test versions 
A and B, 
Stroop color-
word test and 
verbal 
fluency test
Table 9: Clinical trials of the effects of ω-3 fatty acids and either onset of dementia or AD 
or changes in cognitive performance [FOTUHI et al 2009].
These contradicting results may be caused by biological issues. Fish as the 
source of ω-3 PUFAs may be contaminated with heavy metals such as mercury, 
that may be involved in the pathological mechanism of neurodegeneration. 
[MONET-TSCHUDI et al 2006]. Moreover, fish contains not only ω-3 fatty acids, 
other nutrients such as fish protein, selenium and vitamin B12 may also provide 
protective effect against AD, through antioxidative and homocysteine-lowering 
properties [CUNNANE et al 2011]. 
Methodological issues such as the differences in the subtypes, dosage and 
duration in consumption of ω-3 fatty acids or fish, the genetic and environmental 
heterogeneity of subject persons, as well as different measurement and diagnostic 
tools used in the trial may affect the outcome [CUNNANE et al 2011]. 
Future research may also consider intake of another fatty acids in addition to 
DHA , especially ω-6 fatty acids, since their status and functions are strongly 
correlated75. Perhaps is the association of AD with low DHA intake is rather a 
question of too much ω-6 fatty acids consumption [CUNNANE et al 2011]. 
Lowering ω-6 fatty acids intake may modulate the ratio of membranes ω-6:ω-3 
fatty acids, and this ratio is important to maintain normal brain function [HAAG 
2003]. 
75 ω-3 fatty acids DHA and EPA compete with ω-6 fatty acids ARA for the sn-2 position on the membrane 
phospholipids.
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3.4.4. DHA and brain glucose metabolism  
In recent studies, DHA has been shown to have an important role in brain glucose 
utilization. In DHA deficient mice, endothelial and astrocyte GLUT176 at the blood 
brain barrier is decreased, suggesting that glucose transport into the brain is 
disturbed. Evidence from literature pointed that global cerebral metabolic rate for 
glucose (CMRg) is ~20-25% lower in AD, with a more marked difference in some 
cortical regions [CUNNANE et al 2011]. 
Dietary supplementation with DHA increases GLUT 1 expression in rats brain, 
indicating the positive correlation between DHA level and glucose transporter 
expression in the brain [PIFFERI et al 2007]. Since glucose is the main fuel for 
neurons, perturbed glucose transport system may lead to cell's energy deficiency. 
Hypothesis emerges that glucose deficient neurons are forced to use ketone 
bodies as fuel. However, ketogenic response appears to be less efficient in the 
case of glucose intolerance, such as in type 2 diabetes and insulin resistance, 
both predispose to AD [PASQUIER et al 2004]. According to this hypothesis, cell's 
catabolic pathway of gluconeogenesis is the last effort of neurons to obtain fuel. If 
this is true, then increasing brain fuel availability through ketone supplements or 
ketogenic diet, may diminish the risk of further cognitive decline, if implemented 
before symptoms develop [CUNNANE et al 2011]. 
3.4.5. Ketogenic diet 
Ketogenic diet consists of high-fat (up to 80-90% of total energy intake), low-
carbohydrate and adequate protein meals. Low glucose intake forces the liver to 
76 Glucose transporters GLUT1 and GLUT3 are responsible for glucose uptake from blood vessel through 
blood-brain barrier into the brain's neurons. 
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utilize fats and produce ketone bodies such as ß-hydroxybutyrate, acetoacetate 
and acetone, and use them as main energy source. The diet is usually used for 
treating epileptic children, and in most cases this diet is effective to reduce 
seizures [GASIOR et al 2006].
The precise mechanism is still unclear, neuroprotective effect may be the result 
from enhance energy reserves of neurons to withstand metabolic stress. In the 
cellular level, a larger mitochondrial load and a more efficient energy fuel are 
observed in mice brain cell treated with ketogenic diet. Anti-inflammatory and 
antioxidative mechanisms are also postulated as one of the benefits of ketone 
bodies  [GASIOR et al 2006].
In transgenic mice, ketogenic diet high in saturated fat (79%) and very low 
carbohydrate (0,76%) significantly reduce total brain beta amyloid levels by 25% 
[VAN DER AUWERA et al 2005]. The decreased beta amyloid is accompanied by 
weight loss and ketone bodies production. The author conclude, perhaps it was 
not fats in the diet that increases Aß level, but levels of total calories, carbohydrate 
restriction or the metabolic state of the animal. 
In a study by Reger and colleagues, improvement of memory performance in AD 
patients during acute administration of medium-chain triglycerides was positively 
correlated with plasma levels of ß-hydroxybutyrate. Increased plasma ß-
hydroxybutyrate is also observed in ketogenic diet, thus it is expected that 
ketogenic diet would also have beneficial disease-modifying activity in AD [REGER 
et al 2004]. 
At present, evidences are insufficient to conclude that ketogenic diet may be 
beneficial in the case of AD. Further researches and clinical trials are required to 
understand the mechanisms and optimal implementation of the diet that minimize 
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side effect77.
3.4.6. Trans fatty acid (TFA)
High intake of dietary trans fatty acid increases TFA concentration in the brain and 
modify the brain fatty acid profile. Brain DHA concentration is decreased in mice 
fed with 43% TFA of total fatty acids intake, suggesting that TFA may not directly 
involved in pathology of AD [PHIVILAY et al 2009]. In a epidemiological study, TFA 
is positively associated with the risk of AD; individuals consuming ~4,8g TFA/day 
had a fivefold higher relative risk of developing AD than those who ate ~1,8g/day 
of TFA [MORRIS et al 2003]. But in transgenic mice model of AD, TFA does not 
seem to affect the level of beta amyloid , tau protein and synaptic markers 
[PHIVILAY et al 2009]
In conclusion, available data suggests that fats composition in the diet may have 
an important role to maintain proper brain function and prevent the pathogenesis 
of Alzheimer's disease. Since fats are consumed in combination with other 
nutrients in the diet, interaction of fats with other fatty acids and other nutrients 
such as antioxidants may be more effective than the intake of one fatty acid alone. 
Whether dietary fats benefit AD patients in early stages and could be implemented 
as part of therapy or not, is still inconclusive. Further research may consider 
macronutrient profile78 on the diet, when examining the effect of dietary fat on 
biological processes  [VAN DER AUWERA et al 2005]. 
77 Due to its high content of fats, ketogenic diet is difficult to maintain, and is associated with adverse 
effects on bone health and liver [FREEMAN et al 2006].
78 Ratio of fat , protein and carbohydrate in the total energy intake.
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3.5. Antioxidants in prevention and treatment of Alzheimer's 
Disease
Evidences indicate that oxidative stress excessively occur in the brain of AD. 
Intake of antioxidants from diet is thought to decrease the deleterious 
consequences of reactive oxygen species (ROS) and has been proposed to 
prevent cognitive decline, also as treatment for MCI and AD  [BEHL and 
MOOSMANN 2002] [MECOCCI and POLIDORI 2011]. 
Antioxidants can be subdivided in enzymatic79 and non-enzymatic forms, direct 
and indirect80 , also endogenous and exogenous  antioxidants. Non-enzymatic 
antioxidants, which are known as free radicals scavengers, such as vitamin C, 
vitamin E, polyphenols, carotenoids, flavonoids have been tested in clinical trials to 
investigate their efficacy for prevention or treatment of AD. 
 
Compounds such as flavonoids in tea (epigallocatechin gallate EGCG), polyphenol 
compounds in wine (resveratrol), curcumin in turmeric, ginkgo extract and other 
phenolic compounds with antioxidative and anti-inflammatory effects, may have 
potential as therapeutics to attenuate or to prevent neurodegeneration.
3.5.1. Antioxidant vitamins
Vitamin E refers to eight different isoforms, which consist of saturated tocopherols 
(α, β, γ, δ) and unsaturated tocotrienols (α, β, γ, δ).  To date, only  α-tocopherol 
has been extensively investigated in randomized clinical trial, although each form 
79 Enzymatic antioxidants are enzymes , such as superoxide dismutase (SOD), catalase and glutathione 
peroxidase, which scavenge and break down free radicals.
80 Chelating agents, which bind metals ion and prevent formation of ROS, are considered indirect 
antioxidants. 
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has unique biological functions, e.g. antioxidative and anti-inflammatory activity, 
also modulating different signalling pathways [REITER et al 2007]. Compared to α-
tocopherol , γ-tocopherol  is more effective in scavenging reactive nitrogen species 
and tocotrienols are more efficient in neutralizing free radicals  [SEN et al 2007]. 
Moreover,  α-tocotrienol seems to attenuate the arachidonic acid cascade leading 
to oxidative brain injury and inhibit the glutamate-induced neurotoxicity by 
modulating phospholipase A2 activity [MANGIALASCHE et al 2011] [KHANNA et 
al 2010].  The neuroprotective effect of vitamin E seems to be related to the 
combination of different forms of tocopherols and tocotrienols. 
High plasma levels of vitamin E is associated with a reduced risk of AD in 
advanced age. Levels of  all forms of vitamin E are lower in the plasma of AD and 
MCI patients when compared with the healthy elderly [MANGIALASCHE et al 
2011] [MORRIS et al 2005], indicating the connection of these vitamins' status with 
pathology of neurodegeneration. 
Vitamin E crosses the blood brain barrier and accumulate at therapeutical levels in 
the central nervous system. At the molecular level, vitamin E is postulated to 
reduce lipid peroxidation and beta amyloid deposition [MECCOCI and POLIDORI 
2011] [SUNG et al 2004]. 
However, the results from observational studies investigating vitamin intake and 
the risk of AD were inconclusive. The Cache County Study [ZANDI et al 2004], the 
Washington-Heights-Inwood Columbia Aging study [LUCHSINGER et al 2003] and 
Women's Health Study showed no benefit nor significant reduction in AD risk. On 
the other hand, the Honolulu-Asia Aging study [MASAKI et al 2000],  the Chicago 
Health and Aging Project [MORRIS et al 2002], the Nurses' Health Study 
[GRODSTEIN et al 2003] and the Rotterdam Study [ENGELHART et al 2002] 
indicating positive correlation between vitamin intake and risk of developing AD. 
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Data about the implementation of vitamins in the treatment of AD is also unclear. 
One randomized double-blind and placebo controlled study from Sano et al, 341 
AD patients were given 2000IU vitamin E in the form of α-tocopherol each day for 
two years. Result showed a delayed AD progression and delayed admission to 
nursing home for vitamin E group, but no effect on MMSE-score [SANO et al 
1997]. In another trial with 769 MCI subjects, Peterson et al indicated that vitamin 
E has neither cognitive effect nor benefit in patients with MCI [PETERSEN et al 
2005].  
Brewer interprets these studies results as unreliable, due to inappropriate dose, 
timing and monotherapy [BREWER 2010]. High dose of antioxidants may have 
adverse effect, according to Miller and colleagues, long-term use of vitamin E 
supplement above 400IU may increase mortality [MILLER et al 2005]. Moreover, 
starting antioxidants therapy in patients with AD may be too late, since neurons is 
already degenerated [BREWER 2010]. The use of monotherapy may be 
insufficient, since α-tocopherol used in many clinical studies only present modest 
protective effect. 
The neuroprotective effect of vitamin E seems to be related to the combination of 
different forms of tocopherols and tocotrienols [MANGIALASCHE et al 2011]. 
Another argument against monotherapy of vitamin is, that vitamin E needs vitamin 
C for antioxidant regeneration. 
A case control study assessed vitamin C intake and compared its plasma level 
among 4 groups of AD patients; namely severe and moderate AD patients within 
community setting, AD patients in hospital and control subjects. Decreased plasma 
vitamin C was found in all AD subjects compared to control, and its reduction was 
in proportion to the degree of cognitive impairment. Interestingly, all the subject 
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persons in this trial took the same quantity of vitamin C, thus the reduction in 
plasma level could not be caused by lower intake [RIVIÈRE et al 1998]. 
Considering the synergic effect of both vitamins, some studies investigate the 
supplementation of vitamin E and C in connection with dementia prevalence. 
Zandi et al found that the combination of vitamin C and E supplements was 
associated with a lower prevalence of dementia [ZANDI et al 2004]. While 
Luchsinger et al showed neither dietary, supplemental, nor total intake of 
carotenes and vitamins C and E was associated with a decreased risk of AD 
[LUCHSINGER et al 2003]. 
3.5.2. Ginkgo biloba
Extract of the ginkgo leaves has been used in alternative medicine to treat 
circulatory problems, asthma, vertigo, fatigue, tinnitus, and cognitive disturbances. 
As a supplement, ginkgo biloba extract (GbE) is usually standardized to contain 
24% ginkgo-flavone glycosides and 6% terpenoids [KELLEY and KNOPMAN 
2008].  
The positive effect of GbE on cognitive functions may be due to its properties  of 
increasing blood supply by dilating blood vessels, reduction in blood viscosity, 
modification of neurotransmitter systems and also reduction in the density of 
oxygen free radicals [BIRKS and GRIMLEY 2009]. 
Several clinical trials have been conducted to investigate the benefit of GbE for 
dementia patients. A randomized placebo-controlled trial enrolled 309 subjects 
with AD or multi infarct dementia (MID), who received 120mg/d GbE for  52-weeks. 
Results showed a modest improvement, which is unlikely to be clinically relevant 
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[LE BARS et al 1997].  
Another randomized controlled study with 513 AD patients as subjects used 
supplementation of 120mg and 240mg ginkgo extract daily for 6 months. There 
were no significant differences between the treatment and control groups. Since 
there was no adverse event reported in many trials, it seems that a high dose of 
GbE is well tolerated [SCHNEIDER et al 2005].
Overall, although some small and short-term clinical trials have shown modest 
improvement in cognitive function, large and well-designed clinical studies proved 
no efficacy of GbE supplementation for AD patients. No long-term data exists yet, 
and current evidence is inconsistent. 
3.5.3. Curcumin
Data from epidemiological study show that India has the lowest prevalence of 
dementia in the world [VAS et al 2001]. Some scientists hypothesize a connection 
of this fact with the usage of spices in Indian diet. Curcumin, a polyphenol 
compound in curry powder turmeric, is thought to be the agent. In vivo, it passes 
the blood-brain barrier and has favorable properties such as antioxidant, anti-
inflammatory, metal chelator, lowering cholesterol and anti-amyloid activity81. 
In animal experiment , mice fed with curcumin showed decreased total microgial 
activity, decreased cerebral levels of oxidized protein and interleukin -1ß82. Low 
dose (160ppm) of curcumin treatment  seemed to decrease insoluble and soluble 
beta amyloid and plaque burden, while high dose (5000ppm) did not show these 
81 Anti amyloid activity would means to protect cells from beta amyloid cell death
82 Proinflammatory cytokine
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effect [LIM et al 2001]. 
A clinical trial of curcumin therapy in AD patients is currently under way and 
preliminary results look promising [SIKORA et al 2010]. In general, curcumin is 
considered safe, even for a dose as high as 8mg/d, because of its poor 
bioavailability. 
Overall, the data regarding supplementation of antioxidants in prevention and 
therapy of cognitive impairment are inconsistent.  Mecocci and Polidori argue that 
low permeability of antioxidants through  blood brain barrier may interfere with 
studies results. Moreover, correct dosage, choice of monotherapy or multiple 
antioxidants, and role of vascular factors should be considered in the studies 
[MECOCCI and POLIDORI 2011]. Positive results from observational studies may 
be due the synergic effect from combination between antioxidants with other 
nutrients in the diet, such as polyunsaturated fatty acids. Healthy diet rich in 
antioxidants compounds from fruits, vegetables, beverages and spices may be 
effective to prevent cognitive decline, if started early in life, before 
neurodegeneration occur [BREWER 2010].
3.5.4. Role of Metals in neuron degeneration
Some metals are suspected of playing a role in the pathogenesis of AD. In the 
brain of AD patients, metals such as aluminum, copper, iron, zinc are present in 
significant amounts compared to a healthy brain. They may act as catalysts for the 
production of free radicals [CHRISTEN 2000]. 
81
Illustration 8: Hypothesis of how aluminum, iron, copper and zinc may involved  in the 
pathogenesis of Alzheimer's Disease [KAWAHARA 2011].
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Questions arise on how and why these metals accumulate in the brain of AD, also 
how these metals cross the blood-brain barrier. Copper, iron and zinc are dietary 
minerals, the human body requires these trace elements in small quantities as co-
factor for many enzymes. Perhaps a disturbance of the metals' homeostasis or 
absorption of  detrimental metals with no known biological function may  alter the 
balance and lead to neurological disorders  [DUCE and BUSH 2010].
Studies from animal experiment and cell cultures has clarified the connection 
between metals and beta amyloid. From transition metals, beta amyloid can 
generate reactive oxygen species (ROS) radicals and deplete neuronal glutathione 
levels [STRAUSAK et al 2001]. Some studies investigate the effect of some 
chelating agents, which bind metals ion and prevent formation of ROS and 
therefore considered indirect antioxidants.
3.5.5. Aluminum
The connection between aluminum and AD was first proposed in 1965 by Klatzo et 
al. Their experiment reported, that the injection of aluminum salt into a rabbit's 
brain might degenerate neurofibrille and induce the formation of NFT [KLATZO et 
al 1965]. Autopsies showed that aluminum concentration is higher in the brain of 
AD patients, to be exact in the degenerating neurons in hippocampus, when 
compared to a normal healthy brain.
Symptoms similar to AD could be observed by residents of Camelford83, who drank 
high levels84 of aluminum sulphate from drinking water in 1988. Autopsy results 
83 In Camelford, UK, July 1988,  aluminum sulphate accidentally contaminated drinking water supply, and 
caused adverse health effects. 
84 Aluminum concentration found in water was 50-300 times greater than the acceptable limit concentration 
admissible by European Community.
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from one resident who  died due to a rare form of beta amyloid-angiopathy85, 
showed a high level of aluminum in her brain up to 23 µg86 per gram dry weight 
brain tissue [ALTMANN et al 1999]. Also in PAQUID cohort study, the prevalence 
of AD and cognitive decline were higher in residents with high level of aluminum 
intake [RONDEAU 2009].  
Mechanism of how exactly aluminum affect neuronal death is still not yet fully 
understood, aluminum may increase oxidative stress and stimulate iron-induced 
lipid peroxidation, thus accelerate the pathological process  [CHRISTEN 2000].
Aluminum's relation to other minerals is also interesting. Aluminum enters the 
brain through the blood brain barrier with transferrin-mediated transport [FARRAR 
et al 1990]. Silica is known to counteract aluminum absorption in the 
gastrointestinal tract and thus decrease its bioavailability [RONDEAU 2009]. 
3.5.6. Copper
Copper is suspected to cause or at least to play an important role in pathogenesis 
of Alzheimer's disease. Substances that are associated with AD; such as beta 
amyloid, APP, ß-secretase, tau protein; they all bind copper. Moreover, two risk 
factors for AD, apoE ε4 and homocystein also interact with copper [BREWER 
2009]. 
85 Beta amyloid angiopathy is a disease, in which deposits of amyloid befall walls of  blood vessel of central 
nervous system.
86 A high concentration of aluminum is typical of dialysis-associated encephalopathies, a normal level of 
aluminum in brain is 0-2 micrograms per gram dry weight brain tissue.
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Examination of AD patients shows that they have an elevated free copper level87, 
which may be correlated negatively with cognitive performance in AD patients. 
[SQUITTY 2009]. The level of copper in the brain are affected by amyloid 
precursor protein (APP) expression, and the interaction between copper, APP and 
homocysteine can result in increased free radical generation and 
neurodegeneration [WHITE et al 2001]. 
High copper intake together with a diet high in saturated and trans fatty acids may 
be associated with cognitive decline according to one prospective study [MORRIS 
et al 2006]. The increased level of both cholesterol and copper seems to distress 
the brain. Although the mechanism is still unclear, changes in levels of superoxide 
dismutase, glutathione peroxidase and ceruloplasmin suggest that the 
combination of high cholesterol level and copper may promote oxidative stress, 
thus generate neuronal damage [BUSH et al 2003].
3.5.7. Iron
Iron is an essential metal in maintaining the function of the central nervous system, 
but like copper, iron may also induce the oxidative stress in neurons by forming 
free hydroxyl radicals. Two enzymatic indicators of cellular oxidative stress ; heme 
oxygenase (HO-1) and NADPH oxidase, seem to be activated in post mortem 
analysis of  AD patients brain [TAKEDA et al 2000]. 
Accumulation of iron, transferrin and ferritin have been found in the brains of AD 
patients within specific brain regions, displaying selective vulnerability to 
neurodegeneration and their distribution matched the distribution of amyloid 
87 Copper is found in 2 forms in blood,  one is bound to ceruloplasmin and other is rather loosely bound to 
albumin and small molecules in blood.
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plaque and NFT [Bartzokis et al 2004] [SMITH et al 1997]. Evidence suggests that 
metabolism of iron is disturbed in brain of AD, perhaps due to genetic alterations 
specific to iron management protein88.  Mutation in haemochromatosis89 (HFE) 
protein has been linked with increased oxidative stress and severity of AD [BRAAK 
et al 1993] [PULLIAM et al 2003]. Its expression is induces in cells associated with 
neuritic plaques [CONNOR et al 2001]. Experiment in vitro shows, that iron is 
required for beta amyloid toxicity. The deletion of iron or inclusion of iron chelator 
reduce toxicity of beta amyloid [ROTTKAMP et al 2001], suggesting that iron may 
play an important role in the pathology of neurodegenerative diseases [MANDEL 
et al 2007]. 
3.5.8. Zinc
In the brain, zinc is bound to metalloprotein of neurons and glial cells. Its function 
is not yet fully understood, but it could act as a neurotransmitter or 
neuromodulator. Zinc may participate in glutamate storage, release and uptake , 
and in modulation of glutamatergic receptors [TAKEDA 2000]. 
In animal experiments, high zinc concentration is shown to be neurotoxic. Zinc 
binds to beta amyloid and the bond between zinc and APP may change functional 
features of APP and may promote aggregation of beta amyloid protein 
[CHRISTEN 2000]. The mechanism may be through changes in the key proteins, 
such as zinc transporter protein ZnT-6, responsible for the maintenance of zinc 
homeostasis in the early development of Alzheimer's disease [FERRY and 
ROUSSEL 2011]. Studies also found, that total tissue zinc is increased in several 
88 Iron-binding protein and iron regulatory protein (IRPs) such as transferrin, ferritin, IRP1 and IRP2, are 
involved in iron homeostasis and storage. 
89 Haemochromatosis is an iron overload condition, mostly hereditary. 
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brain regions of post mortem AD patients, suggesting that abnormal zinc 
metabolism may contribute to the development of AD [CUAJUNGCO and FAGET 
2003].
Zinc seems to have detrimental effect if consumed both in excessive and deficient 
dose. Deficiency of zinc could induce decreased taste perception and decreased 
desaturase activity, which may impaired body accumulation of polyunsaturated 
fatty acids [CUNNANE and YANG 1995][WAUBEN et al 1999].
In connection with cognitive function, Ortega et al found a positive correlation 
between zinc and cognitive tests MMSE (Mini-Mental State Examination) and 
PSMQ (Pfeiffer's Mental Status Questionnaire) in 260 Spanish subjects [ORTEGA 
et al 1997]. Although further researchs is needed to confirm the relation between 
zinc and neurodegeneration, adequate intake of zinc seems to be an important 
aspect to maintain good cognitive function, especially since elderly persons are at 
risk for zinc deficiency.
3.5.9.  Heavy metals
Pollutants such as lead and mercury are also suspected of playing a role in the 
neuropathology of dementia. Heavy metals may be involved in the pathological 
process of AD, such as mitochondrial dysfunction, oxidative stress, deregulation of 
protein turnover and brain inflammation. Early exposure in life or accumulation 
during prolonged period may present delayed toxic effect later in older age 
[MONET-TSCHUDI 2006]. 
Methylmercury, a non-toxic and the most common form of mercury in the 
environment, may become neurotoxic under pro-oxidant conditions. As shown in 
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cell culture, mercury and lead may induce glial cell reactivity90, increase the 
expression of the amyloid precursor protein and stimulate the formation of 
insoluble beta amyloid in brain [MONET-TSCHUDI 2006] .
3.6. Caloric Restriction
Luchsinger et al showed that high total calorie and fat intake in individuals 
homozygous or heterozygous for ApoE ε4 allele is associated with higher risk of 
AD [LUCHSINGER et al 2002]. On the other hand, calorie restriction91 (CR) 
without malnutrition has been demonstrated to slow the ageing process and 
extend life span in animal experiment. Dietary restriction may induce mild cellular 
stress response in neurons, as its effects on energy availability. Neurons respond 
to this stress by increasing the production of neutrophic factors protein chaperones 
and antiapoptotic proteins; these protein support cellular resistance to neuron 
degeneration and may stimulate neurogenesis and synaptic plasticity [MATTSON 
2003]. Moreover, caloric restriction is also found to decrease homocysteine and 
insulin92 levels, which would be beneficial to prevent age-related damage to 
cerebral blood vessels. 
90 Reactivity of glial cell indicates brain inflammation.
91 Caloric restriction is defined as a reduction of caloric intake (approximately 20%) compared to ad libitum 
feeding without malnutrition.
92 A high insulin level is associated with a decreased in cognitive and memory function. 
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The condition of CR may modulate fat and carbohydrate metabolism, attenuate 
oxidative damage and activate a stress-induced hormetic response that mediates 
improved vitality and disease resistance [BOGAN and BRENNER 2008]. In vitro, 
when placed in sublethal stress condition, cell increases the metabolism of NAD+ 
in a manner that favors sirtuin93 (SIRT1) activity. CR effect of increased lifespan 
did not occur in sirtuins knockout mice, suggesting that sirtuins is necessary for 
93 There are 7 family members of sirtuins identified in human;SIRT1 to SIRT7. 
Illustration 9: Neuroprotective effect of dietary restriction [MATTSON 2003].
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mediating effect of CR [CHEN et al 2005]. In CR-treated mice, SIRT1 activation 
has been proved to reduce Alzheimer's neuropathology [QIN et al 2006].
In another experiment, a 30% CR in mice model of AD resulted in reduced 
contents of Aß1-40 and Aß1-42 peptides and elevation of α-secretase activity, 
which subsequently may lower amyloid pathology [WANG et al 2005]. In addition, 
there was also a reduction of reactive oxygen species and suppression of 
Monoamine oxidase-B94. 
To date, intervention studies in human subjects are few, but available data seems 
to support the hypothesis that CR may be beneficial to prevent cognitive 
deterioration. One clinical trial with  healthy elderly observed improvement of 
verbal memory after 3 months of 30% caloric reduction. Mechanism underlying 
this effect is perhaps correlated with decreased  fasting plasma levels of insulin, 
reduced inflammatory activity and high sensitive C-reactive protein [WITTE et al 
2009].
Interestingly, intermittent fasting95 seem to result in same physiological benefits as 
CR. In mice, both methods result in reduced serum glucose, improved insulin 
sensitivity and increased resistance of neurons in the brain to excitotoxic stress 
[ANSON et al 2003].
Although calorie restriction is promising in prevention of dementia, it is still too 
early to consider its implementation in human. Questions arise such as the right 
dose at which calorie restriction would not cause adverse effects or the right time96 
to begin CR. 
94 Monoamine oxidase is an enzyme that promote oxidative stress in brain.
95 In this experiment, intermittent fasting-mice are deprived of food for 24 hours every other day.
96 In animal studies, CR should be started early in life, it has no value in prolonging life if it is begun too 
late. 
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If  the dietary restriction theory suggests the reduction of calorie intake to prevent 
neurodegeneration, on the other hand, dementia patients are usually encouraged 
to eat more. They usually lose weight at initial onset, and this condition will get 
worse during the course of disease. Malnutrition is the main nutritional issue 
during the course of AD, and CR may bring more risk than benefit in this group. 
3.7. Dietary patterns associated with decreased risk of AD 
Most knowledge about the development of dementia is based on the role of 
nutrients rather than that of foods. But since individuals do not consume nutrients 
in isolation and meals consist of complex combination of nutrients, implementation 
of this knowledge into the diet may be difficult. An alternative approach is to 
assess dietary patterns and its association with neurodegenerative diseases. 
   
Results from a prospective cohort study with 2148 community-based elderly 
subjects showed, that dietary pattern characterized by high intake of salad 
dressing, nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits, and dark and 
green leafy vegetables and low intake of high-fat dairy, red meat , organ meat and 
butter, are strongly associated with lower risk of AD. The diet in this study is rich in 
ω-3 PUFA, ω-6 PUFA, vitamin E, and folate, but low in saturated fatty acids and 
vitamin B12 [GU et al 2010].
One of the diet emphasizing foods rather than nutrients is Mediterranean diet, 
which has been associated with reduced risk for cardiovascular mortality and 
cancer incidence [SOFI et al 2008]. The relationship between Mediterranean diet 
and brain health has only recently explored.
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Mediterranean diet
Mediterranean diet is characterized by high intakes of vegetables, fruit and nuts, 
legumes, cereals, fish, and monounsaturated fatty acids (MUFA); relatively low 
intakes of meats, dairy products; and moderate alcohol consumption [PANZA et al 
2007]. High consumption of extra-virgin olive oil  is the hallmark of this diet. High 
level of MUFA and polyphenolic compounds in extra-virgin olive oil is postulated to 
protect against cognitive decline [SOLFRIZZI et al 2006]. 
Since the diet is varying considerably across Mediterranean countries, 
“Mediterranean Diet Score” has been developed. The score consists of nine food 
groups characterizing the traditional Mediterranean diet (vegetables, fruits, 
legumes, cereals, the ratio of monounsaturated-to-saturated fatty acid, alcohol and 
fish presumed to be beneficial; while meat and dairy products presumed to be 
detrimental), where a value of 0 or 1 is assigned to each group. Higher score 
indicating closer adherence to  Mediterranean diet [FÉART et al 2010].
To date, only two prospective studies have investigated the relation between 
Mediterranean diet and cognitive function [FÉART et al 2010]. Scarmeas et al 
reported, using data from the Washington Heights-Inwood Columbia Aging Project 
(WHICAP),  a higher adherence to Mediterranean diet is associated with lower 
incidence of dementia and AD [SCARMEAS et al 2006]. Moreover, according to 
the same author, adherence to Mediterranean diet may lower the risk of MCI 
patients to develop AD [FÉART et al 2010] [SCARMEAS et al 2009]. 
Another prospective study used data from Three-City (3C) study, concluded that 
higher adherence of Mediterranean diet was associated with better global 
cognitive performances and episodic memory over time, but there was no 
association between Mediterranean diet's adherence and risk of dementia [FÉART 
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et al 2009].
At first, risk reduction of AD is thought to be mediated by the diet-induced 
beneficial vascular risk factors, but significant association remains in both studies 
after adjusted to vascular variables [FÉART et al 2009] [SCARMEAS et al 2006]. 
This may be explained by the content of antioxidants and anti-inflammatory 
nutrients in the diet [FÉART et al 2010].
Féart et al suggested , the Mediterranean diet would only be efficient and 
beneficial for cognitive function, if implemented at least 5 years before the clinical 
diagnosis of dementia. After that, the neurodegeneration may be too advanced to 
be reversed by diet [FÉART et al 2010].
Perhaps it may not direct effect of specific diet or nutrients that provide the 
protection but a healthy diet and moderate lifestyle in general that protects from 
cognitive decline [PANZA et al 2007]. 
Healthy diet, moderate lifestyle and risk of dementia 
Eating in moderation like in Mediterranean diet has been proved to benefit 
cognition, since dietary excess may influence the development of age-related 
disease. One study compared dietary habits between AD and VaD patients with a 
healthy control group. Results showed that AD and VaD patients had a higher 
energy intake. Major sources of energy were grains and animal fats for the AD 
group, while VaD patients consumed mostly grains. Compared to the healthy 
group, excess intake of ω-6 PUFA and deficiencies of ω-3 PUFA, antioxidants, 
vitamin C, carotene and the vitamin B group were observed  [OTSUKA et al 2002]. 
Another study by Luchsinger et al confirmed the result, that high calorie and fat 
intake may be associated with a higher risk of AD, especially for individuals with 
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ApoE ε4 gene [LUCHSINGER et al 2003]. 
Another study investigating the effect of low carbohydrate diet in elderly with mild 
cognitive impairment (MCI). 23 subjects were assigned for either high or very low 
carbohydrate for 6 weeks. In the low carbohydrate group, improvement in memory 
performance, reduction in weight, reduced waist circumference, as well as 
reduced fasting glucose and fasting insulin were observed [KRIKORIAN et al 
2010].
Small et al conducted a 14-day healthy longevity lifestyle program for MCI 
patients, and found that word fluency and activity of some brain area were 
beneficially affected after the intervention. The diet plan was high in antioxidant 
fruits and vegetables, ω-3 PUFA, low glycemic index carbohydrates. The program 
consist not only of nutritional intervention, but also exercise and cardiovascular 
conditioning to reduce stress [SMALL et al 2006].
In conclusion, food choice and dietary habits together with lifestyle factors are 
likely contribute to the development of neurodegenerative diseases. Antioxidant 
compounds, B-vitamins, ω-3 fatty acids, low caloric and low glycemic index 
carbohydrates diets, have been investigated concerning their involvement in the 
pathology of dementia and AD with contradicting results. However, recent 
evidence seems to confirm the role of nutrition. As a modifiable factor, if 
implemented early in life, a healthy diet may present a potential preventive 
approach against dementia.
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3.8. Researchs limitations
It is difficult to design an experiment to study the connection between one specific 
substance and the development of cognitive impairment, since the pathology of 
dementia in humans may take a long time to develop. Moreover, many factors 
interfere with dietary intake; such as  genetic, lifestyle and synergistic or 
antagonistic effects between nutrients; their interactions may contribute to 
deposition of plaque and NFT.   
The confirmed relationship of nutrients to dementia is mostly based on  cell 
cultures, animal experiments and epidemiological studies. Clinical trials available 
today rarely deliver positive result, bias from selection methods (differences in 
baseline status of the subject persons), dose and forms of nutritional intervention 
used (nutrients from supplementation or diet), assessment methods, duration of 
study etc. make it difficult to interpret the results. Issues and limitations to each of 
these study methods should be considered in data interpretation. 
The animal testing has its limitation in its inability to deliver exact data, since not all 
animals naturally develop tangles and plaques – therefore transgenic97 animal 
models are designed through genetic, biochemical, or dietary manipulations to 
develop AD. Fruit fly, mouse, rabbit, dog, primate species and mice are usually 
used. Difference in gene polymorphisms may cause these animals to produce less 
enzymes that support the production of plaques and tangles. This may make the 
identification of true risk factors difficult, e.g. to make transgenic mice 
overexpressing mutant APP to develop amyloid plaques, endogenous level of APP 
have to be make at least 8-fold, while human already develop AD with 50% 
increase in APP [DUFF and SULEMAN 2004]. 
97 Transgenic animals are animals with genes knocked out, inserted or imported from human genes
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Another example is neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine),  that causes parkinsonism in humans. Rodents are much less 
susceptible to the adverse effect of MPTP. Although there are cell death found in 
the substantia nigra,  but parkinsonian symptoms do not appear like in human. It is 
believed that the lower levels of monoaminooxidase-B  (MAO-B) in the rodent may 
be responsible for this [LANGSTON 2002].
Although results from animal studies may be unreliable, in AD research it is still 
necessary, as it is cheaper and less time consuming than other experimental 
methods. Further, it is an efficient method to investigate biological mechanisms 
involved in the pathology of neurodegenerative diseases.
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4. Malnutrition in dementia 
A good nutritional status is beneficial in supporting therapy, to avoid further 
complication and ensure quality of life for patients with dementia. The negative 
impact of malnutrition will bring further complications such as infections, faster loss 
of independence, and a higher mortality rate. But often, it is difficult to maintain a 
good nutritional status, since people with dementia in all stages lose weight, even 
in the early stages before diagnosis. 
All studies agree that malnutrition brings about adverse health effects. Increased 
vulnerability to infection, delayed wound healing, a decreased rate of drug 
metabolism, impairment of physical and cognitive function, and progressive clinical 
deterioration are some of the complications. Furthermore, malnutrition in the 
elderly seems to be more difficult to correct than in younger adults [ FIATARONE 
et al 1994]. 
Even in healthy elderly people, energy regulation may be impaired. Unlike young 
adults, elderly people tend not to adjust their food intake after periods of over- or 
underfeeding, which makes them more prone to acquiring a negative energy 
balance [ROLLS et al 1995]. 
Overall, undernourishment results in increased morbidity and mortality in the 
elderly together with a decreased quality of life  [JORDAN et al  1999]. The 
consequences of malnutrition are summarized in table10.
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Complications: 
– Pressure sore formation
– Compromised immune functions
– muscle atrophy
– Increased rate of infections
– Longer recuperation periods
– Loss of independence
– Decreased mobility with increased risk of falls and fractures 
– Impairment of the immune system and increased susceptibility to infection
– Increased the risk of institutionalization hospitalizations
– Delayed rehabilitation after acute illnesses
– Reduction in quality of life
– Increased mortality
Table 10: Complications of malnutrition in elderly [HIRSCH 2004]
4.1. Definition of malnutrition in context of elderly with dementia
The word malnutrition may has several indications, such as:
1. undernutrition caused by inadequate food intake
2. overnutrition, resulting from excessive food intake
3. specific nutrient deficiencies
4. imbalance because of disproportionate intake
[KELLER 1993] 
In terms of older people, malnutrition is further characterised with :
1. inadequate food intake and 
2. protein caloric malnutrition (PCM) or protein energy malnutrition (PEM)
[CHEN et al 2001]
Insufficient intake of essential nutrients is assumed to deplete nutrients storage 
and then occur a negative energy balance between quantity (and quality) of food 
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intake and energy expenditure.
Loss of lean body mass and fat tissue is the main characteristic of PCM, which 
clinically is divided into 3 types: marasmus, kwashiorkor, or a mixture of both. In 
the elderly, the latter type is most present.
Marasmus Kwashiorkor
Clinical causes Insufficient calorie intake Insufficient protein intake 
during stress/illness
Clinical 
features
Starved appearance
Weight <80% standard for height
Triceps skin fold <3mm
Mid-arm muscle circumference 
<15cm
Well-nourished appearance
easy hair pluckability
oedema
Laboratory 
data
Creatinine-height index <60% 
norm
Albumin <3.5/3.0 g/dL
Time to 
develop 
months weeks
Table 11: Types of Protein Calories Malnutrition  [CHEN et al 2001]
Weight loss in AD patients is more prominent than in the healthy elderly. In one 
study, the BMI in subjects without Alzheimer's disease decrease by an average of 
0.14 a year, compared with 0.52 a year in similar subjects with probable 
Alzheimer's disease, as seen in Figure 3. The severity of Alzheimer's disease do 
not seem to modify weight loss: the body mass index decreased by 0.59 a year in 
subjects with mild disease and by 0.47 in those with advanced disease. [CRONIN-
STUBBS et al 1997]
Weight loss in the development of AD is divided into 2 types. The first type is a 
progressive loss, which occurs in around one third of AD patients, in this case 
body weight is reduced by about 4% in 1 year. The second is a severe type, 
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occuring in  circa 10% of patients, whose weight was reduced by over 5 kg in 6 
months [GUÉRIN et al 2005].
Illustration 10: Estimated weight loss for women with and without AD. The  
graphic below is adjusted for age and sex. [CRONIN-STUBBS et al 1997].
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4.2. Epidemiology
In literature reviews, the prevalence of malnutrition in the elderly with dementia 
varied because of differences in methods applied and the type of settings in which 
the study was conducted. In USA and Canada figures range from 10% to 85% 
[THOMAS 1999].
In Germany, according to Altenbericht 2004, 25 % of people with dementia in 
nursing homes are malnourished. Figures from Austria are similar [MESSER et al 
2005].
The fact that malnutrition is a continuous phenomenon makes it difficult to 
measure.  Assessment of insufficient dietary intake may help evaluate the risk of 
malnutrition, whereas nutritional status reveals the current state an elderly person 
reaches after being undernourished. 
4.3. Risk of malnutrition in elderly people
Physiological changes in old age include increased body fat, reduction in bone 
density, loss of muscle mass, total body water and lean body mass. These 
changes in body composition lead to a decreased98 basal metabolic rate and 
usually alteration in body mass. Humans' body mass tend to increase from 
adulthood to 70-75 years old, afterwards decrease [RITZ 2001]. 
98 Reduction of basal metabolic rate is around 2% per decade [ELMADFA and LEITZMANN 2004]. 
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Fat-free mass tend to be lower in AD patients than healthy subjects, while there is 
no difference in fat mass between two groups. Daily energy expenditure is 14% 
lower, due to lower resting energy expenditure and physical activity [POEHLMAN 
et al 1997]. 
Comparing body compositions of Parkinson's patients with healthy elderly, both fat 
mass and fat-free mass does not differ between groups, therefore resting energy 
expenditure remain the same. Daily energy expenditure is around 15% lower in 
Parkinson's group due to lower physical activity  [TOTH et al 1997]. 
Changes cause
Reduced energy 
expenditure
Decline in BMR
reduced physical activity
decrease in active muscle mass
(increased body weight)
Digestion slowing down Decrease in saliva production
decline in gastric secretion
reduced fat and calcium resorption
reduced carbohydrate tolerance
Decrease adaptation 
capability
Decreased odor and taste perception
decreased thirst
increased chewing difficulties
chronic illness 
Table 12: Changes in body metabolism in older age [ELMADFA  and LEITZMANN 2004] 
Food intake is decreased in aging and make elderly people more prone to develop 
malnutrition. In one observational study, older adults make different food choices, 
they consume less dense sweets and fast food, but  more energy-dilute grains, 
vegetables and fruit [DREWNOWSKI and SCHULTZ 2001]. Reduction in dietary 
variety is also observed, and this may be related to a decreased in overall energy 
intake [KWON et al 2006].
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Weight loss is often observed even if subjects still have satisfactory energy intake. 
Some studies assume the atrophy of the internal temporal cortex or the effect of 
the ApoE ε4 allele in the development of AD may play a role in weight regulation 
[VANHANEN et al 2001].
Malnutrition in elderly may be caused by physiological , pathological, psychological 
and social factors (Table 13). 
Physiologic Pathologic Sociological Psychologic
Decreased 
sensory function 
(smell and taste)
Poor dentition Ability to buy and 
prepare food
Depression
Dysregulation of 
satiation
Dysphagia, 
swallowing problem 
Financial issue : 
poverty
Anxiety
Delayed gastric 
emptying
Chronic diseases 
(cancer, diabetes, 
thyroid, etc. )
Impaired ADL skills Loneliness
Decreased gastric 
acid
Medication Lack of interaction 
with others at 
mealtime
Emotionally 
stressful life 
events
Decreased lean 
body mass
Alcoholism Grief
Decreased 
salivary flow
Dementia 
Table 13: Risk factors for malnourishment in elderly [MORLEY 2002]
Feelings of satiety and hunger are modulated by peripheral signals. Cholecytokinin 
(CCK)99 and Peptide YY (PYY), as short-term postprandial100 signals, have been 
shown to be stronger in the elderly than in younger adults. Further, fasting leptin101 
as well as plasma fasting and postprandial insulin are also higher in elderly 
99 CCK and PYY are involved in the regulation of satiety and hunger.
100Postprandial means after a meal.
101Leptin is a hormone that decrease appetite and is involved in long term satiety. 
103
subjects, which may result in prolonged  satiety and inhibition of hunger. High 
insulin levels are positively associated with satiety [DI FRANCESCO et al 2006].
Presence of a chronic disease in old age may increase the risk of malnutrition. In 
cancer, chronic infection and cardiac disease patients, weight loss mechanism 
involved cytokine mediated cachexia102 syndrome. Proinflammatory cytokines such 
as TNF-α, IL-1, IL-6 and IFN-γ  may alter central and peripheral neurohormonal 
signals that control appetite. Moreover, cancer cachexia is associated with 
changes in carbohydrates, lipid and protein metabolism [BENNANI-BAITI and 
DAVIS 2008]. But in case of patients dementia, weight loss does not seem to be 
cytokine-mediated [REGNARD et al 2010]. 
Partial loss of optimal oral health and sensory perception  may influence appetite 
and the pleasure of eating. Poorly fitting dentures , mouth pain, dry mouth, and 
other symptoms that make eating uncomfortable, may increase the risk of 
malnutrition in elderly. Chewing and swallowing difficulties also limit food selection. 
Oral dysphagia is noticeable as absent or continuous chewing, whereas 
pharyngeal dyphagia showed by delayed swallowing initiation, multiple swallows 
and aspiration, which could lead to pneumonia [LANGMORE et al 2007] .
Some medication could also interfere with vitamin absorption103 , affect oral health, 
decrease salivary flow, cause atrophy of mucus membranes and loss of taste buds 
[MARTIN 1999]. 
Another problem is the deterioration of sensory perception. An elevated taste 
threshold is observed if more drugs are consumed. The table below shows the 
102Cachexia is a progressive wasting syndrome, characterized by a loss of fat and lean body mass (LBM). 
On the contrary, in starvation LBM is preserved. 
103Trimethoprim and phenytoin interfere with folate; Cholestyramine, mineral oil and neomycin interfere 
with vitamin A, Hydralazine interfere with vitamin B6; INH increase urinary excretion of vitamin B6 : 
[GERSHMAN and McCULLOUGH 2002].
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average detection threshold for elderly taking 3-4 medications compared to 
younger adults.
Salty Acid Sweet Bitter 
Times higher 11,6 4,3 2,7 7
Table 14: Detection threshold for elderly , who take medications, in comparison to young 
adult [SCHIFFMAN 1993].
In some studies, the loss of olfactory function is associated with a loss of appetite 
and weight.  Smell loss will be perceived as taste loss according to one study by 
the University of Pennsylvania Test and Smell Center. From 750 subjects who 
complained about taste loss, only about 4% had measurable taste deterioration, 
while 71% had in fact olfactory impairment [DEEMS et al 1991].
Partial loss of vision and hearing may bring difficulties in shopping and preparing 
food. Moreover, it may also affect social contact, reduce competence for activities 
of daily living, increase the risk of falls and fractures,  it also may result in eventual 
stress and depression.
Psychological and social factors should not be underestimated in cases of the 
elderly with dementia.  Depression, loneliness, anxiety and other dysphorie can 
result in refusal to eat. Changes in older life like retirement, loss of partner or 
friends, loneliness, financial problems, dependency, chronic illness, moving to a 
nursing home, forming new attachment and adapting to a new social life may 
increase stress and the risk of depression. It is often reported that institutionalized 
elderly try to run away from care homes, it describes more or less their mental 
state and it is sure difficult to expect a good nutritional status in such condition. 
Indeed, change of living arrangements is one of the risk factors for severe weight 
loss [GUÉRIN et al 2005].  
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Basically, conditions of living for elderly can be sort as follows: 
Housing options Food supply
Staying in one's own home Cooking
Nursing home Nursing home catering
Hospital Hospital catering
Table 15: Conditions of living for elderly with dementia 
After onset of dementia, the deterioration of cognitive function makes it difficult to 
prepare and organize meals. Living alone for the frail elderly is unsafe and over 
time people with dementia become dependent on their caretaker. In Germany, 
around 60% of people with dementia are cared for by a relative [Germany's 4 th 
Ageing Report 2002]. Since they need a high level of maintenance and the 
demands of continuous care become increasingly difficult, both physically and 
psychologically, dementia is the main reason for moving to a nursing home.
4.4. Assessment tools 
Considering the many factors that may cause undernourishment, nutritional 
assessment is mandatory in order to recognise malnutrition early and initiate 
nutritional therapy. Three measurement systems applied to identify malnutrition in 
the elderly are assessment of dietary intake, biochemical indices and 
anthropometrical data.
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Dietary intake <75% of RDA in >=3 key nutrients
<2/3 of RDA in >4 nutrients
<50% of calculated maintenance energy requirement
Biochemical indices Serum albumin <30mg/dL
Serum transferrin <20g/L
Total lymphocyte count <1.5 cells/mm
Anthropometrics BMI <5 percentile
BMI <20
Mid-arm circumference <5 percentile
Arm muscle circumference <5 percentile
Triceps skinfold <5 percentile
Weight <75% standard weight for height
Weight <80 percentile standard weight for height
<90 percentile standard weight for height
Loss of >5% of weight in 6 months
Table 16: Measurement system to identify malnutrition  [CHEN et al 2001]
Other important parameters are weight tracking, nutritional history, medical history, 
observation of eating behavior and laboratory parameters (albumin, protein, fatty 
acid, cholesterol, electrolyte, trace minerals, vitamin B).
One measurement system alone may not be sufficient to recognize a case of 
malnutrition.  Serum albumin, for example, although many physicians consider the 
measurement of serum albumin to be an adequate assessment of nutritional 
status, is however, in hospitalized patients, influenced by many other factors, that 
may disturb the result [COVINSKY et al 2002].
Many nutritional screening and assessment tools104 have been developed in recent 
years containing either clinical, biochemical or anthropometric tests, such as: 
• Mini Nutritional Assessment (MNA)
• Edinburgh Feeding Evaluation in Dementia (EdFED) -Scale
104Screening tools aims to identify those at risk of developing malnourishment, whereas assessment tools is 
performed more extensively to define the state of elderly person.
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• Resident Assessment Instrument – Home Care (RAI HC 2.0)
• Nutritional Form for the elderly (NUFFE)
• Subjective Global Assessment (SGA)
• Nutritional Screening Initiative (NSI)
• Senior in the Community: Risk Evaluation for Eating and Nutrition (SCREEN)
• Nutrition and drinking history (Ess- Trinkbiografie) 
Mini Nutritional Assessment (MNA)
MNA is widely used in many countries and usually assess upon admission to 
nursing home or hospital. Questions cover general health, dietary and 
anthropometric assessment, subjective  and global evaluation, which consists of 
background situational living, medication, psychological condition and diseases 
[10] . Benefits included a reliable , very simple non-invasive, easy to administer, 
patient-friendly, non-expensive, very sensitive, highly specific, reliable and 
validated screening instrument for malnutrition in the elderly [VAN NES et al 
2001] . The MNA scores were found to be significantly correlated with nutritional 
intake [VELLAS et al 2000], though the test intended to assess  general nutritional 
conditions of elderly and therefore might be inadequate for people with dementia. 
Edinburgh Feeding Evaluation in Dementia (EdFED) – Questionnaires105 
One of few assessment tools specialized in nutritional matter of people in late 
-stage dementia is the Edinburgh Feeding in Dementia Questionnaires. This 
assessment questions the frequency of certain behaviors which may indicate 
progressive decline, andthus could be used to measure eating and feeding 
difficulties in elderly with dementia. 
The test consists of 11 questions, the first four reflects behavior which indicates 
how far assistance is required during mealtimes such as how often the patient 
105[Watson and Dreary 1997]
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needs close supervision, physical help, spills food and leaves food on the plate. 
Another 6 questions try to identify functional decline and asks the frequency of 
refusing to eat, turning head away, spitting out food, leaving mouth open and 
refusing to swallow. The last question brings out an overall rating of the support 
needed, with three available options  : 
• supportive-educative assistance, e.g. ihelp in plate setup, refocusing, but still 
able to feed himself/herself
• partly compensatory assistance, is if the patient is involved with the meal but 
physical assistance is needed
• wholly compensatory assistance, namely hand-feeding
This observational test should be administered during meal time and 
inconspicuously. The observer will record how often some distinct characteristic 
behavior appears during a meal. This will be quantified in a scoring system; 0 
points for when the characteristic is never observed, 1 for sometimes and 2 for 
often. A higher score means greater disorder.
Although this test not a diagnostic tool, it is a valuable and helpful instrument to 
observe behavior, determine needs and make an effective intervention plan 
[STOCKDELL et al 2008].
Others assessment tools, such as food biography is sometimes necessary before 
acceptance in nursing homes. That way, it is easier to find out about favorite foods 
and track down personal history regarding eating behavior, in case malnutrition 
emerges. 
Most assessment tools available today, measure objective symptoms and not what 
patients want or need regarding food intake. Anideal screening test is difficult to 
obtain. Some issues with these tests are, that  [YITSHAL and BERNER 2003] : 
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– parameters of test often do not reflect physiological, physical, cognitive and 
emotional function
– nutritional assessment using objective markers is more complicated in older 
subjects because metabolic changes affect some of the routine biochemical 
test results 
– the reference values of the anthropometric measures are not always age-
adjusted
– functional impairment may occur at a subclinical level and precede a 
measurable alteration in body composition
In nursing homes facilities, effective weight tracking and tracking food/fluid intake 
systems may support  the identification of significant weight loss of residents. 
Furthermore, screening tools provide individual informations and help to determine 
intervention plan.
4.5. Prevention of malnutrition
Proper nutritional care can reduce the prevalence of malnutrition. In one study, 
body weight of 33 dementia residents, who are being treated in special care units 
(SCU), can be maintained through comprehensive assessment and intervention, 
including enchanced menu designed to be individualized for ambulatory people 
with dementia [KELLER et al 2003]
A nutritional planning programme should consider not only dietary symptoms, but 
also personality and enviromental factors, such as  declining cognitive abilities and 
the many factors that are involved in mealtime arrangements. Often nutritional 
disorders are not necessarily consequence of dementia, but merely a reaction of 
stress. 
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The table below shows some ideas to support good nutrition and in considering 
eating plan for elderly with dementia. 
Review regularly – Dental health
– Medications intake
– Food and fluid intake
– Observation of eating habits
– Documentation of food intake
– Regular weight control
Food/ dietary factor 
consideration
– Energy-rich diet
– Quality control of food
– Food preparation : make food appealing by 
experimenting with spices and recipes.
– Take into consideration patients wishes 
– If necessary : meal supplementation or meal 
replacement 
– Special diet for elderly with chewing and 
swallowing disorders
Consider how to eat, 
encourage to eat 
independently
– Frequent small meals
– Eat independently or being feed, Provide 
specific tools to dinner
– tools to facilitate independent eating,
– Personal ritual, about how to eat, etc
– don't pay much attention to manners and 
cleanliness /tidiness
Arrange a comfortable 
environment
– Avoid disturbance in eating environment, 
dining atmosphere
– Creating a pleasant atmosphere, make it an 
social events
– take enough time to eat, let eating be an 
pleasant experience
Other considerations – Possibilities to encourage eating : stimulate 
appetite
– Individual supervision during meals
– Upright posture, encourage physical activity
– helping and supporting at meal time, but 
encourage to self-reliance
Table 17:  Intervention to prevent malnutrition in elderly with dementia [HIRSCH 2004] 
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In some literature, tube feeding is considered a prevention measure, whereas will 
be explained in chapter 6, that tube feeding may not be favorable for elderly in the 
advanced stage of dementia. 
4.6. Dehydration and fluid intake
Along with the subsiding feeling of hunger, the feeling of thirst  also declines in old 
age, making the risk of suffering from dehydration greater. Some old habits, such 
as a fear of  a visit to the toilet at night, the fear of incontinence, or the desire to 
reduce the amount of urine in case of incontinence, could worsen the condition. 
Changes in old age, that may influence fluid intake:
– reduced body water
– reduced thirst sensation, thus reduced daily water intake
– difficulty of obtaining liquid
– increased diuresis 
– inadequate compensation for extra-losses (e.g. In summer)
– diuretics medication
Table 18: Influence of age on fluid intake [HIRSCH 2004]
Minimum fluid recommendations for the elderly is 1,5-2L daily. Changes in body 
weight, disorientation, dizziness, weakness, apathy, unconsciousness, kidney and 
(circulatory) failure are some complications as that impact from dehydration, which 
may lead to severe health conditions. 
Intravenous hydration and  subcutaneous hydration have been seen as alternative 
methods of maintaining fluid intake if patients seem to suffer from dehydration. 
Administration of intravenous fluid requires hospitalization, and the elderly with 
dementia may feel disturbed or uncomfortable with equipment attached, it is 
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therefore not a method that can be applied at any time.
Meanwhile, subcutaneous hydration, also called hypodermoclysis is still not 
common in geriatrics practice, although the instrument is quite easy to install, 
relatively safe, simple, cost effective  and has little side effect if applied properly 
[HIRSCH 2004]. Although inadequate to correct severe dehydration and electrolyte 
imbalance, it may provide appropriate treatment if patients are not in hospital and 
like to move steadily. Indication for these methods are mild to moderate 
dehydration, also in the case of dysphagia. It is not recommended in acute 
situations namely severe dehydration and to patients with severe heart failure, it is 
also not for patients with a history of renal failure, coagulation and bleeding 
disorders. 
A butterfly needle is placed and fluid containing 0,9% sodium chloride injected 
subcutaneously, about 500ml given over 8-12 hours, or 1000ml-2000ml over 24 
hours.
To date, there is not enough evidence about the benefits and disadvantages of 
these two methods for the elderly with dementia, thus the decision is normally 
taken by patients or family members by considering preference or convenience 
and the purpose of treatment care.
Although oral drinking does not guaranteed sufficient fluid intake, for some elderly 
with terminal illness, it is still the best way to maintain comfort and quality of life. 
Simple measures, such as giving numbers to glasses in order to observe how 
many glasses are being drunk during the day can bring major changes.
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4.7. Eating problems 
Although eating problems are frequently marked as a complication at the late 
stage, changes in eating behavior or swallowing may occur early in progression of 
disease [PRIEFER and ROBBINS 1997).  Priefer found a difference in swallowing 
patterns and eating behavior from people with mild-AD compared to the healthy 
elderly. People with AD significantly needed more assistance or “act-initiation” 
during mealtime, and in general have a longer swallow duration.  
But it seems that the emergence of eating problems in dementia depends on 
which area of the brain is affected. One study compared eating problems in AD 
and FTD, it concludes, that change in eating behavior was more common in FTD 
than AD subjects  [IKEDA et al 2002]. Disturbance in the right side of orbitofrontal-
insular-striatal, which is common in FTD patients,  is associated with overeating 
[WOOLLEY et al 2007].  Another study also compare eating disorders between 
FTD and AD, found that  FTD patients tend to show disturbance of satiation, 
inappropriate way of  taking food, and unfitting  responses when food was not 
available [MENDEZ et al 2008]. 
Persistence of malnutrition in the elderly with dementia raises a question whether 
weight loss is a natural outcome of this degenerative disease. Naturally, eating 
involved not only food intake but also many other social and psychological 
process, which would need intact brain functions.  
In the advanced stage, if weight loss progressively develops over a short period of 
time and the patient  refuses to eat, the physician may prescribe tube feeding, 
since it is general opinion that food intake should not be waived.  
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5. Is tube feeding a solution against malnourishment for people 
with dementia?
Food intake problems which occur in the late stage of dementia may lead 
physicians and family members to decide on tube feeding. Nowadays dementia 
cases account for 30% of all tube feeding utilization [CALLAHAN et al 2000] 
[MITCHELL et al  2003]. 
 
5.1. Types of feeding tubes
To ensure food intake and nutritional needs are adequate, tube feeding formula is 
delivered through a  5-12F106 tube, given directly into the stomach (enteral) or 
blood vessel (parenteral). Enteral nutrition has been practiced since ancient times 
in Greece and Egypt. Medical practitioners at that time used enemas107 from wine, 
milk, whey, and wheat and barley broth to treat bowel infections [HARKNESS 
2002]. In medieval times, sources reported initial usage of various tubes to transfer 
food to the esophagus or via the nasopharyngeal passageways. Modern tube 
feeding as we now know it, has existed since the 1980s. 
At the moment, there are 5 types of feeding tubes, categorized by access route.
106French unit. 1 F = 0,33mm
107Nutrient enema is a way of providing nutrition through rectum.
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Types Inserted through Feeds into
- Nasogastric tube (NG-tube)
- Nasojejunal tube (NJ-tube)
- Gastrostomy tube (G-tube)108
- Gastrostomy- Jejunostomy tube (GJ-
tube)109
- Jejunostomy tube (J-tube)
Nose
Nose
Abdominal wall
Abdominal wall
Abdominal wall
Stomach
jejunum
Stomach
Stomach and 
Jejunum
Jejunum
Table 19: Types of feeding tube
The type of feeding tube usually used for dementia patients is a Gastrostomy-tube, 
in which an endoscopy procedure is needed. Annual cost for tube feeding is 450€, 
in Germany and Austria, and this is covered by medical insurance. 
Application of a feeding tube allows physicians to control nutrient intake through 
choosing  formula adjusted to the patients condition and specific needs. Many 
types of commercial formulas are available on the market, including e.g. 
polymeric formula, monomeric, fiber-containing, disease-specific formula, and 
special formula contained micronutrients. Moreover,  it is also easier to determine 
mealtimes, since many dementia patients have disturbances in biorhythm time and 
sleep pattern.  
5.2. Application of feeding tube for demented patients
Once a patient stops eating, due to dysphagia or other risk factors described in 
previous chapter, physician usually prescribe tube feeding to ensure nutritional 
intake. But advantages in using  a feeding tube for demented patients is still much 
108Gastrostomy tube is also called PEG-tube (Percutaneous Endoscope Gastrostomy).
109Gastrostomy Jejunostomy tube is also called TJ-tube (Transgastric-jejunal).
116
debated. Benefits cited by those who support tube feeding include (i) prevention of 
malnutrition, (ii) prevention of complications of decubitus ulcer  and (iii) aspiration 
pneumonia, (iv) to extent life,  and (v) improve quality of life by providing comfort 
[MITCHELL et al 2000]. Each of these options will be discussed in the following 
passages. Other non-medical advantages according to the literature are a shorter 
hospitalisation time, less effort for nurses, as well as supporting culture and 
religious belief110. 
5.2.1. Preventing the consequence of malnutrition
Data regarding this matter are inconsistent. Some studies oppose the notion that 
tube feeding would help to prevent the adverse health effects of malnutrition. One 
clinical cohort study with 40 tube-fed patients showed that weight loss, reduction of 
lean body mass, and micronutrient deficiencies continued even if sufficient 
amounts of nutrient were provided [ HENDERSON et al 1992] . Another study 
even found that, along with extended duration of tube feeding, cases of  weight 
loss increased in amount and frequency [KAW and SEKAS 1994]. It was also 
noted that nutritional parameters, like hemoglobin, albumin, hematocrit and 
cholesterol did not improve after tube feeding application [HENDERSON et al 
1992].
A constant body weight, even if subnormal below standard BMI , in advanced 
dementia is considered normal. This subnormal weight could be caused by low 
metabolic rate due to LBM shrinkage, athropic brain, or a physically inactive life. 
The body may also adapt to weight loss history by reducing its metabolic rate . 
[HOFFER 2006]
110In some cultures and religions, providing food for the old and the weak is considered an obligation. Some 
people may feel tube feeding as a way to fulfill this obligation.
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5.2.2. Preventing decubitus ulcer 
Decubitus is skin lesions, caused by continous pressure on the skin on one spot, 
mostly by lying in one position for too long and thus causing circulatory problem 
and damage to the skin and tissue underneath. Elderly people become prone to 
such bedsores because many risk factors are correlated with old age, such as 
immobility, incontinence, sensory loss, as well as poor nutritional status [ALLMAN 
1997].
    
Weight loss and reduced muscle mass may increase pressure on bone areas. 
Certain nutrients such as amino acids arginine, vitamin A, B, C, minerals selenium 
manganese, zinc and copper, play a role in wound healing in animal experiments 
but this is not evident in humans. A diet rich in energy and protein may promote 
healing in human subjects [MALTHUS-VLIEGEN 2004]. 
Thus, theoretically, deployment of a feeding tube is intended to improve nutritional 
status through ensuring an intake of energy and nutrients for the elderly who could 
not maintain regular oral feeding. But data from the literature seems inconsistent 
to this hypothesis. One study that investigated the effect of tube feeding on 
nutritional status and development of decubitus on hip fracture patients failed to 
show improvement in incidence, development and severity of pressure ulcers 
[HARTGRINK et al 1998].  Although nutritional intake may be significantly higher 
with tube feeding, especially using high protein formula, there is no evidence that 
better nutritional status would improve clinical outcome in cases of decubitus 
[THOMAS 2001].  
Additionally, complications from tube feeding may bring contradiction, diarrhea, 
fecal incontinence and restriction to mobility could make worse. In case of 
bedsores, oral feeding is prefered  [MALTHUS-VLIEGEN 2004].
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5.2.3. Preventing risk of aspiration
Aspiration occurs when food or gastric content are inhaled into the respiratory 
tract. Aspiration blocks airways and brings bacteria into the lung111, and may result 
in death. In fact, pneumonia, in addition to infection of pressure ulcers, is one of 
the main causes of death in the elderly with dementia. In advanced stages of 
dementia, aspiration often occurs in cases of patients who have swallowing 
difficulties, thus tube feeding installation may aim to prevent aspiration and 
subsequent pneumonia. 
Current data showed no decrease in the risk of aspiration pneumonia after 
application of tube feeding [LI 2002] [BOURDEL-MARCHASSON et al 1997].  In 
one study, risk of aspiration even increased in the tube feeding group (58%) 
compared to patients without feeding tube (17%) [PECK et al 1990]. This may be 
due to the fact that aspiration is also one of  the complications in tube feeding. 
5.2.4. Prolonging life
Physician and family members hope for prolongation of life as an effect of feeding 
tube placement, this is based on the assumption that food intake is unbearable for 
the functioning of body metabolism. However a few studies have found that 
patients with tube feeding did not have any advantage in the survival rate during 
the survey [MITCHELL et al 1998].  Studies suggest for dementia patients in 
advanced stages, the survival rate is not extended by the use of tube feeding 
[MEIER et al 2001].  With or without feeding tube, the mortality rate in end stage 
dementia is around 6 months [MEIER et al 2001], and in the tube fed group, life-
span is only approximately 7,5 months after application [FINUCANE 1999]. 
111Pneumonitis is the aspiration of gastric content that may cause inflammation of lung tissue. 
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Experts suspect, when it is near the time of death, time, life cannot be prolonged 
again, even with tube feeding. Eating problems and dysphagia may indicate the 
terminal stage of dementia [GILLICK 2000].
Perhaps the physiological condition of patients in advance stage dementia is too 
debilitating to gain benefit from tube feeding, whereas complications from feeding 
tube attachment could add suffering [LI 2002]. 
Nevertheless, Rudberg et. al. in their study showed that residents of a nursing 
home with feeding tube were less likely to die compared with residents without 
tube feeding, even if the differences is not much [RUDBERG  et al 2000]. In this 
trial, the survival rate for patients with feeding tube after 1 year is 50% , while 
residents without feeding tube is 39%. 
5.2.5. Improving the quality of life
It is difficult to assess the quality of life in patients with dementia. Firstly, they may 
not able to communicate, and cognitive ability has been reduced as well. Since 
there is no data, knowledge about hunger sensation and thirst during the dying 
process could be interpolated from cancer patients. They report that they don't feel 
much hunger or thirst and this could be alleviated with minimal intervention, such 
as the application of swabs or ice chips [MC CANN et al 1994].  They may not feel 
they are starving, despite the fears of family members.
Placement of a feeding tube may discomfort the patient's daily life, since they 
often do not understand the purpose of the tube and usually try to pull it out 
[GILLICK 2000]. Restraint in the form of mittens is usually used which could add 
more stress to patient [PECK et al 1990] and increase the use of sedative [LI 
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2002]. Feeding tube placement may also reduce personal contact with caregivers 
[SYNOFZIK 2007].
Furthermore, as medical intervention, additional complications due to tube 
placement may appear. In fact, in older patients, up to one-third experience 
transient gastrointestinal complications, such as vomiting and diarrhea 
[CALLAHAN et al 2000]. Tube dislodgement , blockage and leakage are also 
common [FINUCANE 1999].  Even if major complications are rare (only 1-2%).
 
5.2.6. Conclusion concerning the benefit of tube feeding
Overall, data from the literature fail to show beneficial outcomes of tube feeding for 
elderly with dementia.. But benefit should be distinguished from effectiveness; 
tube feeding may be effective to ensure nutrient intake with some patients. Indeed, 
tube feeding can be used in certain situations in dementia care, such as a case of 
a patient with dysphagia and still having cognitive function, also for independent 
patients who are still able to move, but whether it will benefit and be appropriate in 
the terminal stage, is a controversial matter of debate [MARCKMANN 2007].
Dementia is a terminal illness, where possibilities of recuperation within current 
medical knowledge do not exist. Application of tube feeding should therefore 
consider realistic treatment goals, either prolongation of lifetime even in a 
vegetative condition or providing comfort and quality of life.
However, results from studies available to date do have some limitations:
– Most of the available data concerning tube feeding in the late stage of 
dementia are based on observational studies, retrospective studies, or data 
extrapolated from mixed population [LI 2002]. Ethics, social and procedural 
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difficulties may complicate the designation of a good randomized controlled 
trial [MITCHELL 2007] and to date there is still no randomized clinical trial 
that has been performed [FINUCANE et al 2007]. 
–  Another problem is that existing studies so far do not distinguish the many 
forms of dementia nor different stages of dementia at which feeding tube 
are initiated among patients [SYNOFZIK 2007].
– Difference in patients cohorts may also bias the result, since patients  who 
receive feeding tubes may be weaker than those who do not. Studies may 
include patients with different health conditions in the same group [MC 
NAMARA and KENNEDY 2001].
– Selection of an appropriate control group could lead to bias results, e.g. if 
the control group were hand-fed by loving family members compared to 
those fed by nursing assistants in nursing homes.
– Some studies do not specify whether gastrostomies or nasogastric tubes 
are being assessed [REGNARD et al 2010].
Due to the lack of solid evidence, the question remain open, whether tube feeding 
really does harm, has no effect or is beneficial for the demented patient. Studies in 
the future should also assess outcomes such as patient distress, symptoms of 
malnutrition, hospital admissions, administration of medications. On the other 
hand, survival rate is perhaps not a relevant outcome measure for a terminal 
illness such as dementia  [REGNARD et al 2010].
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5.3. Patients and physician's preference of tube feeding 
Decision making whether to use a feeding tube is affected by a number of factors 
such as age, gender, race, cultural factors, education, current health status at the 
time the study was conducted, and functional status [GARRETT et al 1993].
Some studies have surveyed opinions of elderly subjects regarding the feeding 
tube placement. 
As data showed below, preference of tube feeding from medical workers is quite 
high. Some still regard tube feeding as a solution for patients with advance stage 
dementia. Aside from subjectively perceived benefit, one reason why tube feeding 
is preferable, is perhaps the fear of being accused of neglect [MC NAMARA and 
KENNEDY  2001]. Other reasons may be because tube feeding application is 
simple and convenient, but decision making should not be based on the 
convenience of the carers, but the patient's best interest must be prioritized.
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Author  Subjects Results
Gjerdingen et al 
1999
84 non-demented 
elderly over 65y
Only 4 % agree to be tube fed. The 
proportion of those who do not prefer to tube 
feeding rise with the progressing severity of 
dementia 
Carmel 1999  987 Israeli 
elderly
22% accept tube feeding
O'Brien et al 
1995
379 American 
nursing home 
residents
One-third agree to tube feeding.
Perhaps nursing home residents are used to 
see patients on tube feeding.
Reilly et al 1994 218 community- 
living Americans 
age 60-87
43% would want to be tube fed
Subjects have a better education, thus 
perhaps the result is not relevant for general 
population
Emanuel et al 
1991
405 patients from 
all ages in 
Boston's 
Massachusetts 
General Hospital 
73% refuse tube feeding in case of 
dementia,  while 82% refuse in case of 
dementia with terminal illness
Gerety et al 
1993
52 nursing home 
residents
38% agree to tube feeding in severely 
physical disability state, 25% accept tube 
feeding in persistent vegetative state
Table 20: Preference of elderly to tube feeding methods [MC NAMARA and KENNEDY 
2001].
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Author Subjects Results
Carmel 1999 339 physicians 74,6% physicians prefer to tube feeding 
(versus 22% elderly)  
Hasan et al 
1995 
199 geriatricians, 
speech therapists, 
dieticians, and 
nurses 
47% agree of tube feeding utilization in case 
of dementia with food refusal 
Norberg et al 
1994 
149 nurses Nurses in Australia, Canada, Sweden often 
chose not to tube fed, they give high rank to 
ethical principle of autonomy
Nurses from China and Israel prefer tube 
feeding, giving high rank of sanctity of life
Table 21:  Opinions from physicians and nurses regarding tube feeding application 
5.4. Maintaining oral feeding in elderly with dementia 
Another option in feeding demented patients is oral112 or hand feeding. The 
preference for oral feeding is often expressed in the assertion that it is said to 
preserve the quality of life for the demented patient. But what does quality of life 
means for the elderly with dementia, who have already partially lost their cognitive 
function?
112Oral feeding is defined as intake of food through swallowing act.
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5.4.1. Definition of the quality of life for elderly with terminal illness
Kohlmann [2000] measures the quality of life through physical constitution, 
physiological condition, social relationship and activities of daily living. In geriatrics, 
the term quality of life is often equated with well-being, which shows how 
subjectively perceived well-being being is emphasized in the care of elderly 
people.
Social demographical variables such as housing, financial conditions have less 
attention in determining the well-being of terminally ill demented patients. The 
following tend to be emphasised : (1) the patient's own state, including physical 
and cognitive functioning, psychological state, and physical condition; (2) quality of 
palliative care; (3) physical environment; (4) relationships; and (5) outlook 
[COHEN and LEIS 2002].
In BASE trials113 on over 70 year old elderly demonstrate, there is more correlation 
between well-being and the subjectively perceived health condition, than the 
objectively measured health condition [SMITH et al 1999] . Moreover, the 
subjectively perceived health condition could predict mortality better than the 
objective measured health parameter.
Food is not only about nutrition, but also about comfort114, taste enjoyment and 
social interaction. Food also symbolizes nurture and caring115. Since eating is one 
basic right of human life, oral feeding is regarded as one way of preserving human 
dignity in late life. Thus, eating and drinking is an important aspect in the quality of 
life and should be encouraged and maintained as long as possible [STEPP and 
113BASE stands for Berliner Altersstudie.
114Food intake can be comforting through its effect on hormones, triggered by some substances such as 
theobromine in chocolate.
115Food as a symbol of nurture and caring is originally come from mother and child relationship, feeding a 
baby is considered an expression of maternal love.
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PAKIZ 2001]. 
In conclusion, the argument from supporters of oral feeding are, that hand feeding 
may increase the quality of life through providing more comfort for patients with 
dementia, it also preserves contact with caregivers and food enjoyment 
[SYNOFZIK 2007].
5.4.2. Oral feeding problems and risk of aspiration
To understand the oral feeding problems, four main areas need to be addresses:
– the pre-oral phase116 of eating, intra-oral bolus preparation117 and 
swallowing
– function of respiration 
– the diagnosis, treatment and complications of the underlying medical 
condition
– environmental factor, including availability of carers 
[Royal College of Physicians 2010].
The pre-oral phase, intra-oral bolus preparation and swallowing
In case of AD, pre-oral phase may be disturbed by changes in conduct and 
behaviour, agitation, loss of appetite, problems using cutlery, and restlessness. A 
good dental care and function of the nervous system are required to assure intra-
oral bolus preparation. 
Swallowing is a complex mechanism, it involves laryngeal elevation , laryngeal 
closure, opening of the upper oesophageal sphincter, bolus transit from mouth to 
116Pre-oral phase includes e.g. choosing the order in which the food is to be presented, salivation and other 
behavioral response, as well as social interactions.
117Intra-bolus preparation depends on dentition, salivation, chewing, and control of the bolus by the muscle 
of the tongue.
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oesophagus and subsequent return of the involved structures to their starting 
positions  In a swallow, respiration is normally arrested, otherwise bolus will be 
inhaled. Coughing is a protective response to avoid aspiration. Indeed, the risk of 
aspiration is the main concern of oral feeding [Royal College of Physicians 2010].
The advanced stage is usually marked by swallowing difficulty, although dysphagia 
may also occur in early stages of dementia [PRIEFER and ROBBINS 1997]. The 
reasons why dysphagia is often regarded as a terminal symptom are poor 
screening, atypical presentations and carer adjustment to its presence [REGNARD 
et al 2010]. 
To assess oral feeding problems, records of food history and examination such as 
observation of eating and drinking in periodical intervals are necessary before 
planning strategies to improve food intake. 
5.4.3. Feeding plan – examples from nursing homes projects
Practice of oral feeding have been performed in some nursing homes, such as:
– “Finger food”  and   “Eat by walking”
– “Cooking at bedside”
– “Lunch club”
In his book, Essen als basale Stimulation, Markus Biedermann offer some eating 
concepts for nursing home residents with dementia in Switzerland. Through 
stimulating senses other than taste, such as sight, touch, smell and hearing, he 
tries to make mealtime an experience as pleasant as possible for residents. 
Finger food characterizes food taken by hand, without any cutlery or tools and 
usually cut into nibbles. They are favored for residents with motoric or cognitive 
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disturbance, and thus could spare the use of eating utensils. Hindrance probably 
emerges from background experience, for some elderly eating with the hand is still 
considered barbaric and uncivilized, as they were taught by their parents not to eat 
with fingers since childhood [BIEDERMANN 2004]. Hygiene and the way to eat 
with fingers should be considered. A trial in an Alzheimer's care facility in Ohio 
during two six months periods found, that a change in menu with more finger food 
did not result in weight gain, but typical weight loss did not occur and food 
consumption patterns significantly increased. Inclusion of finger food in the menu 
is an appropriate feeding method for AD residents [SOLTESZ and DAYTON 1995].
The eat by walking concept is a further development from finger food. This 
program aims for  dementia patients who are constantly moving, wandering 
around and can't sit quietly at a table. Finger food is put in strategic places, where 
they often pass by.
Mary Marshall from the Dementia Services Development Centre Stirling University 
Scotland, believed that eating disorders are not necessarily a consequence of 
dementia, but rather a reaction to stress. Therefore, she developed a project 
called Lunch Club, a program where a small group of the elderly with dementia 
have a lunch with healthy persons once or twice a week. During mealtime, stress 
reduction is achieved through a comfortable dining atmosphere in a pleasant 
place, limitation of distraction, a little small talk, and so on. This program gives a 
chance to elderly with dementia to take part in community activities, because living 
in care homes does not mean that the elderly should give up outdoor activities 
[Dementia Service Development Centre 2002]. These oral feeding practices, 
namely finger food /eat by walking and lunch club, could only be applied if 
residents are still mobile. 
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The cooking at the bedside project was conducted in care homes Sonnweid and 
Kühlewil in Switzerland. Six previously chosen bed-ridden demented patients 
participated in this experiment and their reactions were observed. Preparation was 
done in the kitchen, with simple recipes and simple utensils, food is cooked in the 
patient's room for only about 5 minutes, and during this “animation” time food was 
served.  Reactions such as drooling, changing in expression, and eating more 
than usual was observed during the experiment, although these reactions only last 
for about 5 minutes.  Although the project was successful, it should not become 
routine program in nursing homes, since the stimulating effect probably lessens if 
applied too often [BIEDERMANN 2004].  
5.4.4. Strategies to support oral feeding  
Improved feeding techniques may minimize the risk of aspiration, facilitate eating 
and drinking, and eventually reduce the prevalence of malnutrition in demented 
patients.  Depending on mobility and cognitive functions, some of these actions 
are applicable to patients in mild to moderate dementia, namely with feeding 
problems. At the end of life, these measures are hardly useful. Some suggestions 
are listed in table 23. 
130
Factors Strategies 
Modifications of 
food and fluids
– Shape, texture and food consistency are adjusted to 
the ability of chewing, swallowing, and health 
conditions.
– Elderly people usually prefer a small portion, strong 
spices, familiar recipes,  sweet taste.
– Providing a high quality and nutritious food, with 
supplementation if necessary.
– Avoid solid particles in food.
– Arranging a nice food presentation.
– Consider wishes and favorite food of patients. 
Oral feeding 
strategies 
– Organizing frequent small meals
– Use specific utensils
– Considering personal ritual
Swallowing 
strategies 
– Reduced sensation may be helped by a thermal 
stimulation with ice or chilled material applied to the 
oropharyngeal musculature
Positioning and 
postural 
techniques118
– These include chin tuck, head rotation to the affected 
side, head tilt, side lying or remaining upright
Environment and 
external strategies
– Create a comfortable dining atmosphere, without 
unnecessary disturbance/ stimulus, e.g. with simple 
room decoration, relaxing music, or provide a pleasant 
smell of food
– Giving patients enough time to eat.
– Present an aquarium119 in dining area.
– Making mealtime a pleasant social event
118Postural techniques are useful to change direction of the bolus.
119According to one study, the presence of aquarium in dining room can increase nutritional intake of 
demented patients.  The effect is based on the assumption, that contact with natural surroundings may 
reduce stress [EDWARDS and BECK 2002].
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Other options – Minimize adverse medication effect by prescribing 
fewer medications which could affect appetite.
– Individual supervision during meals.
– Encourage physical activity if still possible.
– Relieve stress.
Table 22: Strategies to improve meal services in feeding elderly with dementia [Royal  
College of Physicians 2010] [HIRSCH 2004].
To ensure a successful implementation of the oral feeding intervention, good and 
effective cooperation and communication among the patient, the family, nurses, 
kitchen staff, physicians, SLTs, nutritionists and other medical workers involved are 
necessary. Multidisciplinary approaches on the feeding problem may offer the 
optimal solution and hazard may emerge from a one-sided view.  One study from 
the US showed nursing homes that employed SLTs had a higher rate of tube 
feeding application on its residents. Nutritionists could also focus only on nutrient 
intake and recommend tube feeding [MITCHELL et al 2003]. 
An important factor that was often not included in studies is the role of caregivers. 
Carers may suffer mental or physical health problems due to constant caregiving 
activities. Since most patients are dependent on their carers, their interaction may 
impact the quality of life of the person with dementia. In one study, feeding 
difficulties were significantly associated with the age and behavior of the caregiver 
[RIVIÈRE et al 2002]. To improve caregivers' well-being, dementia management 
should also include programs such as training to improve knowledge in medical 
treatment, psychological service to reduce stress as well as training to improve 
communication skills.   
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5.4.5. Evidence of effectiveness of feeding interventions in literature
A systematic review of feeding interventions in patients with dementia are showed 
in Table 23.  Although not all studies showed positive results, some surveys 
indicated, that high caloric supplementation could be beneficial to gain weight, but 
physical and cognitive function did not improve during trial [LAURA et al 2011]. 
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Study Subject
s
Intervention type Outcomes Differenc
e 
Beck, 2002 66 Liquid supplement Weight No 
Carver, 1995 46 Liquid supplement Weight Yes 
Cereda, 2009 28 Liquid supplement Pressure ulcer 
healing
Yes 
Gazotti, 2003 80 Liquid supplement and 
soup
Weight Yes 
Gil Gregorio, 
2003 
99 Liquid supplement BMI, 
morbidity and 
mortality
Yes 
Yes 
No
Kwok, 2001 47 Milk powder Weight
Cognition
Physical 
function 
No
No
No
Lauque, 2000 78 Liquid supplement
Soup, fruit and dessert
Weight
BMI
Grip strength
Yes
No
No
Lauque, 2004 91 Liquid supplement
Soup, dessert
Weight
BMI
Cognition
Physical 
function 
Yes
Yes
No
No
Parrott, 2006 30 Liquid supplement
High calorie bar
BMI Yes
Planas, 2004 44 Liquid supplement BMI
Cognition
No
No
Wouters-
Wessling, 2002 
35 Micronutrient-enriched 
liquid supplement
Weight Yes
Wouters-
Wessling, 2006
34 Liquid supplement Weight
Physical 
function 
Yes
No
Young, 2004 34 Liquid supplement
High-calorie bar
Weight Yes
Table 23: Studies on the effect of high caloric supplementations for patients with dementia  
[LAURA et al 2011].  
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Study Subject
s
Intervention type Outcomes Differenc
e 
Beck, 2008 121 Chocolate
Hot chocolate
Homemade supplement 
Exercise
Weight
BMI
Yes
Yes
Crogan, 2006 61 Individualized nutrition 
therapy process and care 
plans
BMI
Physical 
function 
No
No
Goddaer, 1994 29 Relaxing music played at 
lunchtime
Behaviors Yes
Keller, 2003 82 Enhanced dietitian time 
and menu
Weight Yes
Remsburg, 
2001
40 Buffet-style dining program Weight No
Robbins, 2008 515 Chin-down posture
Thickened liquids
Pneumonia
Mortality
No
No
Salas-Salvado, 
2005 
56 Lyophilized foods Weight Yes
Simmons, 
2005
17 Megestrol acetate and 
feeding assistance
Weight No
Simmons, 
2008 
69 Feeding assistance Weight
BMI
Yes
Yes
Volicer, 1997 12 Dronabinol Weight
Negative affect
Disruptive 
behavior 
Yes
Yes
No
Yeh, 2000 68 Megestrol acetate Weight Yes
Young, 2005 34 Meals high in 
carbohydrates
Weight
Cognition
Behavior
No
No
No 
Table 24:  Summary of evidence for feeding interventions  [LAURA et al 2011].
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Towards the end of life, eating difficulties may become worse, also severe health 
conditions may leave little room to intervene with an oral feeding program. As food 
and fluid intake lessen, a decision has to be made whether to apply tube feeding 
or to continue the assisted oral feeding with all the attendant risk and benefit. In 
practice, the decision to apply or withdraw tube feeding is not always easy, since it 
is also influenced by other factors, such as ethics and the law. 
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6. Feeding options in the terminal stage of dementia 
In the terminal stages, demented patients usually lose interest in eating and 
drinking and eating difficulties become more severe, resulting in poor food intake 
and subsequent symptoms of malnutrition. Artificial nutrition and hydration (ANH) 
is often used in such cases, in the form of either NSG or PEG. 
In general, there are 4 feeding options for the elderly [Royal College of Physician 
2010] :
– full oral feeding
– a combination of oral and non-oral feeding
– palliative feeding using small amounts of food, mainly for enjoyment
– alternative nutrition using non-oral methods
Making a decision as to which feeding option is applicable in case of terminally ill 
patients with dementia, is difficult and loaded with emotional, ethical and perhaps 
in some cases also legal issues. The patient's deterioration in cognitive function 
and inability to communicate in the end stage make it impossible to ask directly 
his/her wish. 
Illustration 11: Decision making in patients with feeding problems [Royal College of Physicians 2010]
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6.1. Benefit of oral versus tube feeding from medical viewpoints
To date there is no direct comparison between tube and oral feeding for demented 
patients in the end of life, and such trials may be difficult to design [GARROW et al 
2007]. The literature shows that oral feeding does not offer health benefit 
regarding risk of aspiration and mortality [HANSON et al 2011]  except to avoid 
medical intervention at the time of application, as well as complications and 
restraint caused by the feeding tube application. On the other hand, application of 
tube feeding do not provide medical benefits as described in previous chapter. 
In this case, physicians together with family members should determine a realistic 
treatment's goal, so as to preserve the quality of life until the last moments. From 
the medical point of view, this can be reached partly by avoiding burdensome and 
unnecessary medical interventions. 
 
Some evidence proposes that the human body can not utilize or digest nutrients 
and fluid anymore in the end of life phase. Dehydration and starvation for dying 
patients may stimulate the release of natural anesthetic, that promote comfort 
during the last hours of life [ELLERSHAW et al 1995]. Giving artificial nutrition and 
hydration may lead to excess and overload, adding physical metabolic burdens in 
the form of edema and aspiration, also prolonging suffering. 
Distinguishing wasting illness with insufficient nutrient intake would be important 
[FINUCANE et al 2007]. They may show the same symptoms, but require different 
treatments. While malnourished patients can get benefit from nutritional intake 
including from feeding tube, a wasting syndrome requires more complex 
treatments and usually appear in the last stages of incurable disease. 
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6.2. Ethical and legal issues regarding the use of tube feeding for 
demented patients
The application of tube feeding in terminally ill demented patients raises ethical 
questions, concerning the principle of beneficence, non-maleficence, respect for 
autonomy and the principle of justice120 . Beneficence in medical ethics proscribes 
that any medical treatment should bring benefit for patients. Tube feeding for an 
ethicist is considered medical intervention [GOLDSTEIN and FULLER 1994], 
although there was debate whether it falls under definition of a treatment or basic 
care121. As a medical treatment, the risk and benefit  should be carefully looked at 
and weighed up before deciding its application (principle of double effect122). 
Principle of beneficence and non-maleficence
As described in the previous chapter, from data currently available, the benefit of 
tube feeding for patients with advanced stage dementia is not convincing and 
mostly subjectively perceived. Expectation in improved nutritional status, 
prevention from pressure ulcers and aspiration or life prolongation was not proven. 
Moreover, it seemed that complications from tube feeding may even exacerbate 
the patient's condition. And it contradicts with primum non nocere123, also known 
as the principle of non-maleficence.  [SYNOFZIK 2007]. 
Human autonomy and dignity
A consequence of progressive cognitive deterioration is loss of autonomy. 
Autonomy is defined as the right to determine one's own destiny, the right to know, 
to choose and not to be harmed [MC FIE 1996].
120 According to Beauchamps, principles of beneficence, non-maleficence, autonomy and justice are 
principles of ethics applicable in health care [Beauchamps, Childress 1977].
121The basic care here implicates eating and drinking.
122Often in health care,  “do good and avoid evil” could not be applied in the same time,  since every 
medical intervention always has risk of complications (principle of double effect). A treatment is 
considered “safe” if the benefit/effectiveness  surpass the risk/maleficence   [Goldstein, Fuller 1994].
123Primum non nocere means first do no harm.
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In the case of patients with advanced stage dementia, where they may be unable 
to express their opinion, autonomy is shown in the form of advance directive [MC 
NAMARA and KENNEDY 2001]. It contains the preference of medical treatments 
or appointment of a trusted individual124, who will make decisions in case the 
patient is incapable of making informed decisions for themselves, although in most 
situations decision-making is dominated by the physician and medical team [VAN 
ROSENDAAL et al 1999]. In the case that the patient is unable to make informed 
decisions, a health care proxy should decide, based on knowledge about the 
patient's wishes and best interests. 
Legal power of advance directive differs in each country. In 2006 Austria has 
endorsed a regulation about advance care directive, where patients have the right 
to refuse medical treatments but not nursing care. Tube feeding is considered by 
some scholars as a medical treatment , but if artificial nutrition and hydration is 
seen as basic nursing care, withdrawal from tube feeding would mean 
euthanasia125 and is still illegal. Since medical knowledge develops rapidly, 
Austrian regulation requires advance directives to be renewed every 5 years 
[WALLNER 2007] .
If an advance directive and health care proxy are not available, the decision is 
made by family members, physicians and court, respectively126, though 
automatism should be avoided [PEINTINGER 2004], out of respect for the 
patient's autonomy. At first, surrogate decision makers should be clear about any 
treatment's objective. Tube feeding may be applied in the early or middle stage, 
while patients are not dying and as a reconciliation step after a medical 
intervention, and it should be checked regularly whether it is still consistent with 
124In the legal term, this person is called durable power of attorney or health care proxy.
125Euthanasia defines the termination of one's life in order to relieve suffering.
126[Austrian Patientensverfügungs-Gesetz 2006]
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the treatment's objective [WALLNER 2007].  
Without an advance directive, some ethicists may consider PEG as a form of force 
feeding, since nutrient intake without consent of patients and may be counted as 
bodily harm. Use of restraints to keep the feeding tube in place could also mean 
violation of dignity [SYNOFZIK 2007].
Debate emerges as to whether withdrawal of tube feeding; a life-sustaining piece 
of equipment in case of severe demented patients, falls under the definition of 
euthanasia127.  Euthanasia is illegal in most countries, except for the Netherlands, 
Switzerland, Thailand, part of Spain and the US.
Based on a treatment's objective to assure the quality of life, withdrawing and 
withholding a burdensome medical treatment such as tube feeding should be seen 
as allowing the dying person to die in appropriate way. It should be seen in a 
different perspective, unlike patients with persistent vegetative state (PVS).
6.3. Financial matters
6.3.1. Cost, effort and incentives 
For nursing homes, an oral feeding program is resources consuming, more time, 
finance and work are needed to provide good quality of food and hand-feed 
service. Each patient requires 35-40 min per meal [SIMMONS and SCHNELLE 
2006] , and it also means an expensive labor cost. 
127Passive euthanasia defines as omission of life-sustaining treatment, which lead to death.
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To provide a hand feeding service for its demented residents, nursing homes need 
to organize a system where interdisciplinary team members can share information 
and develop effective and efficient methods together.
One retrospective study compares cost of the hand feeding versus tube feeding in 
one  nursing home in Boston over a 6 months period. The results showed that 
hand feeding cost more due to the demands placed on time and labor resources 
[MITCHELL et al 2003]. However, reimbursement from Medicaid (an insurance 
company in the US) is higher in the case of tube feeding. This consideration is 
based on the initial feeding tube placement and hospitalizations visits for the 
management of complications of tube-feeding. The reimbursement rate for tube 
feeding  in the US state of Maryland is also higher than hand feeding, although the 
cost for hand feeding is higher.  These financial advantages may promote the high 
utilization of tube feeding [FINUCANE 2007].
6.3.2. Incentives for health care facilities
Although it should not be considered as the main point in decision making, tube 
feeding is easy, faster and needs less effort. Whereas implementation of hand 
feeding needs creativity, to assess possible risk factors, and then try to find 
solutions appropriate for each situation.  
For nursing home facilities and physicians, tube feeding gives a proven solid 
documentation regarding implementation of basic care128. Since it is a widespread 
assumption that malnourishment could be a result of neglect in care treatment, 
tube feeding protects nursing homes from the accusation that its resident died 
128Some literature data still consider tube feeding as a basic care, namely by providing (artificial) nutrition 
and hydration; while others may think of it as medical intervention. There is still no legal regulation or 
consensus to this issue. 
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because of neglect in providing sufficient nutrition and hydration [SHEIMAN and 
POMERANZ 1998].
Regulation may support facilities to place tube feeding on its residents. Federal 
guidelines of Maryland stated that each nursing home facility must assure each 
resident maintains acceptable parameters of nutritional status, such as body 
weight [FINUCANE 2007]. Again, tube feeding proved that adequate provision has 
been done and would protect facilities against tort litigation. Different federal laws 
in each state of the US may cause variable rates of feeding tube application 
[PASMAN et al 2005].
6.4. Emotional and psychological concerns
For caregivers and family members the decision to apply a feeding tube may be 
loaded with emotional issues. Fearing that a patient may die if the tube feeding 
option is refused, feeling guilty because a patient refuses to eat, or cannot bear to 
“let him starve”  are common arguments. Additionally, caregivers may be afraid of 
burdensome care by providing oral feeding [CALLAHAN et al 1999]. Moreover, the 
emotional symbol of food and water represent nurturing and care-giving, and 
withdrawal of food is considered as punishment or protest action [CRANFORD 
and ASHLEY 1986].  Thus to justify perception, caregivers may feel obliged to 
provide nutrition as a form of nurture.
A mental trait of modern society is a feeling of having to “do something” in case 
something goes wrong or badly. It may be difficult for a medical team to be seen 
“not doing anything”. They may feel powerless or afraid of the consequence of law 
and accusations of malpractice. This phenomenon results in the medicalisation of 
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dying129, where people loses the capacity to accept death and suffering as an 
aspect of life [CLARK 2002].
New ways of thinking  and change of mindset are required to fix such 
presumptions and wrong basic assumptions about the meaning of nutrition and 
hydration in the last stage of dementia. 
6.5. Social , religious and cultural issues 
Decision making processes usually depend on the patient's or family member's 
personal views about life and death. Culture and religion have a great role here 
and physicians need to be sensitive to these matters. Reasons such as hoping for 
a miracle, refusal to give up on the God of faith, a conviction that every moment of 
life is a gift from God and is worth preserving at any cost, and a belief that 
suffering can have redemptive value, can be used to justify aggressive medical 
intervention in end-of-life care [BRETT and JERSILD 2003]. 
6.6. Decision-making
The Royal College of Physicians provide a guide for family members with some 
considerations of decision-making. Support of professionals  from other parties of 
expertise, such as from clinical ethics committees, court or religious leaders may 
also be helpful. 
129Modern medical system regards death as something to be resisted, postponed or avoided. Palliative care 
is a response to calls for greater dignity at the end of life [CLARK 2002]. 
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Consideration factors Explanation
Advance directive Presence of advance directive, to know patients wishes 
and priorities.
Ethical principles Interventions with no beneficial effect should be ruled 
out.
Legal or financial 
concerns
There is a pressure on hospital to place PEG, so that 
the patients can be accepted in a nursing home. 
Emotional factors Provide knowledge to avoid guilt factors, good 
communication skill is required.
Cultural and religious 
background
Be sensitive and understanding about these issues.
Table 25: Considerations in decision-making
6.7. End-of-life care and dementia
In case tube feeding is withdrawn or withheld, an alternative is to hand-feed 
patients with food/thick liquid, that is prepared in such a manner as to avoid the 
risk of aspiration. Hand feeding may not be effective in preventing malnutrition, but 
it can maintain comfort in the patient's care [LI 2002].
 
Near death, it is more important to provide patients with comfort measures, such 
as pain and symptoms management, moistening the lips and good mouth care, 
frequent change of body position to avoid pressure ulcers and family support. 
Palliative care is perhaps the appropriate form of care for persons in the terminal 
stage of dementia. In palliative care, efforts are intended to alleviate symptoms; 
pain relief, accompaniment and quality of life are prioritized over medical 
interventions.  But there are some barriers to good palliative care for people with 
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dementia. It appears, dementia is still not being recognized as a terminal disease. 
This may be due to the unpredictable nature of the disease. There is no accurate 
prognostic marker for advanced stage dementia, which makes it difficult to 
recognize a terminal phase and predict life expectancy [SACHS et al 2004].
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7. Discussion 
Is there really a need for tube feeding placement for patients with dementia? How 
important is the optimal nutritional status for disease progression and in the 
terminal stage of dementia?
Many people, including physicians and medical workers, still consider a good 
nutritional status is important in disease progression. Indeed, malnutrition is 
associated with bad outcomes in the hospitalized elderly, but treating malnutrition 
does not always result in better outcomes. The relationship between malnutrition 
and illness severity is complex and not yet fully understood. Evidence from 
aggressive nutritional intervention such as tube feeding shows that benefit is 
limited to specific subgroups, such as patients with hip fractures or after abdominal 
surgery  [COVINSKY 2002]. 
In the case of patients with dementia in the advanced stage, physicians may 
misunderstand the cachexia syndrome at the end of life as signs of malnutrition 
and thus will try with all means to keep nutritional status and intake at an 
acceptable level. A diagnostic tool to distinguish wasting syndrome with insufficient 
nutritional intake is urgently needed.
 
Tube feeding has no proven benefit for patients in advanced stages of dementia. 
Data from the literature shows a lack of efficacy in preventing malnutrition, 
pressure ulcers and pneumonia. Moreover, as a medical intervention, tube feeding 
has a risk of complication and may be burdensome.  But the evidence is weak, 
study designs were poor and mostly observational. To date, there is no 
randomized clinical trial comparing tube feeding with hand feeding, and perhaps 
considering the linked ethical issues, such study will be difficult to perform. Further 
researches in this matter should consider a better study design, differentiation in 
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types of dementia, specified subject groups, reliable measurement tools and 
reasonable outcomes.
Since most data is based on the frail elderly in advanced stage of illness, there is 
an opinion, that PEG should be used sooner to maintain nutritional status and 
avoid malnutrition. But there is no available data to support such a view. 
Criticism of tube feeding is based on a failure to show beneficial outcome, but 
hand feeding is not effective to improve the medical condition. The argument for a 
hand feeding option is that it treats patients more humanly, thus preserving the 
quality of life by giving them more possibilities for social interaction.  
A new order, “comfort feeding only” (CFO)  is probably be the ideal alternative. The 
feeding is comfort-oriented, the patient will be fed as long as mealtime does not 
cause distress to the patient. An individualized care plan, which focuses on 
treatment goals, is used to document signs of distress, favorite food, effective 
feeding techniques, and at what times of the day feeding is preferable. If the 
patient does not tolerate oral feeding anymore, the carer may continue interaction 
in the form of mouth care, speaking to the patient and giving therapeutic touch 
[PALECEK et al 2010]
Epidemiological data shows a high prevalence of tube feeding application in the 
case of dementia, indicating that some external factors may affect the decision-
making process. The notion of food as a symbol of care and nurture makes it 
difficult for family members to withhold artificial nutrition, interpreting that this 
would mean letting the patient suffer from hunger. Thus, they may feel guilty and 
responsible for the patient's death. Solving this psychological issue will need a 
better understanding of disease progression, a reasonable treatment's goal, and 
public education to shape attitudes towards death. Proper use of language, such 
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as “comfort feeding” instead of “hand feeding” may help to clear misinterpretation 
and stress the patient's goal for care [PALECEK et al 2010].
Treatment for complications of dementia in terminal stages such as infections and 
aspiration, are  usually a routine in hospital and relatively inexpensive, compared 
to the complications of cancer or congestive heart failure. For family members to 
choose palliative care simply means to forgo treatment that is not invasive and 
usually effective in the short run. This may be psychologically and emotionally 
challenging. 
Financial incentives in the health care system appear to support utilization of tube 
feeding for dementia cases. A  higher reimbursement for nursing facilities in the 
case of tube feeding instead of hand feeding is one example. With the current 
state of knowledge about the ineffectiveness of tube feeding, financial incentives 
need to be adjusted.
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8. Summary
The rising prevalence of dementia cases demands a better understanding about 
the pathology and progression of the disease. Researches in recent years 
concentrated on prevention and development of medications. Nutritional 
imbalance may play a role in the pathology of dementia, through oxidative stress 
and inflammation, giving a hope that a modulation of nutritional factors may 
prevent or delay the onset of dementia.  Antioxidant compounds, B-vitamins, ω-3 
fatty acids, low caloric and low glycemic index carbohydrates diets, have been 
investigated concerning their involvement in the pathology of dementia with 
contradicting results. However, if implemented early in life, a healthy diet may 
present a potential preventive approach against dementia.
Observational studies show that feeding problems in dementia are common. Over 
time, the ability to eat orally decline in the elderly with dementia, and family 
members start to consider the utilization of artificial nutrition and hydration. From a 
medical point of view, tube feeding is ineffective prolonging life, avoiding 
malnutrition, healing pressure ulcers and avoiding the risk of aspiration. Benefits 
are likely to be perceived, clinging to the notion that adequate nutrient intake 
would improve the health condition. Severe weight loss perhaps indicates the 
terminal stage of the disease, thus weight loss could not be prevented even with 
invasive nutritional intervention such as tube feeding. 
Decision-making is often difficult and loaded with emotional, ethical and legal 
issues. Considering the terminal nature of the disease, a reasonable care 
treatment will be to preserve the quality of life through comfort feeding and 
continued interactions. To support this, incentives in the health care system need 
to be adjusted.
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9. Zusammenfassung
Die wachsende Zahl der an Demenz erkrankten Personen erfordert ein besseres 
Verständnis über die Ätiologie, Pathogenese und Verlauf der Krankheit. Die 
Forschung in den letzten Jahren konzentrierte sich in der Entwicklung von 
Antidementiva und in der primären Prävention von Demenzerkrankungen. 
Oxidativer Stress und Entzündungsprozess spielen eine wichtige Rolle in der 
Pathogenese  von Demenzerkrankung, welche durch Ernährung beeinflusst 
werden kann. Die Bedeutung von antioxidative Verbindungen, B-Vitamine, ω-3 
Fettsäuren und Kalorienrestriktion in der Pathologie von Demenzerkrankungen 
wurden in vielen Studien untersucht, zum Teil mit widersprüchlichen Ergebnissen.
Beobachtungsstudien zeigen hohe Prävalenz der Ernährungsprobleme bei 
dementiell erkrankten Menschen. Schluckstörungen verursachen, dass Menschen 
mit Demenz immer weniger zu sich nehmen und künstliche Ernährung wird 
eingesetzt um Mangelernährung vorzubeugen.  Studien zeigen, dass PEG kein 
Nutzen haben um das Leben zu verlängern, Fehlernährung zu verhindern, 
Druckulcera zu heilen und  die Risiken der Aspiration zu vermeiden. Die Vorteile 
sind meist nur suggeriert durch die psychologische Bedeutung der Ernährung. Im 
Fall von Demenz, Gewichtsverlust kann auf ein Endstadium der Krankheit 
hinweisen.
Die Entscheidungsfindung zur künstlichen oder oralen Ernährung kann die 
Angehörige mit emotionalen, ethischen und rechtlichen Fragen belasten. Demenz 
ist eine unheilbare Erkrankung, ein vernünftiges Ziel in der Pflege wäre die 
Verbesserung der Lebensqualität durch comfort feeding und kontinuierliche 
Bindung. Eine neue Anpassung der Leistungsanreize im Gesundheitswesen zu 
diesen Kenntnissen ist notwendig.
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